{"Title": ["Incyte To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET", "Nasdaq 100 Movers: ATVI, MCHP", "S&P 500 Movers: NEM, MCHP", "Noteworthy ETF Outflows: RPG, FTNT, PAYC, INCY", "INCY Crosses Above Average Analyst Target", "Notable Tuesday Option Activity: CLX, INCY, FCX", "October 16th Options Now Available For Incyte (INCY)", "MorphoSys Announce Validation Of EMA Application For Tafasitamab", "Incyte To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET", "Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be", "Why Geron Stock Soared 23.4% Today", "First Week of INCY July 17th Options Trading", "Notable ETF Outflow Detected - IBB, ILMN, ALXN, INCY", "MorphoSys : Long-term Data From L-MIND Study Confirms Primary Analysis Results", "BUZZ-U.S. STOCKS ON THE MOVE-Oil stocks, airlines, Peloton, PayPal", "BUZZ-U.S. STOCKS ON THE MOVE-Lyft, Livongo Health, Tonix Pharma", "Incyte To Present At RBC Capital Healthcare Conference; Webcast At 3:05 PM ET", "Incyte Corp (INCY) Q1 2020 Earnings Call Transcript", "Why Incyte's Q1 Loss Isn't As Bad As It Looks", "Incyte Reports a Q1 Loss Due to MorphoSys Deal", "Nasdaq 100 Movers: ALXN, SWKS", "Incyte Slips To Loss In Q1, Despite Higher Revenues - Quick Facts", "Incyte Q1 20 Earnings Conference Call At 8:00 AM ET", "Is Incyte Stock a Buy?", "U.S. FDA approves Novartis drug for a hard-to-treat type of lung cancer", "7 Beautiful Biotech Stocks to Buy Here", "Interesting INCY Put And Call Options For December 18th", "BUZZ-U.S. STOCKS ON THE MOVE-Co-Diagnostics, Xeris Pharma, Cyclacel Pharma", "FDA Approves First Targeted Treatment For Bile Duct Cancer", "Validea's Top Five Healthcare Stocks Based On John Neff - 4/19/2020", "Is Exelixis a Buy?", "Incyte Reaches Analyst Target Price", "Tuesday Sector Laggards: Healthcare, Technology & Communications", "Here Are All the Companies Working on COVID-19 Vaccines, Treatments, and Testing", "Incyte Breaks Above 200-Day Moving Average - Bullish for INCY", "Health Care Sector Update for 04/03/2020: NOVN,INCY,ECOR,LJPC", "Health Care Sector Update for 04/03/2020: INCY,ECOR,LJPC", "Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19", "Incyte to Test Its Cancer Drug Jakafi as a Treatment for COVID-19", "Better Buy: Geron vs. Acceleron", "Reasons for hope: the drugs, tests and tactics that may conquer coronavirus", "Validea's Top Five Healthcare Stocks Based On John Neff - 3/15/2020", "Nasdaq 100 Movers: UAL, CERN", "These 2 Things Will Help Incyte\u2019s Stock Rebound", "MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab", "Incyte To Present At Cowen And Co Conference; Webcast At 11:20 AM ET", "Implied VUG Analyst Target Price: $208", "Better Buy: GlaxoSmithKline vs. Eli Lilly", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 3/15/2020", "Better Buy: Vertex Pharmaceuticals vs. Incyte", "INCY Crosses Above Key Moving Average Level", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 2/16/2020", "Validea's Top Five Healthcare Stocks Based On John Neff - 2/16/2020", "Validea Peter Lynch Strategy Daily Upgrade Report - 2/14/2020", "Incyte Corp (INCY) Q4 2019 Earnings Call Transcript", "How Incyte Beat Wall Street Estimates in Q4", "Incyte's Ruxolitinib Works in Patients With Eczema", "Nasdaq 100 Movers: NTAP, AMAT", "Incyte Q4 Adj. Operating Income Rises; Jakafi Revenues Up 23% - Quick Facts", "Incyte Corporation Q4 adjusted earnings of $0.65 per share", "Incyte Q4 19 Earnings Conference Call At 8:00 AM ET", "Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema", "Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation", "Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA", "Incyte's Fourth-Quarter Report Signals Better Times Ahead", "Here's Why Incyte Stock Tumbled 16.3% in January", "April 17th Options Now Available For Incyte (INCY)", "Validea Peter Lynch Strategy Daily Upgrade Report - 1/31/2020", "Will Eli Lilly Outperform in 2020?", "Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study", "Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial", "Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial", "Stocks to Watch in February", "Interesting INCY Put And Call Options For September 18th", "Validea Martin Zweig Strategy Daily Upgrade Report - 1/22/2020", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 1/19/2020", "Validea's Top Five Healthcare Stocks Based On John Neff - 1/19/2020", "Incyte Stock Is Down: Buy the Dip?", "2 Top Growth Stocks to Buy in January", "Tuesday Sector Leaders: Healthcare, Consumer Products", "Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation", "MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.", "Why Has Vertex Pharmaceuticals' Stock Gained 30% In The Last Quarter?", "Better Buy: Geron vs. Incyte", "Validea Martin Zweig Strategy Daily Upgrade Report - 1/4/2020", "Friday Sector Laggards: Materials, Healthcare", "Incyte is Now Oversold (INCY)", "Here's Why Incyte Fell as Much as 12.6% Today", "Will Theravance Biopharma Finally Break Out in 2020?", "Nasdaq 100 Movers: INCY, TSLA", "S&P 500 Movers: INCY, LW", "DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz", "3 Best Biotech Stocks of 2019: Are They Buys Now?", "A $20 Billion Sweet Spot in Biotech", "3 Biotech Stocks That Crushed It in 2019", "Thursday Sector Laggards: Healthcare, Utilities", "INCY Makes Notable Cross Below Critical Moving Average", "Validea's Top Five Healthcare Stocks Based On John Neff - 12/15/2019", "Are These Biotech Companies Buyout Candidates? Deal Or No Deal?", "Why Incyte Stock Climbed 12.2% in November", "Incyte To Present At Piper Jaffray Healthcare Conference; Webcast At 8:30 AM ET", "INCY Crosses Above Average Analyst Target", "Noteworthy Monday Option Activity: BANC, INCY, HAS", "Monday Sector Leaders: Healthcare, Technology & Communications", "Why Longer-Term Investors Should Buy Amarin Stock on Weakness", "Here's Why Kadmon Holdings Stock Jumped Today", "Here's Why Incyte Corporation Jumped 13.0% in October", "2 Stocks That Crushed It on Tuesday", "Tuesday Sector Leaders: Energy, Healthcare", "Incyte Corp (INCY) Q3 2019 Earnings Call Transcript", "INCY Crosses Above Key Moving Average Level", "Incyte Q3 Profit Surges; Raises FY19 Jakafi Revenue Outlook - Quick Facts", "Wednesday Sector Leaders: Utilities, Healthcare", "Better Buy: Vertex Pharmaceuticals vs. Incyte", "5 Top Healthcare ETFs", "Interesting INCY Put And Call Options For June 2020", "Is Incyte a Buy?", "How The Parts Add Up: SPYX Headed For $80", "10 Great Biotech Stocks to Buy in Q4", "Monday Sector Laggards: Healthcare, Industrial", "Incyte Q3 19 Earnings Conference Call At 8:00 AM ET", "This Could Be a Big Year for Incyte", "Notable Wednesday Option Activity: EXP, INCY, SAFM", "PBE, GILD, ALXN, INCY: Large Outflows Detected at ETF", "Interesting INCY Put And Call Options For January 2022", "Nasdaq 100 Movers: AAL, WDAY", "We Did The Math QQEW Can Go To $74", "Wednesday Sector Laggards: Utilities, Healthcare", "Friday Sector Leaders: Healthcare, Utilities", "10 Stocks to Buy for September", "Nasdaq 100 Movers: ADSK, INCY", "How Big Is Celgene's Latest Good News?", "Look Under The Hood: QUS Has 10% Upside", "Incyte Corp (INCY) Q2 2019 Earnings Call Transcript", "Here's What You'll Want to Know About Incyte's Impressive Q2 Results", "Health Care Sector Update for 07/30/2019: INCY,MEDP,NBIX,HCA", "INCY Makes Notable Cross Below Critical Moving Average", "Incyte Corporation Q2 adjusted earnings Beat Estimates", "Incyte Q2 19 Earnings Conference Call At 8:00 AM ET", "First Week of March 2020 Options Trading For Incyte (INCY)", "Interesting INCY Put And Call Options For August 16th", "INCY Crosses Above Average Analyst Target", "Noteworthy Monday Option Activity: INCY, LIN, TMUS", "Monday Sector Leaders: Energy, Healthcare", "Nasdaq 100 Movers: EXPE, INCY", "Analysts Expect SIZE To Hit $100", "First Week of July 19th Options Trading For Incyte (INCY)", "Incyte Corp (INCY) Q1 2019 Earnings Call Transcript", "5 Biotech Stocks for a Long-Lived Portfolio", "Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib", "Incyte Corporation Q1 adjusted earnings of $0.62 per share", "Commit To Purchase Incyte Corporation At $62.50, Earn 12.3% Using Options", "Nasdaq 100 Movers: ALGN, INCY", "Relative Strength Alert For Incyte", "Relative Strength Alert For Incyte", "The Implied Analyst 12-Month Target For AMCA", "J&J wins U.S. FDA approval for bladder cancer drug", "U.S. FDA approves J&J's bladder cancer drug", "3 Big Stock Charts for Wednesday: Incyte, FMC and LyondellBasell", "Wednesday Sector Laggards: Energy, Healthcare", "Biotech Stocks Facing FDA Decision In May 2019", "NASDAQ Composite Index closes up 19.78 points for the week, rising for the 5th straight day", "Wednesday Sector Laggards: Energy, Healthcare", "Why Is Incyte (INCY) Up 1.7% Since Last Earnings Report?", "Zacks.com featured expert Kevin Matras highlights: Incyte, AMC Entertainment, Covanta and U.S. Silica", "4 Toxic Stocks to Abandon or Sell Short for Solid Gains", "Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda", "Zacks.com featured expert Kevin Matras highlights: First Majestic Silver, Incyte, Covanta and U.S. Silica", "Nasdaq 100 Movers: INCY, AMD", "4 Toxic Stocks to Discard or Sell Short for Solid Gains", "Merck Gets Priority Review for Keytruda in Third-Line SCLC", "Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study", "Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why", "Merck Gets Priority Review for Keytruda Combo in Kidney Cancer", "Incyte (INCY) Q4 2018 Earnings Conference Call Transcript", "Incyte (INCY) Q4 Earnings Lag Estimates", "3 Big Stock Charts for Wednesday: Cabot Oil & Gas, Incyte and Sempra Energy", "Notable ETF Inflow Detected - QQEW, I, CELG, INCY", "Pre-Market Earnings Report for February 14, 2019 : KO, DUK, CME, WM, ZTS, IQV, CCEP, PPL, TU, AZN, INCY, AEE", "Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars", "Zacks.com featured highlights include: Incyte, First Majestic, Mattel and U.S. Silica", "Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer", "4 Toxic Stocks to Abandon or Sell Short for Solid Gains", "Why Incyte Stock Gained 27% in January", "Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat", "Is a Disappointment in Store for Incyte (INCY) Q4 Earnings?", "Incyte Down as FDA Extends Review Period of Jakafi for GVHD", "Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies", "Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2", "First Week of September 20th Options Trading For Incyte (INCY)", "Zacks.com featured highlights include: Incyte, KEYW, First Majestic and Mattel", "3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte", "How The Parts Add Up: QQQ Headed For $186", "Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs", "Commit To Buy Incyte Corporation At $62.50, Earn 8.1% Annualized Using Options", "Close Update: Nasdaq Leads Market Higher as Technology, Health Care Shares Rally", "Market Close Report: NASDAQ Composite Index closes above 7000; up 117.91 points at 7,023.83", "Tuesday Sector Leaders: Healthcare, Technology & Communications", "What's in Store for Merck in 2019 After a Solid Run in '18?", "Analysts Anticipate IECS Will Reach $27", "4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains", "Why Agenus Stock Is Spiking Today", "3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott Laboratories", "Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan", "INCY Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: AAL, CELG", "S&P 500 Movers: LNT, CELG", "Incyte Names Christiana Stamoulis CFO - Quick Facts", "4 Biotechs That Are Potential Buyouts Post Celgene Deal", "Health Care Sector Update for 01/03/2019: INCY,KTOV,CELG,BMY,TEVA", "S&P 500 Movers: LNT, NFLX", "Nasdaq 100 Movers: FB, INCY", "Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review", "The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte", "Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY", "Here Are Biotech\u2019s Big Pipeline Disappointments in 2018", "Why Celgene, Agenus, and Incyte Jumped Today", "Health Care Sector Update for 01/03/2019: INCY,KTOV,CELG,BMY,TEVA", "5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride", "Nasdaq 100 Movers: PEP, INCY", "Roche to Create Companion Diagnostic Test for Merck's Keytruda", "5 Top Drug/Biotech Merger & Acquisition Targets for 2019", "Why MacroGenics Stock Is Getting Hammered Today", "AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study", "Immuno-Oncology Suffered a Setback in 2018. What\u2019s Next?", "Nasdaq 100 Movers: TTWO, WYNN", "Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report?", "NASDAQ Composite Index closes up .85 points for the week, rising for the 3rd straight day", "AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down", "Merck's Keytruda Improves Survival in Esophageal Cancer Study", "Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer", "Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus", "Incyte (INCY) Announces Positive Data on Jakafi for GVHD", "3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte", "Scary Markets, Frightening Stocks, and How to Keep From Panicking", "Nasdaq 100 Movers: CTSH, TTWO", "Incyte (INCY) Misses Q3 Earnings and Revenue Estimates", "Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript", "Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View", "Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation", "Incyte's Shares Have Taken a Beating in 2018 -- Here's Why", "3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte", "Incyte (INCY) to Report Q3 Earnings: What's in the Cards?", "Strong Comeback Saves Market From Another Plunge", "Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales", "5 Reasons Why Investors Should Bet on Merck (MRK) Stock", "3 Top Biotech Stocks to Buy in October", "Market Close Report: NASDAQ Composite index closes at 7,879.51 down -145.58 points", "Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod", "2 Stocks That Could Benefit Big From Geron's Stumble", "Better Buy: Geron Corporation vs. Incyte Corporation", "Nasdaq 100 Movers: MU, AAL", "Health Care Sector Update for 09/21/2018: CRSP,BGNE,XOMA,LLY,AGEN,INCY,MRK", "Health Care Sector Update for 09/21/2018: BGNE,XOMA,AGEN,INCY,MRK", "Agenus Receives Milestone Payment of $5 Million from Incyte", "First Week of INCY March 2019 Options Trading", "Thursday Sector Laggards: Technology & Communications, Healthcare", "Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars", "Incyte, Foundation Medicine Partner for Companion Diagnostics", "Merck's Keytruda Combo Gets Nod for Lung Cancer in Europe", "Health Care Sector Update for 09/11/2018: ACRX, XENE, INCY, KMPH, IMV", "Notable Tuesday Option Activity: UVE, INCY, NXPI", "Why Incyte Stock Gained 11% in August", "Merck's Keytruda Gets Priority Review for Rare Skin Cancer", "Merck Gets Priority Review for Yet Another Keytruda sBLA", "Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report?", "Tuesday Sector Leaders: Healthcare, Financial", "Is Agenus Inc. Stock a Buy?", "Merck Gets FDA Nod for Keytruda Lung Cancer Label Expansion", "S&P 500 Analyst Moves: INCY", "Nasdaq 100 Movers: JD, WDAY", "Agenus (AGEN) Delivering Well on Its Pipeline Candidates", "BBH's Holdings Imply 12% Gain Potential", "Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release", "Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat", "3 Big Stock Charts for Monday: Entergy, Incyte and SL Green Realty", "We Did The Math SPLG Can Go To $36", "Incyte is Now Oversold (INCY)", "Market Close Report: NASDAQ Composite index closes at 7,671.79 up 41.79 points", "Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2", "Nasdaq 100 Movers: JD, STX", "Incyte (INCY) to Report Q2 Earnings: What's in the Cards?", "Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation", "10 Cancer-Fighting Health Care Stocks to Buy", "CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA", "Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?", "The 3 Worst Healthcare Stocks of 2018 (So Far)", "First Week of INCY August 17th Options Trading", "Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT", "Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod", "Nasdaq 100 Movers: INCY, NFLX", "S&P 500 Movers: INCY, GE", "Market Close Report: NASDAQ Composite index closes at 7,561.63 up 29.62 points", "Tuesday Sector Laggards: Financial, Healthcare", "Incyte (INCY) Announces Positive Results on Jakafi for GVHD", "3 NASH Stocks That Could Soar in the Second Half of 2018", "Merck's Keytruda Gets Priority Review in Difficult Lung Cancer", "Here's Why Incyte Rose 10.2% in May", "Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive", "Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis", "Better Know Biotech: 2 Stocks You've Got to Know About", "Incyte (INCY) Up 10.2% Since Earnings Report: Can It Continue?", "3 Biotechs With Huge FDA Decisions in June", "Interesting INCY Put And Call Options For July 20th", "3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate", "A Huge Decision Is on Tap for This Little Biotech Stock", "Is Agenus Inc. (AGEN) a Buy?", "Monday 5/7 Insider Buying Report: ETM, INCY", "Morning Movers: Under Armour Slumps, Tapestry Tumbles, Pfizer Flops", "Incyte (INCY) Reports A Loss in Q1", "Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates", "First Week of INCY December 21st Options Trading", "5 Things AbbVie Investors Need to Know", "Analysts Predict 13% Gains Ahead For The Holdings of IWB", "Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?", "Lessons to Learn From April's Biotech Blowups", "Is Eli Lilly and Company a Buy?", "Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales", "Nasdaq 100 Movers: INCY, CDNS", "Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up", "Should You Sell Incyte (INCY) Before Earnings?", "Market Close Report: NASDAQ Composite index closes at 7,007.35 down -121.25 points", "Health Care Sector Update for 04/24/2018: ENZ,HOLX,BIIB,CNC,INCY", "Health Care Sector Update for 04/24/2018: INCY, BIIB,CNC", "Lilly (LLY) to Report Q1 Earnings: What's in the Cards?", "3 Biotech Stocks With Major Catalysts Incoming", "The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte", "What Incyte's Phase 3 Fail Means for Immuno-Oncology", "Health Care Sector Update for 04/24/2018: LLY, INCY, BIIB, CNC", "What Happened With Incyte's IDO Inhibitor Flop", "Nasdaq 100 Movers: NTES, INCY", "Why One Drug Flop Tanked Incyte's Stock", "Why GoPro, Incyte, and Wynn Resorts Jumped Today", "Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis", "Is Beaten-Down Incyte Corporation Stock a Buy Now?", "Nasdaq 100 Movers: INCY, NTES", "What's Next for Incyte?", "NewLink Shares Plunge After Incyte & Merck's Study Fails", "Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure", "Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge", "Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge", "Relative Strength Alert For Incyte", "Nasdaq 100 Movers: INCY, ULTA", "S&P 500 Movers: INCY, ULTA", "Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge", "Mid-Morning Market Update: Markets Open Lower; Greenbrier Beats Q2 Expectations", "Morning Movers: Are Tariffs a Game of Bluff?", "Health Care Sector Update for 04/06/2018: INCY, MRK, CDXS, MNKD, ACRS, CPHR", "Pre-Market Most Active for Apr 6, 2018 : MU, INCY, TVIX, BP, QQQ, BAC, TOT, NLNK, BTI, SQQQ, SBGL, TLK", "Incyte's Horrible News Derails a Promising Class of Cancer Drugs", "What Happened in the Stock Market Today", "Market Close Report: NASDAQ Composite index closes at 6,915.11 down -161.44 points", "Mid-Morning Market Update: Markets Open Lower; Greenbrier Beats Q2 Expectations", "Mid-Morning Market Update: Markets Open Lower; Greenbrier Beats Q2 Expectations", "Mid-Afternoon Market Update: Crude Oil Down 2%; PriceSmart Shares Spike Higher", "Mid-Afternoon Market Update: Crude Oil Down 2%; PriceSmart Shares Spike Higher", "Why Incyte and NewLink Genetics Crashed Today", "Notable Friday Option Activity: INCY, NFLX, REGN", "Are Short-Sellers Right About Geron Corporation?", "Health Care Sector Update for 04/06/2018: INCY,MRK,ACRS,CDXS,MNKD", "Venture Capital Deals Of The Week: Small Molecules And Software", "Implied VOO Analyst Target Price: $277", "These 3 Biotech Stocks Are Soaring, but Are They Buys Now?", "Incyte Could Have a Problem (or 2!) on Its Hands", "3 Biotechs That Could Get Big Boosts in April", "Incyte (INCY) Up 5.2% Since Earnings Report: Can It Continue?", "Is Geron Corporation's Stock Set to Sail or Sink?", "How Safe Is AbbVie, Inc.'s Dividend Now?", "The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte", "Top Analyst Reports for Royal Dutch Shell, Mastercard & Itau Unibanco", "Noteworthy Thursday Option Activity: INCY, DDD, CRC", "Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo", "Stocks Take the Powell Plunge", "Implied PBUS Analyst Target Price: $30", "Stocks Follow Walmart Lower", "AstraZeneca's Final Data From Key Lung Cancer Study Delayed", "The Zacks Analyst Blog Highlights: Royal Dutch, Mastercard, Itau Unibanco, Suncor and Incyte", "Top Analyst Reports for Royal Dutch Shell, Mastercard & Itau Unibanco", "Get Rid of 5 Toxic Stocks or Sell Short for Profit", "Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today", "Nasdaq 100 Movers: INCY, CSCO", "Incyte (INCY) Beats on Sales in Q4", "Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales", "Zacks.com featured highlights include: Incyte, Altice USA, Archrock, Live Nation and PTC", "Pre-Market Earnings Report for February 15, 2018 : ZTS, WM, INCY, OMC, CCE, FTS, HII, YNDX, ECA, SHOP, EQT, LBTYA", "Notable Wednesday Option Activity: NEM, INCY, ALGN", "Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?", "Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?", "5 Biotech Stocks Set to Trump Estimates This Earnings Season", "AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018", "Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance", "Why Incyte (INCY) Might Surprise This Earnings Season", "Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?", "Merus' Antibody Candidate in Phase II Breast Cancer Study", "Lilly (LLY) to Report Q4 Earnings: What's in the Cards?", "Analysts Anticipate BBH Will Reach $151", "Novartis Tops A High After Crushing Fourth-Quarter Expectations", "These 2 Developments Could Accelerate Johnson & Johnson's Next Acquisition", "Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock", "First Real Pullback of 2018", "Discard These 4 Toxic Stocks or Sell Short for Profit", "Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News", "5 Big Biotech Stocks To Buy In 2018", "Will 2018 Be Agenus Inc.'s Best Year Yet?", "Health Care Sector Update for 01/12/2018: JNJ, PFE, ABT, MRK, AMGN, CNCE, INCY, GSK, PSTI, VRX", "Health Care Sector Update for 01/12/2018: VRX,VRX.TO,PSTI,GSK,CNCE,INCY", "Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today", "Notable Thursday Option Activity: INCY, EBAY, SYF", "Nasdaq 100 Movers: INCY, MYL", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 7,211.78.", "S&P 500 Analyst Moves: INCY", "5 Things You Need to Know From Celgene's J.P. Morgan Presentation", "Celgene to Acquire Impact Biomedicines to Boost Pipeline", "5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers", "Celgene Earnings Beat Views; Biotech Buys Impact Biomedicines", "Health Care Sector Update for 01/12/2018: PSTI,GSK,CNCE,INCY", "Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott", "Morning Movers: Netflix, Target Start 2018 With a Bang", "Abandon These 5 Toxic Stocks or Sell Short for Profit", "Tuesday Sector Leaders: Healthcare, Services", "Commit To Purchase Incyte Corporation At $85, Earn 12.5% Using Options", "3 Promising Cancer Immunotherapies to Watch in 2018", "AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study", "Why These 3 Biotech Stocks Could Outperform Their Peers In 2018", "Zacks.com highlights: Covanta Holding, AMC Entertainment Holdings, Incyte, PTC and Cott", "Monday Sector Laggards: Utilities, Healthcare", "Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors", "Dispose of These 5 Toxic Stocks or Sell Short for Gains", "Wednesday Sector Leaders: Utilities, Healthcare", "3 Top Healthcare Stocks to Buy in December", "Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi", "Navistar International Higher 10% on Earnings", "5 Top-Ranked Drug Stocks that are Broker Favorites", "Incyte is Now Oversold (INCY)", "1 High-Risk Penny Stock That May Be Worth Buying", "10 Blockbuster Drugs of the Future for Big Pharma Stocks", "Nasdaq 100 Movers: NCLH, INCY", "Nasdaq 100 Movers: INCY, MSFT", "Hedge Funds Are Snapping Up These 3 \u2018Strong Buy\u2019 Stocks", "3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise", "Monday Sector Laggards: Healthcare, Energy", "Incyte (INCY) Initiates Essential Thrombocythemia Trial", "AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,789.12.", "Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal", "7 Months in the Green for Dow and S&P", "Casino, Energy Stocks Jump; Which IBD 50 Names Are Red Hot?", "5 Stocks the Top Fund Managers Love", "What's in the Offing for Intercept (ICPT) in Q3 Earnings?", "Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite", "Will Radius Health (RDUS) Disappoint This Earnings Season?", "Get Rid of These 5 Toxic Stocks or Sell Short for Profit", "Why Incyte (INCY) Might Surprise This Earnings Season", "What's in the Offing for Exelixis (EXEL) in Q3 Earnings?", "Midday Update: Wall Street Turns Negative on Missed Earnings", "Incyte Rises On A Beat-And-Raise, Expanding Deal With AstraZeneca", "Why Akamai Technologies, NuVasive, and MacroGenics Jumped Today", "Is a Beat in Store for Alexion (ALXN) This Earnings Season?", "Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco", "Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?", "IBD Biotech Innovator Awards", "6 Top Biotech Companies In Innovation Earn Recognition In New Awards", "Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease", "Why MacroGenics, Inc. Stock Soared Today", "5 Game-Changing Cancer Drug Innovations Being Developed Right Now", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,603.55.", "VOT, ADSK, INCY, EW: Large Outflows Detected at ETF", "Nasdaq 100 Movers: COST, INCY", "Nasdaq 100 Movers: INCY, PAYX", "Friday Sector Leaders: Healthcare, Consumer Products", "Nasdaq 100 Movers: QVCA, AAL", "5 Toxic Stocks to Abandon or Sell Short for Gains", "3 Stocks That Turned $7,000 Into $130,200", "Tech Bounces Back", "J&J's Arthritis Candidate Sirukumab Denied FDA Approval", "Zacks.com featured highlights: PTC, Apache, Incyte, Titan International and Carbonite", "3 Monster Biotech Stocks in the Making", "5 Toxic Stocks to Discard or Sell Short for Profit", "Implied BBH Analyst Target Price: $150", "Agenus (AGEN) Remains Focused on Drug Development Programs", "VOT, FISV, INCY, EW: ETF Outflow Alert", "Interesting INCY Put And Call Options For November 17th", "5 of the Toughest Stocks to Withstand a Downturn", "Lilly/Incyte's Baricitinib Meets Endpoint in Eczema Study", "Notable Friday Option Activity: OKTA, RH, INCY", "Nasdaq 100 Movers: INCY, SYMC", "Market Close Report: NASDAQ Composite index closes at 6,360.19 down -37.68 points", "3 Small-Cap Biotech Stocks to Buy This Fall", "Nasdaq 100 Biotechnology: Beyond Pure Tech; Still Pure Innovation", "Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda", "Top Research Reports for Bank of America, Pepsi & American Express", "Better Buy: Eli Lilly and Company vs. Pfizer Inc.", "Thursday's ETF with Unusual Volume: BBH", "Lilly/Incyte to Re-File Baricitinib NDA Faster Than Expected", "Nasdaq 100 Movers: CTRP, MYL", "Here's Why NewLink Genetics Is Vaulting 45% Higher Today", "Nasdaq 100 Movers: WDC, ADI", "S&P 500 Movers: HRB, ADI", "NASDAQ Composite Index closes up 18.87 points for the week, rising for the 3rd straight day", "5 Biotech Stocks That Are Breaking Higher", "Wednesday Sector Leaders: Technology & Communications, Healthcare", "Tuesday's ETF Movers: FBT, XOP", "4 of the Highest-Growth Stocks in Biotech Today", "Wednesday's ETF Movers: BBH, GDXJ", "3 Most Promising Cancer Drugs in Late-Stage Development", "3 Top Biotech Stocks Under $5", "Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?", "Bb Biotech Ag Buys AveXis Inc, Sells Regeneron Pharmaceuticals Inc, Puma Biotechnology Inc, PTC ...", "Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong", "Incyte Corporation (INCY) Shares Drop on Q2 Loss", "Nasdaq 100 Movers: IDXX, NCLH", "Commit To Purchase Incyte Corporation At $100, Earn 9.7% Using Options", "Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug", "Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed", "Eli Lilly (LLY)'s Seemingly Illogical Reaction To Earnings Beat", "2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't", "3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?", "We Did The Math FBT Can Go To $127", "Monday Sector Laggards: Healthcare, Technology & Communications", "Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline", "Nasdaq 100 Movers: TSLA, LILA", "Incyte & Lilly's Olumiant Gets Marketing Approval in Japan", "Better Buy: Agenus Inc. vs. Kite Pharma", "Stock Exchange: Time For Evidence-Based Trading?", "Aduro Starts Phase II Combo Study with CRS-207 & Keytruda", "Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca", "Thursday Sector Laggards: Technology & Communications, Healthcare", "3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months", "Nasdaq 100 Movers: NTES, MU", "Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger", "Nasdaq 100 Movers: MAT, CA", "Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More", "Update: Wall Street Weighed Down By Oil Declines as Health Stocks Lift Nasdaq", "Wednesday Sector Leaders: Healthcare, Technology & Communications", "A Surprising Disappointment Derails NewLink Genetics -- What's Next?", "Better Days Ahead for the Pharma Sector?", "3 Biotech Stocks That Could Become M&A Targets", "Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...", "3 Beaten-Down Stocks Ready to Bounce Back", "BIB, CELG, AMGN, INCY: ETF Inflow Alert", "Gilead Sciences, Inc.: The Bear Case From a Bull", "Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue?", "Why Is NewLink Genetics Losing One-Third of Its Value Today?", "5 Answers to Questions Gilead Sciences' Investors Probably Have", "Incyte Provides Updated Data on Cancer Combination Therapies", "Incyte Announces Data on Enzyme Inhibitor with Keytruda", "Nasdaq 100 Movers: ORLY, NTES", "Market Close Report: NASDAQ Composite index closes at 6,295.68 down -10.12 points", "Market Close Report: NASDAQ Composite index closes at 6,203.19 down -7 points", "A Week's Worth of Gains", "Stock Exchange: Time to reconsider health care?", "Market Close Report: NASDAQ Composite index closes at 6,297.38 up 22.32 points", "Friday Sector Laggards: Healthcare, Technology & Communications", "Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna", "Company News for May 19, 2017", "Incyte Corporation (INCY) Stock Jumps on Promising Lung Cancer Drug", "Nasdaq 100 Movers: CSCO, INCY", "S&P 500 Movers: CSCO, INCY", "Concert Pharma Falls After Clinical Hold on Hair Loss Drug", "Stock Exchange: Time To Reconsider Healthcare?", "Incyte (INCY) Announces Positive Data on Enzyme Inhibitor", "Market Close Report: NASDAQ Composite index closes at 6,055.13 up 43.89 points", "Thursday Sector Leaders: Services, Healthcare", "Market Close Report: NASDAQ Composite index closes at 6,011.24 down -158.63 points", "Noteworthy Friday Option Activity: CASY, INCY, TWTR", "3 Top Biotech Stocks For May", "Bellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...", "A Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks", "Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat", "Monday Sector Laggards: Healthcare, Services", "VOT, EQIX, APH, INCY: ETF Inflow Alert", "S&P 500 Movers: FLR, MTD", "Nasdaq 100 Movers: INCY, MNST", "Friday Sector Laggards: Healthcare, Financial", "4 Biotech Stocks That Could Be Rocked and Rolled This Month", "S&P 500 Movers: TSN, NWL", "Pre-Market Earnings Report for May 4, 2017 : D, OXY, REGN, CNQ, ZTS, PPL, K, INCY, APA, CCE, WLTW, ABC", "5 Toxic Stocks to Dispose of or Play Short for Profit", "Incyte Corporation (INCY) Leads 11 Activist Investor Filings", "5 Things Bristol-Myers Squibb's Management Wants You to Know", "Should You Get Rid of Incyte Corporation (INCY) Now?", "Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down", "Should Gilead Sciences Acquire NewLink Genetics?", "Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More", "This $26 Billion Company Is the Market's Most Overpriced Biotech Stock", "Zacks Market Edge Highlights: Insulet, Incyte, Intuitive Surgical and Edwards Lifesciences", "Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed", "Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals", "Should You Make a Bet on the Healthcare Stocks?", "Why Incyte Corporation Stock Is Plunging Today", "Mid-Day Market Update: Dow Surges Over 100 Points; Oncomed Shares Slide", "Nasdaq 100 Movers: MAT, INCY", "Eli Lilly and Co (LLY) Stock Holders Choke on FDA Letter for Barictinib", "Nasdaq 100 Movers: INCY, NVDA", "S&P 500 Movers: INCY, ARNC", "Eli Lilly's Rheumatoid Arthritis Drug Gets CRL in the U.S.", "Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain", "5 Toxic Stocks to Shun or Play Short Right Now", "Pre-Market Most Active for Apr 17, 2017 : ALR, SWC, MGI, BAC, XIV, LLY, XXIA, INCY, QQQ, TLT, F, KEP", "Health ETFs Wobble As FDA Spurns Arthritis Drug In Blow To Eli Lilly", "Market Close Report: NASDAQ Composite index closes at 5,856.79 up 51.64 points", "Mid-Afternoon Market Update: Crude Oil Down 1%; MOCON Shares Spike Higher", "Monday Sector Laggards: Energy, Healthcare", "The IDO-Inhibitor Race Is On to Improve Cancer Treatment", "Nasdaq 100 Movers: LILA, ALXN", "Wednesday 4/12 Insider Buying Report: INCY, CBK", "Market Close Report: NASDAQ Composite index closes at 5,836.16 down -30.61 points", "Why Snyder's-Lance, Incyte, and Tenet Healthcare Slumped Today", "S&P 500 Movers: AMD, HES", "INCY Crosses Above Average Analyst Target", "Nasdaq 100 Movers: JD, ESRX", "Stock Exchange: Finding Trading Ideas In A Low Volatility Market", "Market Close Report: NASDAQ Composite index closes at 5,877.81 down -1.14 points", "Friday Sector Leaders: Healthcare, Financial", "Would Gilead Sciences Make This Staggeringly Audacious Move?", "Nasdaq 100 Movers: INCY, TSLA", "Thursday Sector Laggards: Utilities, Healthcare", "Agenus (AGEN) Sharpens Focus on Drug Development Programs", "Why NewLink Genetics Shares Fell 10.3% Today", "Nasdaq 100 Movers: ORLY, TSLA", "S&P 500 Movers: HPE, INCY", "4 FDA Decisions to Watch Out for in Apr 2017", "Bristol-Myers (BMY), Incyte to Advance Clinical Program", "Market Close Report: NASDAQ trading volume joins the top ten ranking for the year. NASDAQ Composite Index closes at 5,878.95", "4 Drug Stocks With Big News Coming in April", "3 Big Healthcare Stocks That Wall Street Predicts Will Grow the Fastest", "Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals", "Market Close Report: NASDAQ Composite index closes at 5,911.74 down -2.60 points", "Friday Sector Laggards: Healthcare, Services", "VO, FISV, APH, INCY: Large Inflows Detected at ETF", "5 Toxic Stocks to Get Rid Of or Play Short to Make Gains", "Monday Sector Leaders: Healthcare, Utilities", "4 Drug Stocks With Big News Coming in April", "Market Close Report: NASDAQ Composite index closes at 5,817.69 down -3.95 points", "Thursday Sector Laggards: Healthcare, Energy", "Nasdaq 100 Movers: CSX, MAR", "Market Close Report: NASDAQ Composite index closes at 5,793.83 down -107.70 points", "Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?", "Noteworthy ETF Outflows: IBB, BIIB, REGN, INCY", "Strange: Bullish INCY Analysts Actually See -6.01% Downside", "5 Toxic Stocks to Dump or Play Short to Make Gains", "3 Reasons Why Gilead Sciences Will Buy Incyte -- and 1 Reason Why It Won't", "S&P 500 Movers: TSCO, DLPH", "Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4", "NASDAQ Composite Index closes up 1.26 points for the week, rising for the 3rd straight day", "Incyte Corporation at the Cowen Healthcare Conference: 4 Things You'll Want to Know", "Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals", "Wednesday Sector Leaders: Services, Healthcare", "Friday Sector Leaders: Healthcare, Financial", "Zacks.com featured highlights: Abercrombie & Fitch, Live Nation Entertainment, Vertex Pharmaceuticals, Etsy and Incyte", "VXF, TSLA, LBTYA, INCY: ETF Inflow Alert", "5 Toxic Stocks to Abandon or Play Short Right Now", "After Hours Most Active for Feb 27, 2017 : ENB, INCY, MENT, PG, SWN, ORCL, HUN, XRX, YHOO, CSCO, QVCA, TLT", "Better Buy: Juno Therapeutics vs. Incyte", "A Trip to 8-Year Bull Run: What's Up, What's Down", "Market Close Report: NASDAQ Composite index closes at 5,845.31 up 9.80 points", "Here's Why Incyte Rose as Much as 8% Today", "Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences", "Troubling Trial Data Weighed on Agenus Inc Stock Today", "What's Driving Lilly's (LLY) Shares after 2016 Decline?", "Nasdaq 100 Movers: INCY, SIRI", "Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data", "Nasdaq 100 Movers: BIDU, INCY", "Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook", "Banks Loved Yellen's Testimony", "Why Agenus Stock Is Surging Today", "Nasdaq 100 Movers: LOGM, INCY", "Lilly's Olumiant Gets Marketing Authorization in Europe", "The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences", "Health Care Sector Update for 02/14/2017: INCY,AGEN,CYNO,HOLX,AVIR", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,819.44.", "Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies", "VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?", "Should You Sell Incyte (INCY) Before Earnings?", "Pre-Market Earnings Report for February 14, 2017 : TMUS, INCY, Q, TAP, DPS, NBL, MLM, BRX, DISCK, TRU, IPGP, LECO", "Is Gilead Sciences Getting Ready for a Massive Acquisition?", "Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?", "Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?", "What's in Store for Avis Budget (CAR) this Earnings Season?", "Strange: Bullish INCY Analysts Actually See -3.72% Downside", "5 Toxic Stocks to Dump or Play Short for Gains", "5 Drug Stocks Poised to Beat Earnings Estimates in Q4", "Can Prothena (PRTA) Pull a Surprise This Earnings Season?", "Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?", "Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?", "GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?", "4 Stocks Under $4 That Could Double", "Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?", "Incyte and Calithera Enter into Deal for Oncology Candidate", "Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%", "Midday Update: Outcry Surrounding Travel Ban Spooks Investors", "Health Care Sector Update for 01/30/2017: JNJ, PFE, ABT, MRK, AMGN, OCRX, CALA, EYEG", "Mid-Day Market Update: Dow Falls Over 150 Points; Calithera Biosciences Shares Spike Higher", "Mid-Morning Market Update: Markets Open Lower; Booz Allen Profit Misses Estimates", "Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys", "Close Update: Immigration Ban Unnerves Wall Street; Travel Stocks Pummeled", "Health Care Sector Update for 01/30/2017: RGLS,CALA,INCY", "Mid-Afternoon Market Update: Tempur Sealy Drops After Loss Of Mattress Firm Contract; Digital Ally Shares Surge", "Zacks.com featured highlights: Live Nation Entertainment, Conns, ConocoPhillips, Etsy and Incyte", "Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company", "5 Toxic Stocks to Dump or Play Short Now", "Incyte Has Insight Into Market With Potential Blockbuster Drugs", "Better Buy: Inovio Pharmaceuticals vs. Incyte Corp.", "Nasdaq 100 Movers: CSX, SWKS", "Nasdaq 100 Movers: INCY, DLTR", "Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended", "Nasdaq 100 Movers: SWKS, INCY", "Notable ETF Inflow Detected - IBB, REGN, ALXN, INCY", "4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal", "Incyte/Merck to Start More Epacadostat-Keytruda Studies", "Incyte Has Insight Into Market With Potential Blockbuster Drugs", "Nasdaq 100 Movers: VOD, INCY", "Incyte Reaches Analyst Target Price", "Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,531.82.", "3 Stocks Expected to More Than Double Their Earnings in 2017", "Biotech Investing: 3 Bold Predictions for 2017", "Noteworthy Friday Option Activity: CBRL, INCY, BWLD", "3 Reasons Geron Corporation Plunged 57% in 2016", "Incyte's Prospects Get Even Brighter With Merck Announcement", "Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day", "Incyte Treats First Patient in Phase II GVHD Study on Jakafi", "Two Key FDA Decisions to Watch Out for in January 2017", "3 Biotech Stocks That Turned $10,000 Into Over $100,000", "The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech", "Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead", "Incyte/Merus Ink Collaboration for Bispecific Antibodies", "Commit To Buy Incyte Corporation At $70, Earn 10.7% Using Options", "Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations", "Futures Mixed After Another Record-Setting Run for Dow and Nasdaq", "Christmas Came Early for These Biotech Stocks", "Close Update: Wall Street Retreats From Record Highs Leaving Dow 20,000 For Another Day", "Health Care Sector Update for 12/21/2016: ALXN,GILD,MRUS,INCY,MACK", "Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher", "Health Care Sector Update for 12/21/2016: CALA,BMY,MRUS,INCY,MACK", "Midday Update: Wall Street Retreats From Record Highs", "3 Biggest Risks for Incyte Corporation", "Could Geron Corporation Be a Millionaire-Maker Stock?", "Nasdaq 100 Movers: INCY, COST", "Nasdaq 100 Movers: INCY, WDC", "NASDAQ Composite Index closes up 24.11 points for the week, rising for the 4th straight day", "GW Pharmaceuticals PLC- ADR (GWPH) Stock Is Just Getting Started", "Gilead Sciences Inc.'s Worst Moves in 2016", "Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis", "3 Biotech Stocks to Buy in December", "3 Biotech Stocks to Buy on Sale", "Intellipharmaceutics Submits NDA for Pain Treatment Rexista", "Read This Before You Buy Any Marijuana Stocks", "Merck (MRK) Announces 2.2% Increase in Quarterly Dividend", "Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod", "When Will Gilead Sciences' Unlucky Streak End?", "Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors", "Ligand's Partner Retrophin Provides New Data on Sparsentan", "Aduro Reports Partial Hold Lift on LADD Studies in U.S.", "Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults", "Nasdaq 100 Movers: HSIC, NFLX", "New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day", "Endo Reports Positive Cellulite Treatment Data on Xiaflex", "Shire Launches Cuvitru in U.S. for Primary Immunodeficiency", "AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials", "Increased Earnings Estimates Seen for Incyte (INCY): Can It Move Higher?", "Gilead Reports Phase III Myelofibrosis Data on Momelotinib", "Bad News for Gilead Sciences Is Good News for Incyte", "Ionis (IONS) Offers Positive Interim Data on Lipid Candidate", "Celldex Stock Up on Positive Data on New Cancer Candidate", "Repros (RPRX) Reports Positive Top-Line Data on Proellex", "Incyte, Eli Lilly Offer Positive Phase III Data on Baricitinib", "3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise", "The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte", "INCY Crosses Above Average Analyst Target", "Drug Stocks Surge on Trump Win: 5 Stocks to Buy Now", "Why Incyte (INCY) Could Be a Potential Winner", "ARIAD (ARIA) Stock Up on Narrower-than-Expected Q3 Loss", "Nasdaq 100 Movers: LVNTA, BIIB", "3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results", "3 Highest Growth Stocks in the Market Today", "Gilead (GILD) Misses Q3 Earnings Estimates, Retains View", "The Waiting Game Sends Geron Corporation Lower by Another 18% in October", "Zoetis (ZTS) Tops Q3 Earnings Estimates, Updates Outlook", "Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y", "Market Close Report: NASDAQ Composite index closes at 5,153.58 down -35.56 points", "Noteworthy ETF Inflows: XBI, SRPT, TSRO, INCY", "BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus", "Market Close Report: NASDAQ Composite index closes at 5,046.37 down -12.04 points", "Agenus (AGEN) Reports Wider-than-Expected Loss in Q3", "Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook", "Bristol-Myers (BMY) Beats on Q3 Earnings, Ups 2016 View", "Zacks.com featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners", "Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View", "5 Profitable Stocks for Outstanding Returns", "Aduro Stock Down on Partial Clinical Hold on LADD Studies", "ARIAD (ARIA): Is a Beat in the Cards this Earnings Season?", "Agenus (AGEN): What's Ahead for the Stock in Q3 Earnings?", "Roche (RHHBY) Misses Q3 Sales Estimates, 2016 View Intact", "SPDR S&P Biotech ETF Experiences Big Outflow", "Roche's Tecentriq Wins FDA Nod for Additional Indication", "Abbott Labs (ABT) Beats on Q3 Earnings, Narrows 2016 View", "Regeneron & Teva Hit by Clinical Hold on Chronic Pain Study", "Shire (SHPG) Updates Vyvanse Label with New Efficacy Data", "Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates", "Intercept (ICPT) Ocaliva Wins Positive CHMP Opinion for PBC", "Celgene to Present Phase Ib Data on Crohn's Disease Drug", "Bristol-Myers Wins CHMP Nod for Opdivo Label Expansion", "Ocular's (OCUL) Stock Jumps on Collaboration with Regeneron", "BioMarin Issues Encouraging Update on Hemophilia A Drug", "Merck KGaA Offers Portfolio Updates at Market Day Event", "Horizon (HZNP) Stock Down on Dull Q3 View; Cuts '16 Outlook", "Nasdaq 100 Movers: INCY, MAT", "Mylan Up on EpiPen Medicaid Settlement, Cuts 2016 Outlook", "Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO", "3 Biotechs Most Likely to Be Acquired", "XBI, SRPT, IONS, INCY: Large Outflows Detected at ETF", "New Strong Buy Stocks for October 11th", "Will Gilead Sciences Inc. Set Its Sights on Incyte?", "Can the Rally in Incyte (INCY) Shares Continue?", "Alnylam (ALNY) to Continue Phase III Study on Patisiran", "Nasdaq 100 Movers: LBTYK, INCY", "These Are the Fastest Growing Profitable Biotech Stocks", "Market Close Report: NASDAQ Composite index closes at 5,292.41 down -14.44 points", "Nasdaq 100 Movers: TSLA, LRCX", "ARIAD (ARIA) Leukemia Drug Iclusig Gets Approval in Japan", "Nasdaq 100 Movers: PAYX, INCY", "Market Close Report: NASDAQ Composite index closes at 5,318.55 up 12.84 points", "10 Hot Stocks That Made Millionaires in 10 Years", "National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for September 28, 2016", "National Research Corporation (NRCIB) Ex-Dividend Date Scheduled for September 28, 2016", "Nasdaq 100 Movers: NTES, WDC", "3 Buyout Targets That Could Get Snatched Up", "Nasdaq 100 Movers: INCY, SWKS", "The Implied Analyst 12-Month Target For QQEW", "2 Companies Johnson & Johnson Should Consider Buying", "Wednesday's ETF with Unusual Volume: FTC", "CAR-T Isn't the Only Play in Immunotherapy Stocks", "CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up", "INCY Crosses Above Key Moving Average Level", "Nasdaq 100 Movers: INTU, INCY", "Nasdaq 100 Movers: MYL, AMAT", "Monday's ETF Movers: BBH, SIL", "Nasdaq 100 Movers: VIAB, INCY", "Notable ETF Outflow Detected - PBE, INCY, BMRN, REGN", "CAR-T Isn't the Only Play in Immunotherapy Stocks", "Add Up The Pieces: GURU Could Be Worth $27", "Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation", "Nasdaq 100 Movers: INCY, YHOO", "Why Ariad Pharmaceuticals Gained 26.9% in July", "Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline", "Nasdaq 100 Movers: NFLX, QVCA", "2 Cancer Therapy Stocks That Are Ridiculously Cheap Right Now", "Pre-Market Earnings Report for August 9, 2016 : CHTR, EXC, PPL, HCP, INCY, TDG, COH, LNG, WWAV, NCLH, BR, VRX", "Can TransDigm (TDG) Spring a Surprise in Q3 Earnings?", "What's in Store for Myriad Genetics (MYGN) in Q4 Earnings?", "BioDelivery (BDSI) Q2 Earnings: Will the Stock Disappoint?", "Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?", "Mylan (MYL) Q2 Earnings: Will the Stock Disappoint?", "Celldex (CLDX): What's Ahead for the Stock in Q2 Earnings?", "Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More", "Repros (RPRX) Q2 Earnings: What's in Store for the Stock?", "Kite (KITE) Q2 Earnings: What's in Store for the Stock?", "ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat", "Why Ariad Pharmaceuticals Shares Jumped 12.5% Today", "Nasdaq 100 Movers: AKAM, AAPL", "ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?", "Incyte Breaks Above 200-Day Moving Average - Bullish for INCY", "Allergan (AGN) Q2 Earnings: Will the Stock Disappoint?", "Is Agenus or Ariad Pharmaceuticals the Better Long-Term Buy?", "Nasdaq 100 Movers: NCLH, INCY", "Nasdaq 100 Movers: NXPI, CSX", "Better Buy: Alnylam Pharmaceuticals, Inc. vs. Incyte", "Nasdaq 100 Movers: AAL, ENDP", "Why Agenus' Stock Has Stumbled in 2016", "Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD", "Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain?", "Commit To Buy Incyte Corporation At $45, Earn 11.6% Using Options", "Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?", "Incyte's Jakafi Positive in Phase III for Polycythemia Study", "3 Reasons Ariad Pharmaceuticals Inc. Stock Rose 23.3% in May", "Incyte Reports Five-Year Data from Phase III Study on Jakafi", "Nasdaq 100 Movers: FAST, WFM", "4 Catalysts Send Incyte Corporation 17% Higher in May", "Incyte Reports Epacadostat Combination Study Initiation", "ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)", "Nasdaq 100 Movers: NCLH, AMZN", "The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma", "QQEW's Underlying Holdings Could Mean 19% Gain Potential", "Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More", "Pre-Market Earnings Report for May 9, 2016 : JD, XEL, TSN, HCP, INCY, QVCA, SLW, AES, LVNTA, STWD, ON, RBA", "Nasdaq 100 Movers: SBAC, ALXN", "Noteworthy Friday Option Activity: SRNE, INCY, BWLD", "Why Agenus Inc. Stock Soared 43% in March", "Could This Biotech Company Be About to Soar Higher?", "3 Big Battles Brewing in Biotech", "Last Week's Best Healthcare ETF", "Incyte Buys Rights to Jakafi for Graft-Versus-Host Disease", "Analysts Anticipate MTUM Will Reach $81", "This Deal Sent Incyte Shares Soaring 12% Today", "Vanguard Boosts Stake in Incyte in \u2013st Quarter", "Nasdaq 100 Movers: ENDP, INCY", "Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson", "Mid-Day Market Update: Crude Oil Down 2.8%; KB Home Shares Surge Following Strong Results", "Nasdaq 100 Movers: PYPL, INCY", "Nasdaq 100 Movers: NCLH, BMRN", "Nasdaq 100 Movers: REGN, WDC", "Agenus' Q4 Loss in Line with Estimates, Revenues Impress", "Better Buy: Juno Therapeutics vs. Incyte", "Nasdaq 100 Movers: ENDP, INCY", "Top Insider Trades of the Past Week", "The Zacks Analyst Blog Highlights: Incyte, Intercept Pharma, Gilead, Aegerion and Clovis", "Nasdaq 100 Movers: CERN, PCLN", "Biotech Stock Roundup: Incyte Down on Jakafi Update, Is Intercept a Buyout Target?", "Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation", "Incyte (INCY) Beats on Q4 Earnings and Revenue Estimates", "Frank Sands Acquires Stake in Netflix", "Why Incyte's Shares Are Tumbling Today", "Nasdaq 100 Movers: INCY, TRIP", "Mid-Morning Market Update: Markets Open Lower; PepsiCo Posts In-Line Q4 Profit", "Pre-Market Earnings Report for February 11, 2016 : PEP, RAI, TRI, K, TU, NLSN, TAP, INCY, CCE, AAP, BG, MOS", "VXF, LNKD, INCY, BMRN: ETF Outflow Alert", "Shares of Incyte Corporation Plummeted in January -- Here's Why", "Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention", "Mid-Day Market Update: Dow Drops Over 300 Points; Cisco Shares Surge Following Strong Q2 Results", "Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line", "Mid-Day Market Update: Facebook Surges On Strong Results; ServiceNow Shares Slip", "Notable ETF Inflow Detected - VXF, LNKD, INCY, BMRN", "Nasdaq 100 Movers: EBAY, FB", "Mid-Morning Market Update: Markets Open Higher; Ford Tops Q4 Views", "Why Incyte's Shares Crashed 12% Today", "Mid-Afternoon Market Update: Dow Rises Over 100 Points; eBay Shares Drop On Disappointing Outlook", "The Math Shows QQQ Can Go To $129", "Thursday's ETF Movers: OIH, FBT", "Nasdaq 100 Movers: INCY, SBAC", "Nasdaq 100 Movers: SNDK, MAT", "Nasdaq 100 Movers: SBUX, SBAC", "Why Shares of Agenus Are Breaking Out Today", "2 Speculative Small-Cap Biotech Stocks That Could Double", "What Makes Incyte (INCY) a Strong Sell?", "Incyte Halts Phase II Jakafi-Stivarga Combination Study", "Incyte Corporation (INCY) in Focus: Stock Plunges 11%", "Incyte (INCY) Provides Update on Pipeline Candidates", "Geron Corporation Exploded 49% Higher in 2015 -- Here's Why", "VXF, LNKD, INCY, BMRN: ETF Inflow Alert", "Nasdaq 100 Movers: BIDU, ILMN", "Nasdaq 100 Movers: STX, MAT", "PBE, BMRN, INCY, VRTX: Large Outflows Detected at ETF", "Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis", "VXF, ILMN, LNKD, INCY: Large Inflows Detected at ETF", "January 2018 Options Now Available For Incyte (INCY)", "Nasdaq 100 Movers: BMRN, JD", "Time Provides the Best Cure for Geron's Recent Weakness", "Nasdaq 100 Movers: WYNN, INCY", "Incyte Down on Data from Epacadostat Combination Study", "Incyte (INCY) Shares Cross Below 200 DMA", "Thursday's ETF Movers: GDX, BBH", "Incyte Q3 Loss Narrower than Expected, Ups Jakafi Outlook", "Nasdaq 100 Movers: VIP, GMCR", "Pre-Market Earnings Report for November 3, 2015 : EMR, ADM, SRE, MHFI, K, TRP, ZTS, INCY, FIS, S, HCP, NCLH", "Nasdaq 100 Movers: WYNN, SNDK", "5 Immunotherapy Stocks to Watch for Treating Cancer", "Why Incyte Corporation (INCY) Isn't Done Growing Earnings Yet", "Incyte & Merck Expand Melanoma Treatment Collaboration", "Why Incyte Corporation Shares Are Crashing Today", "Incyte Q3 Loss Narrower than Expected, Ups Jakafi Outlook", "Nasdaq 100 Movers: VIP, GMCR", "Pre-Market Earnings Report for November 3, 2015 : EMR, ADM, SRE, MHFI, K, TRP, ZTS, INCY, FIS, S, HCP, NCLH", "3 Reasons Why Incyte Corporation (INCY) is a Great Momentum Stock", "3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical", "Could CTI BioPharma's FDA Shortcut Spell Trouble for Incyte?", "After Hours Most Active for Oct 6, 2015 : YUM, ALTR, CSCO, INCY, ETE, MSFT, INTC, GE, OLN, BAC, CIE, QQQ", "Eli Lilly, Incyte's Baricitinib Scores in Phase III Study", "Incyte & Eli Lilly Post Positive Phase III Data on Baricitinib", "Biotech Stock Roundup: Pricing Concerns Hit Biotech Stocks, EU Nod for Regeneron's Praluent", "National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for September 28, 2015", "Aduro (ADRO) to Acquire BioNovion in Cash and Stock Deal", "Interesting INCY Put And Call Options For November 20th", "Could These 2 Biopharmas Be the Real Apples of Gilead Sciences' Eye?", "This Small-Cap Biotech Could Wind Up Devouring a Much Larger Foe's Revenue Stream", "Incyte (INCY) Shows Strength: Stock Adds 7.2% in Session", "Here's Why Geron Corporation's Stock Is Ripping Higher Today", "Incyte & Hengrui to Develop Anti-PD-1 Monoclonal Antibody", "Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying?", "Interesting INCY Put And Call Options For December 2016", "Why Incyte Corporation (INCY) Might Be a Diamond in the Rough", "Incyte Q2 Loss Narrower-than-Expected, Ups Jakafi Outlook - Analyst Blog", "Health Care Sector Update for 08/05/2015: ARIA, SCMP, INCY", "Aduro-Incyte in Clinical Trial Agreement for Ovarian Cancer", "Here's Why Geron Corporation's Stock Is Ripping Higher Today", "New Strong Sell Stocks for July 13th - Tale of the Tape", "National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for June 26, 2015", "What Caused Eli Lilly and Co. Shares to Vault Higher in May?", "Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog", "Why Shares in Advaxis, Inc. Are Surging Higher", "The Highest Paid CEOs in Biotech", "Pre-Market Earnings Report for August 4, 2015 : CVS, REGN, AET, EMR, ADM, SRE, ZTS, HCN, K, CHTR, INCY, HCP", "Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog", "3 Growth Stocks Near 52-Week Highs Worth Selling", "3 Stable Large-Cap Biotech Stocks to Buy Now - Analyst Blog", "Why Agenus Inc. Shares Surged Higher In Early Trading Today", "Why Agenus Inc. Shares Are Soaring Today", "FXH, INCY, UTHR, MDVN: Large Inflows Detected at ETF", "Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog", "Earnings Estimates Moving Higher for Incyte (INCY): Time to Buy? - Tale of the Tape", "The Reason Behind Geron Corporation's 25% Catapult Higher in March", "Why It's Not Too Late to Buy Agenus, Inc. Stock", "National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for March 27, 2015", "Novartis' Jakavi Gets EC Approval for Polycythemia Vera - Analyst Blog", "Commit To Purchase Incyte Corporation At $67.50, Earn 7% Annualized Using Options", "Why CTI BioPharma Corp Is Surging Higher Today", "Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog", "Monday's ETF Movers: XBI, GDXJ", "Should You Sell Incyte (INCY) Before Earnings? - Tale of the Tape", "3 All-or-Nothing Biotech Stocks We're Closely Watching", "Incyte's Phase III RESPONSE Data on Jakafi Published - Analyst Blog", "Will Incyte (INCY) Continue to Surge Higher? - Tale of the Tape", "AstraZeneca Inks Immuno-Oncology Agreement with Omnis - Analyst Blog", "Biotech Stock Roundup: Shire to Acquire NPSP, Celgene & Pharmacyclics Give Strong Outlook - Analyst Blog", "A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week", "Incyte Posts Wider-than-Expected Q4 Loss; Revenues Miss - Analyst Blog", "Agenus Soars on Immuno-Oncology Agreement with Incyte - Analyst Blog", "Midday Update: Stock Market Rally Stalls Following Anemic Wage Growth, More Energy Sector Losses", "US Stock Futures Edge Up After More Than Expected Jobs Added to Economy, Unemployment Drops to 5.6%", "US Futures Slip Ahead of Jobs Report", "AbbVie 2015 Earnings Guidance Projects Strong Y/Y Growth - Analyst Blog", "Closing Update: Stocks End Volatile Week Lower After Weak Wages Taint Strong Hiring Report", "Health Care Sector Update for 01/09/2015: AGEN,INCY,EDAP,CNAT", "Agenus (AGEN) Worth Watching: Stock Soars 28.7% - Tale of the Tape", "Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog", "Alexion Reports Disappointing Phase II Data on Soliris - Analyst Blog", "Biodel Posts Positive Preliminary Data on its Diabetes Drug - Analyst Blog", "Alkermes Soars on Positive Schizophrenia Drug Results - Analyst Blog", "Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog", "Gilead to Purchase Liver Disease Program from Phenex - Analyst Blog", "Celsion Submits Study Protocol for Oncology Candidate - Analyst Blog", "Why Shares of Agenus Inc Spiked", "Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog", "Akebia Progresses with Chronic Kidney Disease Candidate - Analyst Blog", "Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog", "Amgen Upgraded to Strong Buy; is it in Your Portfolio? - Analyst Blog", "Bull of the Day: Incyte (INCY) - Bull of the Day", "3 Biotech Stocks That Could Double in 2015", "National Research Corporation (NRCIA) Ex-Dividend Date Scheduled for December 29, 2014", "Salix CEO to Step Down, Inventory Issues Remain in Focus - Analyst Blog", "Incyte (INCY) Gains on Positive Baricitinib Study Results - Analyst Blog", "Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog", "Incyte's Jakafi Gets FDA Approval for Polycythemia Vera - Analyst Blog", "1 Big FDA Decision I'm Watching This Month", "After Hours Most Active for Nov 25, 2014 : HBAN, SIRI, INTC, SWKS, PGH, AAPL, INCY, BTU, HPQ, PFE, T, AVP", "Moving Average Crossover Alert: Incyte (INCY) - Tale of the Tape", "Incyte Building Blockbuster Drug One Disease At A Time", "National Research Corporation (NRCIB) Ex-Dividend Date Scheduled for December 29, 2014", "Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape", "Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog", "Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog", "Incyte Breaks Above 200-Day Moving Average - Bullish for INCY", "Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update - Analyst Blog", "Incyte Receives $60M Milestone Payment Related to Jakavi - Analyst Blog", "Earnings Estimates Moving Higher for Incyte Corporation (INCY): Time to Buy? - Tale of the Tape", "Biotech: And Yet We've Just Begun...", "ETF Outlook: SPDR S&P Biotech ETF (XBI)", "Incyte Posts Wider-than-Expected Q2 Loss, Raises Sales View - Analyst Blog", "Incyte's Jakafi Fails to Provide RELIEF in Polycythemia Vera - Analyst Blog", "Incyte (INCY) Enters Oversold Territory - Tale of the Tape", "Incyte Earns Milestone Payment on Japanese Approval of Jakavi - Analyst Blog", "Moving Average Crossover Alert: Incyte (INCY) - Tale of the Tape", "Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog", "Bullish Two Hundred Day Moving Average Cross - INCY", "Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN", "Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO - Analyst Blog", "Incyte Gains on Positive Jakafi Data - Analyst Blog", "Data on Incyte's Jakafi - Analyst Blog", "INCY Makes Notable Cross Below Critical Moving Average", "Incyte Joins Forces with Bristol-Myers - Analyst Blog", "Interesting INCY Put And Call Options For July 19th", "Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.", "Celldex Gains on Bristol-Myers Squibb Deal - Analyst Blog", "Thursday's ETF Movers: BSCF, FBT", "Wider-than-Expected Q1 Loss at Incyte - Analyst Blog", "Sector Update: Healthcare Shares Lower Pre-Market; Mylan Q1 Earnings Top Street View", "Sector Update: Healthcare", "Incyte Breaks Below 200-Day Moving Average - Notable for INCY", "Update on Merck's MK-3475 - Analyst Blog", "Incyte to Collaborate with AstraZeneca - Analyst Blog", "Friday's ETF Movers: GXC, BBH", "Positive Data on Novartis' Jakavi - Analyst Blog", "First Trust Health Care AlphaDEX Fund Experiences Big Inflow", "Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines ...", "Wider-than-Expected Q4 Loss at Incyte - Analyst Blog", "First Trust Health Care AlphaDEX Fund Experiences Big Inflow", "Stocks Scream for Yellen", "Bear of the Day: Genomic Health (GHDX) - Bear of the Day", "Friday's ETF Movers: GXC, BBH", "Incyte Reiterated at Neutral - Analyst Blog", "Incyte Corporation (INCY): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report", "Positive Data on Incyte's Jakafi - Analyst Blog", "Incyte's Q3 Loss in Line - Analyst Blog", "4 Pharma Stocks Set to Deliver Earnings Surprises - Earnings ESP", "Incyte Progresses with JAK Inhibitors - Analyst Blog", "Pre-Market Earnings Report for February 12, 2014 : DE, TRI, LO, RCI, INCY, DPS, HSP, VAL, OC, SPW, TWTC, WCG", "Sector Update: Healthcare", "Bear of the Day: Genomic Health (GHDX) - Bear of the Day", "Maxygen, Inc. (MAXY) Ex-Dividend Date Scheduled for August 30, 2013", "Incyte Soars on Positive Jakafi Data - Analyst Blog", "New Stock Coverage: Time to Hit the Brakes on Tesla Motors Inc?", "Sector Update: Healthcare Lower Pre-Market; Incyte Up 22% on Phase II Results of Ruxolintinib", "Pre-Market Most Active for Aug 21, 2013 : SPLS, CODE, TGT, LOW, NOK, AEO, INCY, BAC, FB, AAPL, QQQ, TSLA", "Sector Update: Healthcare Stocks Flat; Incyte Psoriasis Drug Show Effective in Phase 2 Study", "Benzinga Market Wrap For August 21: FOMC Minutes Send Markets Spinning", "Earnings Miss at Incyte in Q2 - Analyst Blog", "BioMarin Files Vimizim MA in Brazil - Analyst Blog", "Positive Data on Novartis' Jakavi - Analyst Blog", "Positive Data on Incyte's Jakafi - Analyst Blog", "Positive Data on Incyte/LLY's Baricitinib - Analyst Blog", "Incyte's Jakafi Label Updated - Analyst Blog", "Sector Update: Healthcare", "Incyte Reveals Data on Oncology Candidate - Analyst Blog", "After Hours Most Active for May 30, 2013 : FCX, HPQ, MSFT, DPZ, MRK, PFE, PXP, INTC, SIRI, QQQ, VMED, INCY", "Alnylam Narrows Loss, Sales Fall - Analyst Blog", "Arena Pharma Narrows Loss - Analyst Blog", "Narrower-Than-Expected Loss at Incyte - Analyst Blog", "Optimer's Dificid Cleared Down Under - Analyst Blog", "BioMarin Widens Loss, Maintains View - Analyst Blog", "Incyte Presents Positive Jakafi Data - Analyst Blog", "Incyte Reveals Data on Oncology Candidate - Analyst Blog", "National Research Corporation (NRCI) Ex-Dividend Date Scheduled for February 14, 2013", "Update on Lilly's Tabalumab - Analyst Blog", "Incyte Pharmaceuticals Is Primed For A Run", "Eli Lilly Scraps a Phase III Study - Analyst Blog", "Novartis Presents Jakavi Data - Analyst Blog", "Mid-Day Market Update: Markets Trim Losses, Incyte Drops", "Incyte Progresses on RA Candidate - Analyst Blog", "Incyte Narrows Loss - Analyst Blog", "Novartis' Jakavi Gains EU Approval - Analyst Blog", "Incyte Corp. Enters Oversold Territory - Tale of the Tape", "Revenues Rise at Incyte - Analyst Blog", "After Hours Most Active for Aug 2, 2012 : SD, KCG, NOK, BAC, ORCL, ITUB, JPM, FB, QQQ, AAPL, INCY, ONNN", "Incyte Stays Neutral - Analyst Blog", "NVS Discusses Data Readout Plans - Analyst Blog", "After Hours Most Active for Apr 30, 2012 : PFE, SVU, LLY, EXC, SO, AEP, INCY, ACAS, ERIC, MSFT, CSCO, INTC", "Loss at Incyte Widens on Higher Costs - Analyst Blog", "Incyte Upped to Neutral - Analyst Blog", "Complex trade used as Incyte hedge", "Incyte Cut to Underperform - Analyst Blog", "Drab Quarter at Incyte, Shares Down - Analyst Blog", "Incyte in Neutral Lane - Analyst Blog", "Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE", "Incyte Drug Cleared in the US - Analyst Blog", "Bears target Incyte before FDA ruling", "Exelixis: Setting The Facts Straight", "10 Biotech Stocks Trading at Deep Discounts to Analyst Target Prices", "Pfizer Poised to Introduce Blockbuster Arthritis Pill", "The Cancer Conference Trade: Picking Up Biotech Bargains", "The Top 20 Most Undervalued Healthcare Stocks By Target Price", "Five ETFs that started 2012 strong"], "Elapsed Time": ["4 DAYS AGO", "JUN 3, 2020", "JUN 3, 2020", "JUN 2, 2020", "JUN 1, 2020", "MAY 26, 2020", "MAY 21, 2020", "MAY 20, 2020", "4 DAYS AGO", "MAY 17, 2020", "MAY 15, 2020", "MAY 15, 2020", "MAY 15, 2020", "MAY 14, 2020", "MAY 7, 2020", "MAY 7, 2020", "MAY 19, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "MAY 5, 2020", "APR 29, 2020", "MAY 6, 2020", "APR 24, 2020", "APR 23, 2020", "APR 20, 2020", "APR 20, 2020", "APR 19, 2020", "APR 16, 2020", "APR 15, 2020", "APR 28, 2020", "APR 7, 2020", "APR 6, 2020", "APR 3, 2020", "APR 3, 2020", "APR 3, 2020", "APR 2, 2020", "MAR 27, 2020", "APR 13, 2020", "MAR 15, 2020", "MAR 12, 2020", "MAR 4, 2020", "MAR 3, 2020", "MAR 2, 2020", "MAR 2, 2020", "FEB 23, 2020", "MAR 15, 2020", "FEB 19, 2020", "FEB 19, 2020", "FEB 16, 2020", "FEB 16, 2020", "FEB 14, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 19, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 13, 2020", "FEB 12, 2020", "FEB 11, 2020", "FEB 11, 2020", "FEB 13, 2020", "FEB 7, 2020", "FEB 7, 2020", "JAN 31, 2020", "JAN 30, 2020", "JAN 30, 2020", "JAN 28, 2020", "JAN 27, 2020", "FEB 10, 2020", "JAN 23, 2020", "JAN 22, 2020", "JAN 19, 2020", "JAN 19, 2020", "JAN 15, 2020", "JAN 15, 2020", "JAN 14, 2020", "JAN 27, 2020", "JAN 13, 2020", "JAN 9, 2020", "JAN 7, 2020", "JAN 4, 2020", "JAN 3, 2020", "JAN 3, 2020", "JAN 3, 2020", "JAN 14, 2020", "JAN 3, 2020", "JAN 3, 2020", "JAN 2, 2020", "DEC 29, 2019", "DEC 28, 2019", "DEC 28, 2019", "DEC 26, 2019", "JAN 3, 2020", "DEC 15, 2019", "DEC 14, 2019", "DEC 4, 2019", "DEC 4, 2019", "DEC 2, 2019", "NOV 25, 2019", "NOV 25, 2019", "DEC 19, 2019", "NOV 12, 2019", "NOV 7, 2019", "OCT 29, 2019", "OCT 29, 2019", "OCT 29, 2019", "OCT 29, 2019", "OCT 29, 2019", "NOV 13, 2019", "OCT 27, 2019", "OCT 26, 2019", "OCT 22, 2019", "OCT 22, 2019", "OCT 10, 2019", "OCT 7, 2019", "SEP 23, 2019", "OCT 29, 2019", "SEP 18, 2019", "SEP 18, 2019", "SEP 17, 2019", "SEP 17, 2019", "SEP 16, 2019", "SEP 9, 2019", "SEP 4, 2019", "SEP 20, 2019", "AUG 29, 2019", "AUG 28, 2019", "AUG 18, 2019", "AUG 8, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 30, 2019", "SEP 4, 2019", "JUL 30, 2019", "JUL 30, 2019", "JUL 23, 2019", "JUN 26, 2019", "JUN 24, 2019", "JUN 17, 2019", "JUN 17, 2019", "JUL 30, 2019", "JUN 13, 2019", "MAY 24, 2019", "APR 30, 2019", "APR 30, 2019", "APR 30, 2019", "APR 30, 2019", "APR 29, 2019", "JUN 17, 2019", "APR 15, 2019", "APR 15, 2019", "APR 12, 2019", "APR 12, 2019", "APR 12, 2019", "APR 10, 2019", "APR 3, 2019", "APR 25, 2019", "APR 3, 2019", "APR 3, 2019", "MAR 16, 2019", "MAR 14, 2019", "MAR 13, 2019", "MAR 5, 2019", "FEB 27, 2019", "APR 3, 2019", "FEB 26, 2019", "FEB 21, 2019", "FEB 20, 2019", "FEB 19, 2019", "FEB 18, 2019", "FEB 14, 2019", "FEB 14, 2019", "FEB 27, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 13, 2019", "FEB 12, 2019", "FEB 12, 2019", "FEB 11, 2019", "FEB 11, 2019", "FEB 14, 2019", "FEB 11, 2019", "FEB 8, 2019", "FEB 5, 2019", "FEB 4, 2019", "JAN 29, 2019", "JAN 28, 2019", "JAN 28, 2019", "FEB 11, 2019", "JAN 23, 2019", "JAN 22, 2019", "JAN 15, 2019", "JAN 15, 2019", "JAN 15, 2019", "JAN 14, 2019", "JAN 10, 2019", "JAN 25, 2019", "JAN 7, 2019", "JAN 4, 2019", "JAN 4, 2019", "JAN 3, 2019", "JAN 3, 2019", "JAN 3, 2019", "JAN 3, 2019", "JAN 8, 2019", "JAN 3, 2019", "DEC 31, 2018", "DEC 31, 2018", "DEC 21, 2018", "DEC 20, 2018", "DEC 19, 2018", "DEC 18, 2018", "JAN 3, 2019", "DEC 17, 2018", "DEC 14, 2018", "DEC 12, 2018", "DEC 12, 2018", "DEC 10, 2018", "DEC 10, 2018", "DEC 7, 2018", "DEC 18, 2018", "DEC 3, 2018", "NOV 29, 2018", "NOV 28, 2018", "NOV 19, 2018", "NOV 15, 2018", "NOV 12, 2018", "NOV 8, 2018", "DEC 4, 2018", "NOV 1, 2018", "NOV 1, 2018", "OCT 30, 2018", "OCT 30, 2018", "OCT 30, 2018", "OCT 30, 2018", "OCT 28, 2018", "NOV 2, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 24, 2018", "OCT 11, 2018", "OCT 8, 2018", "OCT 8, 2018", "OCT 4, 2018", "OCT 24, 2018", "SEP 29, 2018", "SEP 28, 2018", "SEP 21, 2018", "SEP 21, 2018", "SEP 21, 2018", "SEP 18, 2018", "SEP 14, 2018", "OCT 4, 2018", "SEP 12, 2018", "SEP 12, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 11, 2018", "SEP 6, 2018", "SEP 5, 2018", "SEP 13, 2018", "AUG 30, 2018", "AUG 28, 2018", "AUG 23, 2018", "AUG 21, 2018", "AUG 20, 2018", "AUG 15, 2018", "AUG 15, 2018", "SEP 5, 2018", "AUG 14, 2018", "AUG 10, 2018", "AUG 6, 2018", "AUG 2, 2018", "AUG 1, 2018", "JUL 31, 2018", "JUL 31, 2018", "AUG 14, 2018", "JUL 27, 2018", "JUL 26, 2018", "JUL 20, 2018", "JUL 19, 2018", "JUL 19, 2018", "JUL 19, 2018", "JUL 3, 2018", "JUL 30, 2018", "JUN 27, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 26, 2018", "JUN 22, 2018", "JUN 15, 2018", "JUL 3, 2018", "JUN 8, 2018", "JUN 6, 2018", "JUN 4, 2018", "JUN 1, 2018", "MAY 31, 2018", "MAY 31, 2018", "MAY 25, 2018", "JUN 10, 2018", "MAY 16, 2018", "MAY 12, 2018", "MAY 7, 2018", "MAY 1, 2018", "MAY 1, 2018", "MAY 1, 2018", "APR 30, 2018", "MAY 18, 2018", "APR 30, 2018", "APR 27, 2018", "APR 25, 2018", "APR 25, 2018", "APR 25, 2018", "APR 24, 2018", "APR 24, 2018", "APR 30, 2018", "APR 24, 2018", "APR 24, 2018", "APR 24, 2018", "APR 20, 2018", "APR 20, 2018", "APR 16, 2018", "APR 16, 2018", "APR 24, 2018", "APR 13, 2018", "APR 12, 2018", "APR 12, 2018", "APR 12, 2018", "APR 11, 2018", "APR 11, 2018", "APR 9, 2018", "APR 16, 2018", "APR 9, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 9, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 6, 2018", "APR 2, 2018", "APR 6, 2018", "MAR 31, 2018", "MAR 29, 2018", "MAR 29, 2018", "MAR 29, 2018", "MAR 28, 2018", "MAR 19, 2018", "MAR 18, 2018", "APR 1, 2018", "MAR 9, 2018", "MAR 8, 2018", "MAR 1, 2018", "FEB 28, 2018", "FEB 28, 2018", "FEB 26, 2018", "FEB 21, 2018", "MAR 13, 2018", "MAR 9, 2018", "FEB 20, 2018", "FEB 19, 2018", "FEB 16, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 21, 2018", "FEB 14, 2018", "FEB 14, 2018", "FEB 12, 2018", "FEB 9, 2018", "FEB 6, 2018", "FEB 2, 2018", "JAN 31, 2018", "FEB 14, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 29, 2018", "JAN 26, 2018", "JAN 24, 2018", "JAN 22, 2018", "JAN 18, 2018", "JAN 31, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 17, 2018", "JAN 16, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 12, 2018", "JAN 18, 2018", "JAN 11, 2018", "JAN 11, 2018", "JAN 10, 2018", "JAN 9, 2018", "JAN 8, 2018", "JAN 7, 2018", "JAN 7, 2018", "JAN 12, 2018", "JAN 3, 2018", "JAN 2, 2018", "JAN 2, 2018", "JAN 2, 2018", "DEC 22, 2017", "DEC 22, 2017", "DEC 21, 2017", "JAN 5, 2018", "JAN 3, 2018", "DEC 18, 2017", "DEC 15, 2017", "DEC 14, 2017", "DEC 13, 2017", "DEC 12, 2017", "DEC 11, 2017", "DEC 19, 2017", "DEC 5, 2017", "DEC 4, 2017", "DEC 4, 2017", "NOV 30, 2017", "NOV 30, 2017", "NOV 28, 2017", "NOV 27, 2017", "DEC 11, 2017", "NOV 20, 2017", "NOV 16, 2017", "NOV 9, 2017", "NOV 8, 2017", "NOV 1, 2017", "NOV 1, 2017", "NOV 1, 2017", "NOV 20, 2017", "OCT 30, 2017", "OCT 30, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 27, 2017", "OCT 25, 2017", "OCT 31, 2017", "OCT 25, 2017", "OCT 24, 2017", "OCT 24, 2017", "OCT 18, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 16, 2017", "OCT 25, 2017", "OCT 12, 2017", "OCT 11, 2017", "OCT 10, 2017", "OCT 6, 2017", "OCT 3, 2017", "SEP 29, 2017", "SEP 28, 2017", "OCT 12, 2017", "SEP 28, 2017", "SEP 27, 2017", "SEP 26, 2017", "SEP 25, 2017", "SEP 24, 2017", "SEP 22, 2017", "SEP 21, 2017", "SEP 28, 2017", "SEP 21, 2017", "SEP 19, 2017", "SEP 18, 2017", "SEP 15, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 8, 2017", "SEP 21, 2017", "SEP 6, 2017", "SEP 1, 2017", "SEP 1, 2017", "SEP 1, 2017", "AUG 31, 2017", "AUG 31, 2017", "AUG 31, 2017", "SEP 7, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 30, 2017", "AUG 29, 2017", "AUG 24, 2017", "AUG 30, 2017", "AUG 22, 2017", "AUG 19, 2017", "AUG 13, 2017", "AUG 11, 2017", "AUG 2, 2017", "AUG 1, 2017", "AUG 1, 2017", "AUG 23, 2017", "JUL 26, 2017", "JUL 25, 2017", "JUL 25, 2017", "JUL 21, 2017", "JUL 20, 2017", "JUL 19, 2017", "JUL 17, 2017", "JUL 26, 2017", "JUL 10, 2017", "JUL 4, 2017", "JUL 2, 2017", "JUN 30, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUN 29, 2017", "JUL 15, 2017", "JUN 26, 2017", "JUN 22, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 21, 2017", "JUN 19, 2017", "JUN 28, 2017", "JUN 17, 2017", "JUN 16, 2017", "JUN 16, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 9, 2017", "JUN 8, 2017", "JUN 18, 2017", "JUN 6, 2017", "JUN 5, 2017", "JUN 5, 2017", "JUN 5, 2017", "MAY 30, 2017", "MAY 30, 2017", "MAY 26, 2017", "JUN 7, 2017", "MAY 26, 2017", "MAY 23, 2017", "MAY 19, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 26, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 18, 2017", "MAY 17, 2017", "MAY 12, 2017", "MAY 11, 2017", "MAY 11, 2017", "MAY 18, 2017", "MAY 8, 2017", "MAY 8, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 5, 2017", "MAY 4, 2017", "MAY 8, 2017", "MAY 3, 2017", "MAY 2, 2017", "MAY 1, 2017", "APR 29, 2017", "APR 26, 2017", "APR 25, 2017", "APR 21, 2017", "MAY 3, 2017", "APR 20, 2017", "APR 19, 2017", "APR 19, 2017", "APR 18, 2017", "APR 18, 2017", "APR 17, 2017", "APR 17, 2017", "APR 21, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 17, 2017", "APR 13, 2017", "APR 13, 2017", "APR 12, 2017", "APR 12, 2017", "APR 17, 2017", "APR 10, 2017", "APR 10, 2017", "APR 7, 2017", "APR 7, 2017", "APR 7, 2017", "APR 7, 2017", "APR 7, 2017", "APR 10, 2017", "APR 6, 2017", "APR 5, 2017", "APR 4, 2017", "APR 3, 2017", "APR 3, 2017", "APR 3, 2017", "APR 3, 2017", "APR 6, 2017", "APR 2, 2017", "APR 2, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 31, 2017", "MAR 30, 2017", "MAR 30, 2017", "APR 3, 2017", "MAR 24, 2017", "MAR 23, 2017", "MAR 23, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 17, 2017", "MAR 16, 2017", "MAR 30, 2017", "MAR 15, 2017", "MAR 15, 2017", "MAR 13, 2017", "MAR 10, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 16, 2017", "MAR 8, 2017", "MAR 3, 2017", "FEB 28, 2017", "FEB 28, 2017", "FEB 27, 2017", "FEB 27, 2017", "FEB 24, 2017", "MAR 9, 2017", "FEB 24, 2017", "FEB 24, 2017", "FEB 22, 2017", "FEB 22, 2017", "FEB 16, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 24, 2017", "FEB 15, 2017", "FEB 15, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 14, 2017", "FEB 15, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 13, 2017", "FEB 12, 2017", "FEB 10, 2017", "FEB 10, 2017", "FEB 13, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 9, 2017", "FEB 8, 2017", "FEB 8, 2017", "FEB 3, 2017", "FEB 2, 2017", "FEB 9, 2017", "FEB 1, 2017", "JAN 31, 2017", "JAN 31, 2017", "JAN 30, 2017", "JAN 30, 2017", "JAN 30, 2017", "JAN 30, 2017", "FEB 1, 2017", "JAN 30, 2017", "JAN 30, 2017", "JAN 30, 2017", "JAN 26, 2017", "JAN 25, 2017", "JAN 25, 2017", "JAN 23, 2017", "JAN 30, 2017", "JAN 20, 2017", "JAN 17, 2017", "JAN 16, 2017", "JAN 12, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 20, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 9, 2017", "JAN 8, 2017", "JAN 6, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 10, 2017", "JAN 3, 2017", "JAN 2, 2017", "JAN 2, 2017", "DEC 31, 2016", "DEC 28, 2016", "DEC 27, 2016", "DEC 22, 2016", "JAN 3, 2017", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 17, 2016", "DEC 12, 2016", "DEC 8, 2016", "DEC 7, 2016", "DEC 7, 2016", "DEC 6, 2016", "DEC 6, 2016", "DEC 19, 2016", "DEC 1, 2016", "NOV 29, 2016", "NOV 28, 2016", "NOV 26, 2016", "NOV 24, 2016", "NOV 23, 2016", "NOV 23, 2016", "DEC 1, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 18, 2016", "NOV 18, 2016", "NOV 17, 2016", "NOV 23, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 17, 2016", "NOV 16, 2016", "NOV 15, 2016", "NOV 15, 2016", "NOV 15, 2016", "NOV 17, 2016", "NOV 11, 2016", "NOV 10, 2016", "NOV 10, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 7, 2016", "NOV 7, 2016", "NOV 11, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 2, 2016", "NOV 1, 2016", "OCT 28, 2016", "OCT 28, 2016", "NOV 4, 2016", "OCT 28, 2016", "OCT 27, 2016", "OCT 27, 2016", "OCT 26, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 25, 2016", "OCT 28, 2016", "OCT 24, 2016", "OCT 21, 2016", "OCT 20, 2016", "OCT 19, 2016", "OCT 19, 2016", "OCT 18, 2016", "OCT 18, 2016", "OCT 25, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 17, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 14, 2016", "OCT 12, 2016", "OCT 17, 2016", "OCT 12, 2016", "OCT 12, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 11, 2016", "OCT 10, 2016", "OCT 10, 2016", "OCT 12, 2016", "OCT 7, 2016", "OCT 7, 2016", "OCT 7, 2016", "OCT 6, 2016", "SEP 30, 2016", "SEP 28, 2016", "SEP 28, 2016", "OCT 10, 2016", "SEP 27, 2016", "SEP 27, 2016", "SEP 26, 2016", "SEP 21, 2016", "SEP 15, 2016", "SEP 15, 2016", "SEP 9, 2016", "SEP 28, 2016", "SEP 7, 2016", "AUG 30, 2016", "AUG 24, 2016", "AUG 24, 2016", "AUG 23, 2016", "AUG 22, 2016", "AUG 22, 2016", "SEP 8, 2016", "SEP 7, 2016", "AUG 15, 2016", "AUG 11, 2016", "AUG 11, 2016", "AUG 10, 2016", "AUG 10, 2016", "AUG 8, 2016", "AUG 18, 2016", "AUG 8, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 5, 2016", "AUG 4, 2016", "AUG 8, 2016", "AUG 4, 2016", "AUG 4, 2016", "JUL 29, 2016", "JUL 28, 2016", "JUL 27, 2016", "JUL 26, 2016", "JUL 21, 2016", "AUG 4, 2016", "JUL 19, 2016", "JUL 15, 2016", "JUL 14, 2016", "JUL 7, 2016", "JUL 6, 2016", "JUN 27, 2016", "JUN 24, 2016", "JUL 21, 2016", "JUN 21, 2016", "JUN 14, 2016", "JUN 10, 2016", "JUN 9, 2016", "JUN 7, 2016", "JUN 6, 2016", "JUN 3, 2016", "JUN 23, 2016", "MAY 11, 2016", "MAY 10, 2016", "MAY 9, 2016", "MAY 9, 2016", "MAY 6, 2016", "MAY 6, 2016", "MAY 3, 2016", "MAY 20, 2016", "APR 11, 2016", "APR 10, 2016", "APR 10, 2016", "APR 8, 2016", "APR 7, 2016", "APR 7, 2016", "APR 6, 2016", "MAY 3, 2016", "MAR 31, 2016", "MAR 31, 2016", "MAR 24, 2016", "MAR 24, 2016", "MAR 22, 2016", "MAR 9, 2016", "MAR 4, 2016", "MAR 31, 2016", "FEB 20, 2016", "FEB 20, 2016", "FEB 18, 2016", "FEB 17, 2016", "FEB 17, 2016", "FEB 16, 2016", "FEB 12, 2016", "FEB 24, 2016", "FEB 11, 2016", "FEB 11, 2016", "FEB 11, 2016", "FEB 10, 2016", "FEB 8, 2016", "FEB 7, 2016", "FEB 3, 2016", "FEB 11, 2016", "JAN 31, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "JAN 28, 2016", "FEB 3, 2016", "JAN 28, 2016", "JAN 26, 2016", "JAN 25, 2016", "JAN 22, 2016", "JAN 21, 2016", "JAN 21, 2016", "JAN 20, 2016", "JAN 28, 2016", "JAN 14, 2016", "JAN 13, 2016", "JAN 11, 2016", "DEC 28, 2015", "DEC 24, 2015", "DEC 14, 2015", "DEC 10, 2015", "JAN 20, 2016", "NOV 18, 2015", "NOV 16, 2015", "NOV 12, 2015", "NOV 11, 2015", "NOV 9, 2015", "NOV 9, 2015", "NOV 6, 2015", "DEC 3, 2015", "NOV 4, 2015", "NOV 3, 2015", "NOV 2, 2015", "OCT 19, 2015", "OCT 16, 2015", "OCT 14, 2015", "OCT 14, 2015", "NOV 6, 2015", "NOV 4, 2015", "NOV 3, 2015", "OCT 9, 2015", "OCT 7, 2015", "OCT 7, 2015", "OCT 6, 2015", "OCT 6, 2015", "OCT 14, 2015", "SEP 30, 2015", "SEP 30, 2015", "SEP 25, 2015", "SEP 25, 2015", "SEP 23, 2015", "SEP 17, 2015", "SEP 11, 2015", "OCT 5, 2015", "SEP 3, 2015", "SEP 3, 2015", "AUG 17, 2015", "AUG 14, 2015", "AUG 11, 2015", "AUG 5, 2015", "AUG 5, 2015", "SEP 11, 2015", "SEP 3, 2015", "JUL 13, 2015", "JUN 25, 2015", "JUN 4, 2015", "JUN 4, 2015", "JUN 1, 2015", "MAY 30, 2015", "AUG 3, 2015", "MAY 4, 2015", "MAY 1, 2015", "APR 29, 2015", "APR 28, 2015", "APR 24, 2015", "APR 22, 2015", "APR 22, 2015", "MAY 27, 2015", "APR 9, 2015", "MAR 31, 2015", "MAR 26, 2015", "MAR 18, 2015", "MAR 11, 2015", "MAR 9, 2015", "FEB 24, 2015", "APR 13, 2015", "FEB 12, 2015", "FEB 9, 2015", "JAN 29, 2015", "JAN 28, 2015", "JAN 14, 2015", "JAN 14, 2015", "JAN 13, 2015", "FEB 13, 2015", "JAN 12, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 9, 2015", "JAN 12, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 8, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 7, 2015", "JAN 9, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 6, 2015", "JAN 5, 2015", "JAN 2, 2015", "DEC 29, 2014", "DEC 26, 2014", "JAN 6, 2015", "DEC 10, 2014", "DEC 9, 2014", "DEC 5, 2014", "DEC 4, 2014", "NOV 25, 2014", "NOV 21, 2014", "NOV 17, 2014", "DEC 26, 2014", "OCT 31, 2014", "OCT 31, 2014", "OCT 29, 2014", "OCT 23, 2014", "OCT 8, 2014", "OCT 6, 2014", "AUG 27, 2014", "NOV 14, 2014", "AUG 13, 2014", "AUG 1, 2014", "JUL 24, 2014", "JUL 16, 2014", "JUL 9, 2014", "JUL 2, 2014", "JUN 12, 2014", "AUG 25, 2014", "JUN 8, 2014", "JUN 4, 2014", "JUN 4, 2014", "JUN 3, 2014", "JUN 2, 2014", "MAY 28, 2014", "MAY 20, 2014", "JUN 9, 2014", "MAY 15, 2014", "MAY 15, 2014", "MAY 2, 2014", "MAY 1, 2014", "MAY 1, 2014", "APR 14, 2014", "APR 8, 2014", "MAY 15, 2014", "MAR 21, 2014", "MAR 10, 2014", "FEB 24, 2014", "FEB 24, 2014", "FEB 13, 2014", "FEB 11, 2014", "FEB 11, 2014", "APR 3, 2014", "MAR 21, 2014", "JAN 7, 2014", "JAN 6, 2014", "DEC 10, 2013", "NOV 1, 2013", "OCT 22, 2013", "OCT 7, 2013", "FEB 11, 2014", "OCT 3, 2013", "OCT 3, 2013", "AUG 29, 2013", "AUG 22, 2013", "AUG 22, 2013", "AUG 21, 2013", "AUG 21, 2013", "OCT 3, 2013", "AUG 21, 2013", "AUG 2, 2013", "JUL 5, 2013", "JUN 18, 2013", "JUN 18, 2013", "JUN 14, 2013", "JUN 13, 2013", "AUG 21, 2013", "JUN 4, 2013", "MAY 30, 2013", "MAY 7, 2013", "MAY 6, 2013", "MAY 3, 2013", "MAY 1, 2013", "APR 29, 2013", "JUN 5, 2013", "JUN 4, 2013", "FEB 12, 2013", "FEB 11, 2013", "FEB 5, 2013", "DEC 17, 2012", "DEC 12, 2012", "MAR 18, 2013", "NOV 20, 2012", "NOV 6, 2012", "AUG 28, 2012", "AUG 10, 2012", "AUG 6, 2012", "AUG 2, 2012", "MAY 24, 2012", "NOV 29, 2012", "APR 30, 2012", "APR 30, 2012", "MAR 26, 2012", "MAR 9, 2012", "FEB 24, 2012", "FEB 16, 2012", "FEB 10, 2012", "MAY 14, 2012", "NOV 17, 2011", "NOV 8, 2011", "NOV 7, 2011", "OCT 31, 2011", "SEP 11, 2011", "JUL 21, 2011", "JAN 14, 2011", "JAN 31, 2012"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/incyte-to-present-at-goldman-sachs-global-healthcare-conference-webcast-at-8%3A00-am-et-2020", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-atvi-mchp-2020-06-03", "https://www.nasdaq.com/articles/sp-500-movers%3A-nem-mchp-2020-06-03", "https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-rpg-ftnt-payc-incy-2020-06-02", "https://www.nasdaq.com/articles/incy-crosses-above-average-analyst-target-2020-06-01", "https://www.nasdaq.com/articles/notable-tuesday-option-activity%3A-clx-incy-fcx-2020-05-26", "https://www.nasdaq.com/articles/october-16th-options-now-available-for-incyte-incy-2020-05-21", "https://www.nasdaq.com/articles/morphosys-announce-validation-of-ema-application-for-tafasitamab-2020-05-20", "https://www.nasdaq.com/articles/incyte-to-present-at-goldman-sachs-global-healthcare-conference-webcast-at-8%3A00-am-et-2020", "https://www.nasdaq.com/articles/why-gileads-remdesivir-might-not-be-the-mega-moneymaker-some-think-it-will-be-2020-05-17", "https://www.nasdaq.com/articles/why-geron-stock-soared-23.4-today-2020-05-15", "https://www.nasdaq.com/articles/first-week-of-incy-july-17th-options-trading-2020-05-15", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-ibb-ilmn-alxn-incy-2020-05-15", "https://www.nasdaq.com/articles/morphosys-%3A-long-term-data-from-l-mind-study-confirms-primary-analysis-results-2020-05-14", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-oil-stocks-airlines-peloton-paypal-2020-05-07", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-lyft-livongo-health-tonix-pharma-2020-05-07", "https://www.nasdaq.com/articles/incyte-to-present-at-rbc-capital-healthcare-conference-webcast-at-3%3A05-pm-et-2020-05-19", "https://www.nasdaq.com/articles/incyte-corp-incy-q1-2020-earnings-call-transcript-2020-05-06", "https://www.nasdaq.com/articles/why-incytes-q1-loss-isnt-as-bad-as-it-looks-2020-05-05", "https://www.nasdaq.com/articles/incyte-reports-a-q1-loss-due-to-morphosys-deal-2020-05-05", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-alxn-swks-2020-05-05", "https://www.nasdaq.com/articles/incyte-slips-to-loss-in-q1-despite-higher-revenues-quick-facts-2020-05-05", "https://www.nasdaq.com/articles/incyte-q1-20-earnings-conference-call-at-8%3A00-am-et-2020-05-05", "https://www.nasdaq.com/articles/is-incyte-stock-a-buy-2020-04-29", "https://www.nasdaq.com/articles/u.s.-fda-approves-novartis-drug-for-a-hard-to-treat-type-of-lung-cancer-2020-05-06", "https://www.nasdaq.com/articles/7-beautiful-biotech-stocks-to-buy-here-2020-04-24", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-for-december-18th-2020-04-23", "https://www.nasdaq.com/articles/buzz-u.s.-stocks-on-the-move-co-diagnostics-xeris-pharma-cyclacel-pharma-2020-04-20", "https://www.nasdaq.com/articles/fda-approves-first-targeted-treatment-for-bile-duct-cancer-2020-04-20", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-4-19-2020-2020-04-19", "https://www.nasdaq.com/articles/is-exelixis-a-buy-2020-04-16", "https://www.nasdaq.com/articles/incyte-reaches-analyst-target-price-2020-04-15", "https://www.nasdaq.com/articles/tuesday-sector-laggards%3A-healthcare-technology-communications-2020-04-28", "https://www.nasdaq.com/articles/here-are-all-the-companies-working-on-covid-19-vaccines-treatments-and-testing-2020-04-07", "https://www.nasdaq.com/articles/incyte-breaks-above-200-day-moving-average-bullish-for-incy-2020-04-06", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-03-2020%3A-novnincyecorljpc-2020-04-03", "https://www.nasdaq.com/articles/health-care-sector-update-for-04-03-2020%3A-incyecorljpc-2020-04-03", "https://www.nasdaq.com/articles/novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-2020-04-03", "https://www.nasdaq.com/articles/incyte-to-test-its-cancer-drug-jakafi-as-a-treatment-for-covid-19-2020-04-03", "https://www.nasdaq.com/articles/better-buy%3A-geron-vs.-acceleron-2020-03-27", "https://www.nasdaq.com/articles/reasons-for-hope%3A-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-2020-04-13", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ual-cern-2020-03-12", "https://www.nasdaq.com/articles/these-2-things-will-help-incytes-stock-rebound-2020-03-04", "https://www.nasdaq.com/articles/morphosys-incyte-receive-antitrust-clearance-for-collaboration-on-tafasitamab-2020-03-03", "https://www.nasdaq.com/articles/incyte-to-present-at-cowen-and-co-conference-webcast-at-11%3A20-am-et-2020-03-02", "https://www.nasdaq.com/articles/implied-vug-analyst-target-price%3A-%24208-2020-03-02", "https://www.nasdaq.com/articles/better-buy%3A-glaxosmithkline-vs.-eli-lilly-2020-02-23", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-3-15-2020-2020-03-15", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-incyte-2020-02-19", "https://www.nasdaq.com/articles/incy-crosses-above-key-moving-average-level-2020-02-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-2-16-2020-2020-02-16", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-2-14-2020-2020-02-14", "https://www.nasdaq.com/articles/incyte-corp-incy-q4-2019-earnings-call-transcript-2020-02-13", "https://www.nasdaq.com/articles/how-incyte-beat-wall-street-estimates-in-q4-2020-02-13", "https://www.nasdaq.com/articles/incytes-ruxolitinib-works-in-patients-with-eczema-2020-02-19", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-ntap-amat-2020-02-13", "https://www.nasdaq.com/articles/incyte-q4-adj.-operating-income-rises-jakafi-revenues-up-23-quick-facts-2020-02-13", "https://www.nasdaq.com/articles/incyte-corporation-q4-adjusted-earnings-of-%240.65-per-share-2020-02-13", "https://www.nasdaq.com/articles/incyte-q4-19-earnings-conference-call-at-8%3A00-am-et-2020-02-13", "https://www.nasdaq.com/articles/eli-lilly-and-incyte-record-another-positive-clinical-trial-for-olumiant-works-in-eczema", "https://www.nasdaq.com/articles/lillys-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-2020-02-11", "https://www.nasdaq.com/articles/potential-lung-cancer-drug-from-incyte-and-novartis-to-get-a-priority-review-from-fda-2020", "https://www.nasdaq.com/articles/incytes-fourth-quarter-report-signals-better-times-ahead-2020-02-13", "https://www.nasdaq.com/articles/heres-why-incyte-stock-tumbled-16.3-in-january-2020-02-07", "https://www.nasdaq.com/articles/april-17th-options-now-available-for-incyte-incy-2020-02-07", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-1-31-2020-2020-01-31", "https://www.nasdaq.com/articles/will-eli-lilly-outperform-in-2020-2020-01-30", "https://www.nasdaq.com/articles/eli-lilly-incyte%3A-baricitinib-meets-primary-endpoint-in-breeze-ad5-study-2020-01-30", "https://www.nasdaq.com/articles/incytes-eczema-drug-ruxolitinib-works-in-a-late-stage-clinical-trial-2020-01-28", "https://www.nasdaq.com/articles/eli-lilly-and-incytes-olumiant-helps-eczema-patients-in-a-late-stage-clinical-trial-2020", "https://www.nasdaq.com/articles/stocks-to-watch-in-february-2020-02-10", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-for-september-18th-2020-01-23", "https://www.nasdaq.com/articles/validea-martin-zweig-strategy-daily-upgrade-report-1-22-2020-2020-01-22", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-1-19-2020-2020-01-19", "https://www.nasdaq.com/articles/incyte-stock-is-down%3A-buy-the-dip-2020-01-15", "https://www.nasdaq.com/articles/2-top-growth-stocks-to-buy-in-january-2020-01-15", "https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-healthcare-consumer-products-2020-01-14", "https://www.nasdaq.com/articles/lilly-%3A-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-2020-01-27", "https://www.nasdaq.com/articles/morphosys-incyte-agree-to-co-commercialize-tafasitamab-in-the-u.s.-2020-01-13", "https://www.nasdaq.com/articles/why-has-vertex-pharmaceuticals-stock-gained-30-in-the-last-quarter-2020-01-10", "https://www.nasdaq.com/articles/better-buy%3A-geron-vs.-incyte-2020-01-07", "https://www.nasdaq.com/articles/validea-martin-zweig-strategy-daily-upgrade-report-1-4-2020-2020-01-04", "https://www.nasdaq.com/articles/friday-sector-laggards%3A-materials-healthcare-2020-01-03", "https://www.nasdaq.com/articles/incyte-is-now-oversold-incy-2020-01-03", "https://www.nasdaq.com/articles/heres-why-incyte-fell-as-much-as-12.6-today-2020-01-03", "https://www.nasdaq.com/articles/will-theravance-biopharma-finally-break-out-in-2020-2020-01-14", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-incy-tsla-2020-01-03", "https://www.nasdaq.com/articles/sp-500-movers%3A-incy-lw-2020-01-03", "https://www.nasdaq.com/articles/drrx-plunges-on-psoriasis-trial-data-incy-fails-gravitas-301-test-agrx-abuzz-2020-01-02", "https://www.nasdaq.com/articles/3-best-biotech-stocks-of-2019%3A-are-they-buys-now-2019-12-29", "https://www.nasdaq.com/articles/a-%2420-billion-sweet-spot-in-biotech-2019-12-28", "https://www.nasdaq.com/articles/3-biotech-stocks-that-crushed-it-in-2019-2019-12-28", "https://www.nasdaq.com/articles/thursday-sector-laggards%3A-healthcare-utilities-2019-12-26", "https://www.nasdaq.com/articles/incy-makes-notable-cross-below-critical-moving-average-2020-01-03", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-john-neff-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-2019-12-14", "https://www.nasdaq.com/articles/why-incyte-stock-climbed-12.2-in-november-2019-12-04", "https://www.nasdaq.com/articles/incyte-to-present-at-piper-jaffray-healthcare-conference-webcast-at-8%3A30-am-et-2019-12-04", "https://www.nasdaq.com/articles/incy-crosses-above-average-analyst-target-2019-12-02", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-banc-incy-has-2019-11-25", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-healthcare-technology-communications-2019-11-25", "https://www.nasdaq.com/articles/why-longer-term-investors-should-buy-amarin-stock-on-weakness-2019-12-19", "https://www.nasdaq.com/articles/heres-why-kadmon-holdings-stock-jumped-today-2019-11-12", "https://www.nasdaq.com/articles/heres-why-incyte-corporation-jumped-13.0-in-october-2019-11-07", "https://www.nasdaq.com/articles/2-stocks-that-crushed-it-on-tuesday-2019-10-30", "https://www.nasdaq.com/articles/tuesday-sector-leaders%3A-energy-healthcare-2019-10-29", "https://www.nasdaq.com/articles/incyte-corp-incy-q3-2019-earnings-call-transcript-2019-10-29", "https://www.nasdaq.com/articles/incy-crosses-above-key-moving-average-level-2019-10-29", "https://www.nasdaq.com/articles/incyte-q3-profit-surges-raises-fy19-jakafi-revenue-outlook-quick-facts-2019-10-29", "https://www.nasdaq.com/articles/wednesday-sector-leaders%3A-utilities-healthcare-2019-11-13", "https://www.nasdaq.com/articles/better-buy%3A-vertex-pharmaceuticals-vs.-incyte-2019-10-27", "https://www.nasdaq.com/articles/5-top-healthcare-etfs-2019-10-26", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-for-june-2020-2019-10-22", "https://www.nasdaq.com/articles/is-incyte-a-buy-2019-10-22", "https://www.nasdaq.com/articles/how-the-parts-add-up%3A-spyx-headed-for-%2480-2019-10-10", "https://www.nasdaq.com/articles/10-great-biotech-stocks-to-buy-in-q4-2019-10-07", "https://www.nasdaq.com/articles/monday-sector-laggards%3A-healthcare-industrial-2019-09-23", "https://www.nasdaq.com/articles/incyte-q3-19-earnings-conference-call-at-8%3A00-am-et-2019-10-29", "https://www.nasdaq.com/articles/this-could-be-a-big-year-for-incyte-2019-09-18", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-exp-incy-safm-2019-09-18", "https://www.nasdaq.com/articles/pbe-gild-alxn-incy%3A-large-outflows-detected-at-etf-2019-09-17", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-for-january-2022-2019-09-17", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-aal-wday-2019-09-16", "https://www.nasdaq.com/articles/we-did-the-math-qqew-can-go-to-%2474-2019-09-09", "https://www.nasdaq.com/articles/wednesday-sector-laggards%3A-utilities-healthcare-2019-09-04", "https://www.nasdaq.com/articles/friday-sector-leaders%3A-healthcare-utilities-2019-09-20", "https://www.nasdaq.com/articles/10-stocks-to-buy-for-september-2019-08-29", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-adsk-incy-2019-08-28", "https://www.nasdaq.com/articles/how-big-is-celgenes-latest-good-news-2019-08-18", "https://www.nasdaq.com/articles/look-under-the-hood%3A-qus-has-10-upside-2019-08-08", "https://www.nasdaq.com/articles/incyte-corp-incy-q2-2019-earnings-call-transcript-2019-07-30", "https://www.nasdaq.com/articles/heres-what-youll-want-to-know-about-incytes-impressive-q2-results-2019-07-30", "https://www.nasdaq.com/articles/health-care-sector-update-for-07-30-2019%3A-incymedpnbixhca-2019-07-30", "https://www.nasdaq.com/articles/incy-makes-notable-cross-below-critical-moving-average-2019-09-04", "https://www.nasdaq.com/articles/incyte-corporation-q2-adjusted-earnings-beat-estimates-2019-07-30", "https://www.nasdaq.com/articles/incyte-q2-19-earnings-conference-call-at-8%3A00-am-et-2019-07-30", "https://www.nasdaq.com/articles/first-week-of-march-2020-options-trading-for-incyte-incy-2019-07-23", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-for-august-16th-2019-06-26", "https://www.nasdaq.com/articles/incy-crosses-above-average-analyst-target-2019-06-24", "https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-incy-lin-tmus-2019-06-17", "https://www.nasdaq.com/articles/monday-sector-leaders%3A-energy-healthcare-2019-06-17", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-expe-incy-2019-07-30", "https://www.nasdaq.com/articles/analysts-expect-size-hit-%24100-2019-06-13", "https://www.nasdaq.com/articles/first-week-july-19th-options-trading-incyte-incy-2019-05-24", "https://www.nasdaq.com/articles/incyte-corp-incy-q1-2019-earnings-call-transcript-2019-04-30", "https://www.nasdaq.com/articles/5-biotech-stocks-for-a-long-lived-portfolio-2019-04-30", "https://www.nasdaq.com/articles/incyte-no-longer-participate-co-funding-development-baricitinib-2019-04-30", "https://www.nasdaq.com/articles/incyte-corporation-q1-adjusted-earnings-%240.62-share-2019-04-30", "https://www.nasdaq.com/articles/commit-purchase-incyte-corporation-62.50-earn-12.3-using-options-2019-04-29", "https://www.nasdaq.com/articles/nasdaq-100-movers%3A-algn-incy-2019-06-17", "https://www.nasdaq.com/articles/relative-strength-alert-incyte-2019-04-15", "https://www.nasdaq.com/articles/relative-strength-alert-incyte-2019-04-15-0", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-amca-2019-04-12", "https://www.nasdaq.com/articles/jj-wins-us-fda-approval-bladder-cancer-drug-2019-04-12", "https://www.nasdaq.com/articles/us-fda-approves-jjs-bladder-cancer-drug-2019-04-12", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-incyte-fmc-and-lyondellbasell-2019-04-10", "https://www.nasdaq.com/articles/wednesday-sector-laggards-energy-healthcare-2019-04-03", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-may-2019-2019-04-26", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-1978-points-week-rising-5th-straight-day-2019-04-03", "https://www.nasdaq.com/articles/wednesday-sector-laggards-energy-healthcare-2019-04-03-0", "https://www.nasdaq.com/articles/why-is-incyte-incy-up-1.7-since-last-earnings-report-2019-03-16", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-incyte-amc-entertainment-covanta-and-u", "https://www.nasdaq.com/articles/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains-2019-03-13", "https://www.nasdaq.com/articles/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda-2019-03-05", "https://www.nasdaq.com/articles/zacks.com-featured-expert-kevin-matras-highlights%3A-first-majestic-silver-incyte-covanta", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-amd-2019-04-03", "https://www.nasdaq.com/articles/4-toxic-stocks-to-discard-or-sell-short-for-solid-gains-2019-02-26", "https://www.nasdaq.com/articles/merck-gets-priority-review-for-keytruda-in-third-line-sclc-2019-02-21", "https://www.nasdaq.com/articles/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study-2019-02-20", "https://www.nasdaq.com/articles/mercks-mrk-stock-up-almost-50-in-a-year%3A-heres-why-2019-02-19", "https://www.nasdaq.com/articles/merck-gets-priority-review-for-keytruda-combo-in-kidney-cancer-2019-02-18", "https://www.nasdaq.com/articles/incyte-incy-q4-2018-earnings-conference-call-transcript-2019-02-14", "https://www.nasdaq.com/articles/incyte-incy-q4-earnings-lag-estimates-2019-02-14", "https://www.nasdaq.com/articles/3-big-stock-charts-for-wednesday%3A-cabot-oil-gas-incyte-and-sempra-energy-2019-02-27", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-qqew-i-celg-incy-2019-02-13", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-14-2019-ko-duk-cme-wm-zts-iqv-ccep-ppl-tu-azn-incy-aee", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-regeneron-impresses-in-q4-gilead-slumps-macrogenics-soars-2019-02", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-incyte-first-majestic-mattel-and-u.s.-silica-2019", "https://www.nasdaq.com/articles/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer-2019-02-12", "https://www.nasdaq.com/articles/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains-2019-02-11", "https://www.nasdaq.com/articles/why-incyte-stock-gained-27-january-2019-02-11", "https://www.nasdaq.com/articles/incyte-incy-q4-earnings-miss-estimates-revenues-beat-2019-02-14", "https://www.nasdaq.com/articles/is-a-disappointment-in-store-for-incyte-incy-q4-earnings-2019-02-11", "https://www.nasdaq.com/articles/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd-2019-02-08", "https://www.nasdaq.com/articles/lilly-incytes-olumiant-meets-endpoint-in-eczema-studies-2019-02-05", "https://www.nasdaq.com/articles/lilly-baricitinib-meets-primary-endpoint-breeze-ad1-and-breeze-ad2-2019-02-04", "https://www.nasdaq.com/articles/first-week-september-20th-options-trading-incyte-incy-2019-01-29", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-incyte-keyw-first-majestic-and-mattel-2019-01-28", "https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-pfizer-mgm-resorts-and-incyte-2019-01-28", "https://www.nasdaq.com/articles/how-parts-add-qqq-headed-186-2019-02-11", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs-2019-01-23", "https://www.nasdaq.com/articles/commit-buy-incyte-corporation-6250-earn-81-annualized-using-options-2019-01-22", "https://www.nasdaq.com/articles/close-update-nasdaq-leads-market-higher-technology-health-care-shares-rally-2019-01-15", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-above-7000-11791-points-702383-2019-01", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-technology-communications-2019-01-15", "https://www.nasdaq.com/articles/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18-2019-01-14", "https://www.nasdaq.com/articles/analysts-anticipate-iecs-will-reach-27-2019-01-10", "https://www.nasdaq.com/articles/4-toxic-stocks-to-get-rid-off-or-sell-short-for-solid-gains-2019-01-25", "https://www.nasdaq.com/articles/why-agenus-stock-spiking-today-2019-01-07", "https://www.nasdaq.com/articles/3-big-stock-charts-for-friday%3A-incyte-schlumberger-and-abbott-laboratories-2019-01-04", "https://www.nasdaq.com/articles/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan-2019-01-04", "https://www.nasdaq.com/articles/incy-crosses-above-key-moving-average-level-2019-01-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-aal-celg-2019-01-03", "https://www.nasdaq.com/articles/sp-500-movers-lnt-celg-2019-01-03", "https://www.nasdaq.com/articles/incyte-names-christiana-stamoulis-cfo-quick-facts-2019-01-03", "https://www.nasdaq.com/articles/4-biotechs-are-potential-buyouts-post-celgene-deal-2019-01-08", "https://www.nasdaq.com/articles/health-care-sector-update-01032019-incyktovcelgbmyteva-2019-01-03", "https://www.nasdaq.com/articles/sp-500-movers-lnt-nflx-2018-12-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-fb-incy-2018-12-31", "https://www.nasdaq.com/articles/mercks-sbla-for-keytruda-in-lung-cancer-gets-extended-review-2018-12-21", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amgen-aduro-vertex-evofem-and-incyte-2018-12-20", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-pipeline-updates-from-vrtx-amgn-adro-teams-up-with-lly-2018-12-19", "https://www.nasdaq.com/articles/here-are-biotechs-big-pipeline-disappointments-2018-2018-12-18", "https://www.nasdaq.com/articles/why-celgene-agenus-and-incyte-jumped-today-2019-01-03", "https://www.nasdaq.com/articles/incyte-incy-collaborates-with-innovent-for-3-candidates-2018-12-17", "https://www.nasdaq.com/articles/5-biotech-stocks-set-bounce-back-19-after-rough-ride-2018-12-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-pep-incy-2018-12-12", "https://www.nasdaq.com/articles/roche-to-create-companion-diagnostic-test-for-mercks-keytruda-2018-12-12", "https://www.nasdaq.com/articles/5-top-drugbiotech-merger-acquisition-targets-2019-2018-12-10", "https://www.nasdaq.com/articles/why-macrogenics-stock-getting-hammered-today-2018-12-10", "https://www.nasdaq.com/articles/astrazenecas-imfinzi-fails-in-head-and-neck-cancer-study-2018-12-07", "https://www.nasdaq.com/articles/immuno-oncology-suffered-setback-2018-whats-next-2018-12-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-ttwo-wynn-2018-12-03", "https://www.nasdaq.com/articles/why-is-incyte-incy-up-1.5-since-last-earnings-report-2018-11-29", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-85-points-week-rising-3rd-straight-day-2018-11-28", "https://www.nasdaq.com/articles/astrazenecas-imfinzi-fails-in-lung-cancer-study-stock-down-2018-11-19", "https://www.nasdaq.com/articles/mercks-keytruda-improves-survival-in-esophageal-cancer-study-2018-11-15", "https://www.nasdaq.com/articles/mercks-mrk-keytruda-gets-fda-approval-for-liver-cancer-2018-11-12", "https://www.nasdaq.com/articles/agenus-agen-q3-loss-wider-than-expected-pipeline-in-focus-2018-11-08", "https://www.nasdaq.com/articles/incyte-incy-announces-positive-data-on-jakafi-for-gvhd-2018-12-04", "https://www.nasdaq.com/articles/3-big-stock-charts-for-thursday%3A-walmart-prologis-and-incyte-2018-11-01", "https://www.nasdaq.com/articles/scary-markets-frightening-stocks-and-how-keep-panicking-2018-11-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctsh-ttwo-2018-10-30", "https://www.nasdaq.com/articles/incyte-incy-misses-q3-earnings-and-revenue-estimates-2018-10-30", "https://www.nasdaq.com/articles/incyte-corp-incy-q3-2018-earnings-conference-call-transcript-2018-10-30", "https://www.nasdaq.com/articles/incyte-incy-misses-on-q3-earnings-revenues-updates-view-2018-10-30", "https://www.nasdaq.com/articles/better-buy-vertex-pharmaceuticals-incorporated-vs-incyte-corporation-2018-10-28", "https://www.nasdaq.com/articles/incytes-shares-have-taken-beating-2018-heres-why-2018-11-02", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-june-2019-2018-10-24", "https://www.nasdaq.com/articles/incyte-incy-to-report-q3-earnings%3A-whats-in-the-cards-2018-10-24", "https://www.nasdaq.com/articles/strong-comeback-saves-market-another-plunge-2018-10-24", "https://www.nasdaq.com/articles/incytes-jakafi-demand-strong-label-expansion-to-boost-sales-2018-10-11", "https://www.nasdaq.com/articles/5-reasons-why-investors-should-bet-on-merck-mrk-stock-2018-10-08", "https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-october-2018-10-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-787951-down-14558-points-2018-10-04", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-biib-tops-mack-plunges-regns-asthma-drug-gets-fda-nod-2018-10-24", "https://www.nasdaq.com/articles/2-stocks-could-benefit-big-gerons-stumble-2018-09-29", "https://www.nasdaq.com/articles/better-buy-geron-corporation-vs-incyte-corporation-2018-09-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-mu-aal-2018-09-21", "https://www.nasdaq.com/articles/health-care-sector-update-09212018-crspbgnexomallyagenincymrk-2018-09-21", "https://www.nasdaq.com/articles/health-care-sector-update-09212018-bgnexomaagenincymrk-2018-09-21", "https://www.nasdaq.com/articles/agenus-receives-milestone-payment-of-%245-million-from-incyte-2018-09-18", "https://www.nasdaq.com/articles/first-week-incy-march-2019-options-trading-2018-09-14", "https://www.nasdaq.com/articles/thursday-sector-laggards-technology-communications-healthcare-2018-10-04", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-gilds-arthritis-drug-successful-in-phase-iii-prqr-soars-2018-09-12", "https://www.nasdaq.com/articles/incyte-foundation-medicine-partner-for-companion-diagnostics-2018-09-12", "https://www.nasdaq.com/articles/mercks-keytruda-combo-gets-nod-for-lung-cancer-in-europe-2018-09-11", "https://www.nasdaq.com/articles/health-care-sector-update-09112018-acrx-xene-incy-kmph-imv-2018-09-11", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-uve-incy-nxpi-2018-09-11", "https://www.nasdaq.com/articles/why-incyte-stock-gained-11-august-2018-09-06", "https://www.nasdaq.com/articles/mercks-keytruda-gets-priority-review-for-rare-skin-cancer-2018-09-05", "https://www.nasdaq.com/articles/merck-gets-priority-review-for-yet-another-keytruda-sbla-2018-09-13", "https://www.nasdaq.com/articles/why-is-incyte-incy-up-12.9-since-last-earnings-report-2018-08-30", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-financial-2018-08-28", "https://www.nasdaq.com/articles/agenus-inc-stock-buy-2018-08-23", "https://www.nasdaq.com/articles/merck-gets-fda-nod-for-keytruda-lung-cancer-label-expansion-2018-08-21", "https://www.nasdaq.com/articles/sp-500-analyst-moves-incy-2018-08-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-wday-2018-08-15", "https://www.nasdaq.com/articles/agenus-agen-delivering-well-on-its-pipeline-candidates-2018-08-15", "https://www.nasdaq.com/articles/bbhs-holdings-imply-12-gain-potential-2018-09-05", "https://www.nasdaq.com/articles/heres-why-merck-mrk-stock-is-up-since-q2-earnings-release-2018-08-14", "https://www.nasdaq.com/articles/agenus-agen-q2-loss-narrower-than-expected-revenues-beat-2018-08-10", "https://www.nasdaq.com/articles/3-big-stock-charts-for-monday%3A-entergy-incyte-and-sl-green-realty-2018-08-06", "https://www.nasdaq.com/articles/we-did-math-splg-can-go-36-2018-08-02", "https://www.nasdaq.com/articles/incyte-now-oversold-incy-2018-08-01", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-767179-4179-points-2018-07-31", "https://www.nasdaq.com/articles/incyte-incy-earnings-miss-revenues-beat-estimates-in-q2-2018-07-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-stx-2018-08-14", "https://www.nasdaq.com/articles/incyte-incy-to-report-q2-earnings%3A-whats-in-the-cards-2018-07-27", "https://www.nasdaq.com/articles/better-buy-inovio-pharmaceuticals-inc-vs-incyte-corporation-2018-07-26", "https://www.nasdaq.com/articles/10-cancer-fighting-health-care-stocks-buy-2018-07-20", "https://www.nasdaq.com/articles/cti-biopharma-tanks-post-type-b-talks-on-pacritinib-with-fda-2018-07-19", "https://www.nasdaq.com/articles/can-eli-lilly-lly-keep-the-earnings-streak-alive-in-q2-2018-07-19", "https://www.nasdaq.com/articles/3-worst-healthcare-stocks-2018-so-far-2018-07-19", "https://www.nasdaq.com/articles/first-week-incy-august-17th-options-trading-2018-07-03", "https://www.nasdaq.com/articles/drug-stocks-to-report-q2-earnings-on-jul-31%3A-pfe-incy-ecyt-2018-07-30", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-pbyi-soars-mack-crashes-gilds-biktarvy-gets-ec-nod-2018-06-27", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-nflx-2018-06-26", "https://www.nasdaq.com/articles/sp-500-movers-incy-ge-2018-06-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-756163-2962-points-2018-06-26", "https://www.nasdaq.com/articles/tuesday-sector-laggards-financial-healthcare-2018-06-26", "https://www.nasdaq.com/articles/incyte-incy-announces-positive-results-on-jakafi-for-gvhd-2018-06-22", "https://www.nasdaq.com/articles/3-nash-stocks-could-soar-second-half-2018-2018-06-15", "https://www.nasdaq.com/articles/mercks-keytruda-gets-priority-review-in-difficult-lung-cancer-2018-07-03", "https://www.nasdaq.com/articles/heres-why-incyte-rose-102-may-2018-06-08", "https://www.nasdaq.com/articles/abbvies-abbv-upadacitinib-fifth-ra-study-data-positive-2018-06-06", "https://www.nasdaq.com/articles/eli-lillys-olumiant-gets-fda-nod-for-rheumatoid-arthritis-2018-06-04", "https://www.nasdaq.com/articles/better-know-biotech-2-stocks-youve-got-know-about-2018-06-01", "https://www.nasdaq.com/articles/incyte-incy-up-10.2-since-earnings-report%3A-can-it-continue-2018-05-31", "https://www.nasdaq.com/articles/3-biotechs-huge-fda-decisions-june-2018-05-31", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-july-20th-2018-05-25", "https://www.nasdaq.com/articles/3-reasons-expect-smooth-sailing-abbvies-mission-critical-candidate-2018-06-10", "https://www.nasdaq.com/articles/huge-decision-tap-little-biotech-stock-2018-05-16", "https://www.nasdaq.com/articles/agenus-inc-agen-buy-2018-05-12", "https://www.nasdaq.com/articles/monday-57-insider-buying-report-etm-incy-2018-05-07", "https://www.nasdaq.com/articles/morning-movers-under-armour-slumps-tapestry-tumbles-pfizer-flops-2018-05-01", "https://www.nasdaq.com/articles/incyte-incy-reports-loss-q1-2018-05-01", "https://www.nasdaq.com/articles/incyte-incy-incurs-loss-in-q1-revenues-miss-estimates-2018-05-01", "https://www.nasdaq.com/articles/first-week-incy-december-21st-options-trading-2018-04-30", "https://www.nasdaq.com/articles/5-things-abbvie-investors-need-know-2018-05-18", "https://www.nasdaq.com/articles/analysts-predict-13-gains-ahead-holdings-iwb-2018-04-30", "https://www.nasdaq.com/articles/can-jafaki-help-incyte-incy-beat-earnings-estimates-in-q1-2018-04-27", "https://www.nasdaq.com/articles/lessons-learn-aprils-biotech-blowups-2018-04-25", "https://www.nasdaq.com/articles/eli-lilly-and-company-buy-2018-04-25", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-prta-down-amgn-revises-view-biib-misses-on-sales-2018-04-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-cdns-2018-04-24", "https://www.nasdaq.com/articles/lilly-lly-tops-on-q1-earnings-raises-18-view-stock-up-2018-04-24", "https://www.nasdaq.com/articles/should-you-sell-incyte-incy-before-earnings-2018-04-30", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-700735-down-12125-points-2018-04-24", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-enzholxbiibcncincy-2018-04-24", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-incy-biibcnc-2018-04-24", "https://www.nasdaq.com/articles/lilly-lly-to-report-q1-earnings%3A-whats-in-the-cards-2018-04-20", "https://www.nasdaq.com/articles/3-biotech-stocks-major-catalysts-incoming-2018-04-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-agios-pharmaceuticals-biomarin-pharmaceutical-vertex", "https://www.nasdaq.com/articles/what-incytes-phase-3-fail-means-immuno-oncology-2018-04-16", "https://www.nasdaq.com/articles/health-care-sector-update-04242018-lly-incy-biib-cnc-2018-04-24", "https://www.nasdaq.com/articles/what-happened-incytes-ido-inhibitor-flop-2018-04-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntes-incy-2018-04-12", "https://www.nasdaq.com/articles/why-one-drug-flop-tanked-incytes-stock-2018-04-12", "https://www.nasdaq.com/articles/why-gopro-incyte-and-wynn-resorts-jumped-today-2018-04-12", "https://www.nasdaq.com/articles/biotech-stock-roundup%3A-spectrum-up-incyte-down-avexis-to-merge-with-novartis-2018-04-11", "https://www.nasdaq.com/articles/beaten-down-incyte-corporation-stock-buy-now-2018-04-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-ntes-2018-04-09", "https://www.nasdaq.com/articles/whats-next-incyte-2018-04-16", "https://www.nasdaq.com/articles/newlink-shares-plunge-after-incyte-mercks-study-fails-2018-04-09", "https://www.nasdaq.com/articles/incyte-corporation-stock-plunges-melanoma-drug-trial-failure-2018-04-06", "https://www.nasdaq.com/articles/mid-day-market-update-dow-falls-350-points-incyte-shares-plunge-2018-04-06", "https://www.nasdaq.com/articles/mid-day-market-update-dow-falls-350-points-incyte-shares-plunge-2018-04-06-0", "https://www.nasdaq.com/articles/relative-strength-alert-incyte-2018-04-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-ulta-2018-04-06", "https://www.nasdaq.com/articles/sp-500-movers-incy-ulta-2018-04-06", "https://www.nasdaq.com/articles/incytes-epacadostat-fails-in-melanoma-study-shares-plunge-2018-04-09", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-greenbrier-beats-q2-expectations-2018-04-06-0", "https://www.nasdaq.com/articles/morning-movers-are-tariffs-game-bluff-2018-04-06", "https://www.nasdaq.com/articles/health-care-sector-update-04062018-incy-mrk-cdxs-mnkd-acrs-cphr-2018-04-06", "https://www.nasdaq.com/articles/pre-market-most-active-apr-6-2018-mu-incy-tvix-bp-qqq-bac-tot-nlnk-bti-sqqq-sbgl-tlk-2018", "https://www.nasdaq.com/articles/incytes-horrible-news-derails-promising-class-cancer-drugs-2018-04-06", "https://www.nasdaq.com/articles/what-happened-stock-market-today-2018-04-06", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-691511-down-16144-points-2018-04-06", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-greenbrier-beats-q2-expectations-2018-04-06", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-greenbrier-beats-q2-expectations-2018-04-06-0", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-2-pricesmart-shares-spike-higher-2018-04-06-0", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-2-pricesmart-shares-spike-higher-2018-04-06", "https://www.nasdaq.com/articles/why-incyte-and-newlink-genetics-crashed-today-2018-04-06", "https://www.nasdaq.com/articles/notable-friday-option-activity-incy-nflx-regn-2018-04-06", "https://www.nasdaq.com/articles/are-short-sellers-right-about-geron-corporation-2018-04-02", "https://www.nasdaq.com/articles/health-care-sector-update-04062018-incymrkacrscdxsmnkd-2018-04-06", "https://www.nasdaq.com/articles/venture-capital-deals-week-small-molecules-and-software-2018-03-31", "https://www.nasdaq.com/articles/implied-voo-analyst-target-price-277-2018-03-29", "https://www.nasdaq.com/articles/these-3-biotech-stocks-are-soaring-are-they-buys-now-2018-03-29", "https://www.nasdaq.com/articles/incyte-could-have-problem-or-2-its-hands-2018-03-29", "https://www.nasdaq.com/articles/3-biotechs-could-get-big-boosts-april-2018-03-28", "https://www.nasdaq.com/articles/incyte-incy-up-5.2-since-earnings-report%3A-can-it-continue-2018-03-19", "https://www.nasdaq.com/articles/geron-corporations-stock-set-sail-or-sink-2018-03-18", "https://www.nasdaq.com/articles/how-safe-abbvie-incs-dividend-now-2018-04-01", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-royal-dutch-mastercard-itau-unibanco-suncor-and-incyte", "https://www.nasdaq.com/articles/top-analyst-reports-royal-dutch-shell-mastercard-itau-unibanco-2018-03-08", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-incy-ddd-crc-2018-03-01", "https://www.nasdaq.com/articles/biotech-stock-round-up%3A-celgene-suffers-setback-gilead-teams-up-with-sangamo-2018-02-28", "https://www.nasdaq.com/articles/stocks-take-powell-plunge-2018-02-28", "https://www.nasdaq.com/articles/implied-pbus-analyst-target-price-30-2018-02-26", "https://www.nasdaq.com/articles/stocks-follow-walmart-lower-2018-02-21", "https://www.nasdaq.com/articles/astrazenecas-final-data-from-key-lung-cancer-study-delayed-2018-03-13", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-royal-dutch-mastercard-itau-unibanco-suncor-and-incyte", "https://www.nasdaq.com/articles/incyte-incy-q4-2017-earnings-conference-call-transcript-2018-02-20", "https://www.nasdaq.com/articles/get-rid-of-5-toxic-stocks-or-sell-short-for-profit-2018-02-19", "https://www.nasdaq.com/articles/heres-why-calithera-biosciences-inc-rose-much-252-today-2018-02-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-csco-2018-02-15", "https://www.nasdaq.com/articles/incyte-incy-beats-sales-q4-2018-02-15", "https://www.nasdaq.com/articles/incyte-incy-beats-on-q4-revenues-on-strong-jakafi-sales-2018-02-15", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-include%3A-incyte-altice-usa-archrock-live-nation-and-ptc-2018", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-15-2018-zts-wm-incy-omc-cce-fts-hii-yndx-eca-shop-eqt", "https://www.nasdaq.com/articles/notable-wednesday-option-activity-nem-incy-algn-2018-02-14", "https://www.nasdaq.com/articles/can-jakafi-performance-drive-incytes-incy-q4-earnings-2018-02-12", "https://www.nasdaq.com/articles/will-prothena-prta-disappoint-investors-in-q4-earnings-2018-02-09", "https://www.nasdaq.com/articles/5-biotech-stocks-set-to-trump-estimates-this-earnings-season-2018-02-06", "https://www.nasdaq.com/articles/astrazeneca-azn-beats-on-q4-earnings-guides-for-2018-2018-02-02", "https://www.nasdaq.com/articles/lilly-lly-beats-on-q4-earnings-raises-2018-eps-guidance-2018-01-31", "https://www.nasdaq.com/articles/why-incyte-incy-might-surprise-this-earnings-season-2018-02-14", "https://www.nasdaq.com/articles/will-amgen-amgn-benefit-from-growth-drugs-in-q4-earnings-2018-01-29", "https://www.nasdaq.com/articles/merus-antibody-candidate-in-phase-ii-breast-cancer-study-2018-01-29", "https://www.nasdaq.com/articles/lilly-lly-to-report-q4-earnings%3A-whats-in-the-cards-2018-01-29", "https://www.nasdaq.com/articles/analysts-anticipate-bbh-will-reach-151-2018-01-26", "https://www.nasdaq.com/articles/novartis-tops-high-after-crushing-fourth-quarter-expectations-2018-01-24", "https://www.nasdaq.com/articles/these-2-developments-could-accelerate-johnson-johnsons-next-acquisition-2018-01-22", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-covanta-holding-altice-usa-incyte-and-archrock-2018-01-18", "https://www.nasdaq.com/articles/first-real-pullback-2018-2018-01-31", "https://www.nasdaq.com/articles/discard-these-4-toxic-stocks-or-sell-short-for-profit-2018-01-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-juno-surges-acquisition-rumor-concert-down-patent-news-2018-01-17", "https://www.nasdaq.com/articles/5-big-biotech-stocks-buy-2018-2018-01-17", "https://www.nasdaq.com/articles/will-2018-be-agenus-incs-best-year-yet-2018-01-16", "https://www.nasdaq.com/articles/health-care-sector-update-01122018-jnj-pfe-abt-mrk-amgn-cnce-incy-gsk-psti-vrx-2018-01-12", "https://www.nasdaq.com/articles/health-care-sector-update-01122018-vrxvrxtopstigskcnceincy-2018-01-12", "https://www.nasdaq.com/articles/why-concert-pharmaceuticals-inc-singing-blues-today-2018-01-12", "https://www.nasdaq.com/articles/notable-thursday-option-activity-incy-ebay-syf-2018-01-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-myl-2018-01-11", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-721178-2018-01", "https://www.nasdaq.com/articles/sp-500-analyst-moves-incy-2018-01-10", "https://www.nasdaq.com/articles/5-things-you-need-know-celgenes-jp-morgan-presentation-2018-01-09", "https://www.nasdaq.com/articles/celgene-to-acquire-impact-biomedicines-to-boost-pipeline-2018-01-08", "https://www.nasdaq.com/articles/5-biggest-new-drugs-2018-and-how-you-can-profit-their-makers-2018-01-07", "https://www.nasdaq.com/articles/celgene-earnings-beat-views-biotech-buys-impact-biomedicines-2018-01-07", "https://www.nasdaq.com/articles/health-care-sector-update-01122018-pstigskcnceincy-2018-01-12", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-covanta-holding-amc-entertainment-holdings-incyte-ptc-and-cott-2018", "https://www.nasdaq.com/articles/morning-movers-netflix-target-start-2018-bang-2018-01-02", "https://www.nasdaq.com/articles/abandon-these-5-toxic-stocks-or-sell-short-for-profit-2018-01-02", "https://www.nasdaq.com/articles/tuesday-sector-leaders-healthcare-services-2018-01-02", "https://www.nasdaq.com/articles/commit-purchase-incyte-corporation-85-earn-125-using-options-2017-12-22", "https://www.nasdaq.com/articles/3-promising-cancer-immunotherapies-watch-2018-2017-12-22", "https://www.nasdaq.com/articles/abbvies-ra-candidate-meets-endpoints-in-3rd-phase-iii-study-2017-12-21", "https://www.nasdaq.com/articles/why-these-3-biotech-stocks-could-outperform-their-peers-2018-2018-01-05", "https://www.nasdaq.com/articles/zacks.com-highlights%3A-covanta-holding-amc-entertainment-holdings-incyte-ptc-and-cott-2018", "https://www.nasdaq.com/articles/monday-sector-laggards-utilities-healthcare-2017-12-18", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-incyte-amc-entertainment-mercadolibre-ptc-and-clean-harbors", "https://www.nasdaq.com/articles/dispose-of-these-5-toxic-stocks-or-sell-short-for-gains-2017-12-14", "https://www.nasdaq.com/articles/wednesday-sector-leaders-utilities-healthcare-2017-12-13", "https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-december-2017-12-12", "https://www.nasdaq.com/articles/incyte-incy-reports-phase-iii-follow-up-data-for-jakafi-2017-12-11", "https://www.nasdaq.com/articles/navistar-international-higher-10-earnings-2017-12-19", "https://www.nasdaq.com/articles/5-top-ranked-drug-stocks-are-broker-favorites-2017-12-05", "https://www.nasdaq.com/articles/incyte-now-oversold-incy-2017-12-04", "https://www.nasdaq.com/articles/1-high-risk-penny-stock-may-be-worth-buying-2017-12-04", "https://www.nasdaq.com/articles/10-blockbuster-drugs-future-big-pharma-stocks-2017-11-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-incy-2017-11-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-msft-2017-11-28", "https://www.nasdaq.com/articles/hedge-funds-are-snapping-up-these-3-strong-buy-stocks-2017-11-27", "https://www.nasdaq.com/articles/3-stocks-focus-biotech-ma-hopes-2018-rise-2017-12-11", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-energy-2017-11-20", "https://www.nasdaq.com/articles/incyte-incy-initiates-essential-thrombocythemia-trial-2017-11-16", "https://www.nasdaq.com/articles/astrazeneca-azn-misses-q3-earnings-tweaks-2017-eps-view-2017-11-09", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-678912-2017-11", "https://www.nasdaq.com/articles/incyte-tops-q3-earnings-sales-extends-astrazeneca-deal-2017-11-01", "https://www.nasdaq.com/articles/7-months-green-dow-and-sp-2017-11-01", "https://www.nasdaq.com/articles/casino-energy-stocks-jump-which-ibd-50-names-are-red-hot-2017-11-01", "https://www.nasdaq.com/articles/5-stocks-the-top-fund-managers-love-2017-11-20", "https://www.nasdaq.com/articles/whats-in-the-offing-for-intercept-icpt-in-q3-earnings-2017-10-30", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-incyte-apache-titan-international-amc-entertainment-and", "https://www.nasdaq.com/articles/will-radius-health-rdus-disappoint-this-earnings-season-2017-10-27", "https://www.nasdaq.com/articles/get-rid-of-these-5-toxic-stocks-or-sell-short-for-profit-2017-10-27", "https://www.nasdaq.com/articles/why-incyte-incy-might-surprise-this-earnings-season-2017-10-27", "https://www.nasdaq.com/articles/whats-in-the-offing-for-exelixis-exel-in-q3-earnings-2017-10-27", "https://www.nasdaq.com/articles/midday-update-wall-street-turns-negative-missed-earnings-2017-10-25", "https://www.nasdaq.com/articles/incyte-rises-beat-and-raise-expanding-deal-astrazeneca-2017-10-31", "https://www.nasdaq.com/articles/why-akamai-technologies-nuvasive-and-macrogenics-jumped-today-2017-10-25", "https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2017-10-24", "https://www.nasdaq.com/articles/lilly-lly-beats-on-q3-earnings-explores-sale-of-elanco-2017-10-24", "https://www.nasdaq.com/articles/eli-lilly-lly-to-report-q3-earnings%3A-whats-in-store-2017-10-18", "https://www.nasdaq.com/articles/ibd-biotech-innovator-awards-2017-10-16", "https://www.nasdaq.com/articles/6-top-biotech-companies-innovation-earn-recognition-new-awards-2017-10-16", "https://www.nasdaq.com/articles/incyte-cancer-treatment-uses-patients-immune-system-fight-disease-2017-10-16", "https://www.nasdaq.com/articles/why-macrogenics-inc-stock-soared-today-2017-10-25", "https://www.nasdaq.com/articles/5-game-changing-cancer-drug-innovations-being-developed-right-now-2017-10-12", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-660355-2017-10", "https://www.nasdaq.com/articles/vot-adsk-incy-ew-large-outflows-detected-etf-2017-10-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-cost-incy-2017-10-06", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-payx-2017-10-03", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-consumer-products-2017-09-29", "https://www.nasdaq.com/articles/nasdaq-100-movers-qvca-aal-2017-09-28", "https://www.nasdaq.com/articles/5-toxic-stocks-to-abandon-or-sell-short-for-gains-2017-10-12", "https://www.nasdaq.com/articles/3-stocks-turned-7000-130200-2017-09-28", "https://www.nasdaq.com/articles/tech-bounces-back-2017-09-27", "https://www.nasdaq.com/articles/jjs-arthritis-candidate-sirukumab-denied-fda-approval-2017-09-26", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ptc-apache-incyte-titan-international-and-carbonite-2017-09", "https://www.nasdaq.com/articles/3-monster-biotech-stocks-making-2017-09-24", "https://www.nasdaq.com/articles/5-toxic-stocks-to-discard-or-sell-short-for-profit-2017-09-22", "https://www.nasdaq.com/articles/implied-bbh-analyst-target-price-150-2017-09-21", "https://www.nasdaq.com/articles/agenus-agen-remains-focused-on-drug-development-programs-2017-09-28", "https://www.nasdaq.com/articles/vot-fisv-incy-ew-etf-outflow-alert-2017-09-21", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-november-17th-2017-09-19", "https://www.nasdaq.com/articles/5-of-the-toughest-stocks-to-withstand-a-downturn-2017-09-18", "https://www.nasdaq.com/articles/lilly-incytes-baricitinib-meets-endpoint-in-eczema-study-2017-09-15", "https://www.nasdaq.com/articles/notable-friday-option-activity-okta-rh-incy-2017-09-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-symc-2017-09-08", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-636019-down-3768-points-2017-09-08", "https://www.nasdaq.com/articles/3-small-cap-biotech-stocks-buy-fall-2017-09-21", "https://www.nasdaq.com/articles/nasdaq-100-biotechnology-beyond-pure-tech-still-pure-innovation-2017-09-06", "https://www.nasdaq.com/articles/incyte-incy-reports-positive-data-on-epacadostat-keytruda-2017-09-01", "https://www.nasdaq.com/articles/top-research-reports-bank-america-pepsi-american-express-2017-09-01", "https://www.nasdaq.com/articles/better-buy-eli-lilly-and-company-vs-pfizer-inc-2017-09-01", "https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-bbh-2017-08-31", "https://www.nasdaq.com/articles/lilly-incyte-to-re-file-baricitinib-nda-faster-than-expected-2017-08-31", "https://www.nasdaq.com/articles/nasdaq-100-movers-ctrp-myl-2017-08-31", "https://www.nasdaq.com/articles/heres-why-newlink-genetics-vaulting-45-higher-today-2017-09-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-wdc-adi-2017-08-30", "https://www.nasdaq.com/articles/sp-500-movers-hrb-adi-2017-08-30", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-1887-points-week-rising-3rd-straight-day-2017-08-30", "https://www.nasdaq.com/articles/5-biotech-stocks-that-are-breaking-higher-2017-08-30", "https://www.nasdaq.com/articles/wednesday-sector-leaders-technology-communications-healthcare-2017-08-30", "https://www.nasdaq.com/articles/tuesdays-etf-movers-fbt-xop-2017-08-29", "https://www.nasdaq.com/articles/4-highest-growth-stocks-biotech-today-2017-08-24", "https://www.nasdaq.com/articles/wednesdays-etf-movers-bbh-gdxj-2017-08-30", "https://www.nasdaq.com/articles/3-most-promising-cancer-drugs-late-stage-development-2017-08-22", "https://www.nasdaq.com/articles/3-top-biotech-stocks-under-5-2017-08-19", "https://www.nasdaq.com/articles/why-has-2017-been-horrible-year-so-far-biotech-acquisitions-2017-08-13", "https://www.nasdaq.com/articles/bb-biotech-ag-buys-avexis-inc-sells-regeneron-pharmaceuticals-inc-puma-biotechnology-inc", "https://www.nasdaq.com/articles/incyte-incy-q2-loss-wider-than-expected-jakafi-strong-2017-08-02", "https://www.nasdaq.com/articles/incyte-corporation-incy-shares-drop-on-q2-loss-2017-08-01", "https://www.nasdaq.com/articles/nasdaq-100-movers-idxx-nclh-2017-08-01", "https://www.nasdaq.com/articles/commit-purchase-incyte-corporation-100-earn-97-using-options-2017-08-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-amgen-biogen-top-q2-estimates-update-incyte-ra-drug-2017-07-26", "https://www.nasdaq.com/articles/lilly-lly-q2-earnings-top-baricitinib-re-filing-delayed-2017-07-25", "https://www.nasdaq.com/articles/eli-lilly-llys-seemingly-illogical-reaction-earnings-beat-2017-07-25", "https://www.nasdaq.com/articles/2-reasons-incyte-better-growth-stock-exelixis-and-1-reason-it-isnt-2017-07-21", "https://www.nasdaq.com/articles/3-hottest-biotech-stocks-2017-are-they-still-buys-now-2017-07-20", "https://www.nasdaq.com/articles/we-did-math-fbt-can-go-127-2017-07-19", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-technology-communications-2017-07-17", "https://www.nasdaq.com/articles/key-takeaways-lillys-lly-q2-call-baricitinib-cancer-pipeline-2017-07-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-lila-2017-07-10", "https://www.nasdaq.com/articles/incyte-lillys-olumiant-gets-marketing-approval-in-japan-2017-07-04", "https://www.nasdaq.com/articles/better-buy-agenus-inc-vs-kite-pharma-2017-07-02", "https://www.nasdaq.com/articles/stock-exchange-time-evidence-based-trading-2017-06-30", "https://www.nasdaq.com/articles/aduro-starts-phase-ii-combo-study-with-crs-207-keytruda-2017-06-29", "https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-johnson-johnson-incyte-pfizer-novartis-and-astrazeneca", "https://www.nasdaq.com/articles/thursday-sector-laggards-technology-communications-healthcare-2017-06-29", "https://www.nasdaq.com/articles/3-stocks-turned-1000-least-2017-12-months-2017-07-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntes-mu-2017-06-26", "https://www.nasdaq.com/articles/stocks-fight-cancer-why-immunotherapy-gamechanger-2017-06-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-mat-ca-2017-06-21", "https://www.nasdaq.com/articles/small-cancer-biotech-space-in-focus-3-stocks-up-100-more-2017-06-21", "https://www.nasdaq.com/articles/update-wall-street-weighed-down-oil-declines-health-stocks-lift-nasdaq-2017-06-21", "https://www.nasdaq.com/articles/wednesday-sector-leaders-healthcare-technology-communications-2017-06-21", "https://www.nasdaq.com/articles/surprising-disappointment-derails-newlink-genetics-whats-next-2017-06-19", "https://www.nasdaq.com/articles/better-days-ahead-pharma-sector-2017-06-28", "https://www.nasdaq.com/articles/3-biotech-stocks-could-become-ma-targets-2017-06-17", "https://www.nasdaq.com/articles/baker-bros-advisors-lp-buys-incyte-corp-avexis-inc-la-jolla-pharmaceutical-co-sells-abbvie", "https://www.nasdaq.com/articles/3-beaten-down-stocks-ready-bounce-back-2017-06-16", "https://www.nasdaq.com/articles/bib-celg-amgn-incy-etf-inflow-alert-2017-06-09", "https://www.nasdaq.com/articles/gilead-sciences-inc-bear-case-bull-2017-06-09", "https://www.nasdaq.com/articles/incyte-incy-up-3.4-since-earnings-report%3A-can-it-continue-2017-06-09", "https://www.nasdaq.com/articles/why-newlink-genetics-losing-one-third-its-value-today-2017-06-08", "https://www.nasdaq.com/articles/5-answers-questions-gilead-sciences-investors-probably-have-2017-06-18", "https://www.nasdaq.com/articles/incyte-provides-updated-data-on-cancer-combination-therapies-2017-06-06", "https://www.nasdaq.com/articles/incyte-announces-data-on-enzyme-inhibitor-with-keytruda-2017-06-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-orly-ntes-2017-06-05", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-629568-down-1012-points-2017-06-05", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-620319-down-7-points-2017-05-30", "https://www.nasdaq.com/articles/weeks-worth-gains-2017-05-30", "https://www.nasdaq.com/articles/stock-exchange-time-reconsider-health-care-2017-05-26", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-629738-2232-points-2017-06-07", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-technology-communications-2017-05-26", "https://www.nasdaq.com/articles/edward-owens-buys-abbott-labs-sells-allergan-amgen-aetna-2017-05-23", "https://www.nasdaq.com/articles/company-news-for-may-19-2017-2017-05-19", "https://www.nasdaq.com/articles/incyte-corporation-incy-stock-jumps-promising-lung-cancer-drug-2017-05-18", "https://www.nasdaq.com/articles/nasdaq-100-movers-csco-incy-2017-05-18", "https://www.nasdaq.com/articles/sp-500-movers-csco-incy-2017-05-18", "https://www.nasdaq.com/articles/concert-pharma-falls-after-clinical-hold-on-hair-loss-drug-2017-05-18", "https://www.nasdaq.com/articles/stock-exchange-time-reconsider-healthcare-2017-05-26", "https://www.nasdaq.com/articles/incyte-incy-announces-positive-data-on-enzyme-inhibitor-2017-05-18", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-605513-4389-points-2017-05-18", "https://www.nasdaq.com/articles/thursday-sector-leaders-services-healthcare-2017-05-18", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-601124-down-15863-points-2017-05-17", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-casy-incy-twtr-2017-05-12", "https://www.nasdaq.com/articles/3-top-biotech-stocks-may-2017-05-11", "https://www.nasdaq.com/articles/bellevue-group-ag-buys-align-technology-inc-anthem-inc-walgreens-boots-alliance-inc-sells", "https://www.nasdaq.com/articles/doomed-trump-presidency-would-be-terrifying-development-pharmaceutical-stocks-2017-05-18", "https://www.nasdaq.com/articles/incyte-incy-q1-loss-narrower-than-expected-revenues-beat-2017-05-08", "https://www.nasdaq.com/articles/monday-sector-laggards-healthcare-services-2017-05-08", "https://www.nasdaq.com/articles/vot-eqix-aph-incy-etf-inflow-alert-2017-05-05", "https://www.nasdaq.com/articles/sp-500-movers-flr-mtd-2017-05-05", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-mnst-2017-05-05", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-financial-2017-05-05", "https://www.nasdaq.com/articles/4-biotech-stocks-that-could-be-rocked-and-rolled-this-month-2017-05-04", "https://www.nasdaq.com/articles/sp-500-movers-tsn-nwl-2017-05-08", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-4-2017-d-oxy-regn-cnq-zts-ppl-k-incy-apa-cce-wltw-abc-2017", "https://www.nasdaq.com/articles/5-toxic-stocks-to-dispose-of-or-play-short-for-profit-2017-05-02", "https://www.nasdaq.com/articles/incyte-corporation-incy-leads-11-activist-investor-filings-2017-05-01", "https://www.nasdaq.com/articles/5-things-bristol-myers-squibbs-management-wants-you-know-2017-04-29", "https://www.nasdaq.com/articles/should-you-get-rid-of-incyte-corporation-incy-now-2017-04-26", "https://www.nasdaq.com/articles/lilly-lly-tops-q1-earnings-misses-sales-shares-down-2017-04-25", "https://www.nasdaq.com/articles/should-gilead-sciences-acquire-newlink-genetics-2017-04-21", "https://www.nasdaq.com/articles/drug-stock-q1-earnings-releases-on-may-4%3A-zts-regn-more-2017-05-03", "https://www.nasdaq.com/articles/26-billion-company-markets-most-overpriced-biotech-stock-2017-04-20", "https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-insulet-incyte-intuitive-surgical-and-edwards-lifesciences", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-oncomed-2017-04-19", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ptc-covanta-holding-live-nation-entertainment-incyte-and", "https://www.nasdaq.com/articles/should-you-make-bet-healthcare-stocks-2017-04-18", "https://www.nasdaq.com/articles/why-incyte-corporation-stock-plunging-today-2017-04-17", "https://www.nasdaq.com/articles/mid-day-market-update-dow-surges-over-100-points-oncomed-shares-slide-2017-04-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-mat-incy-2017-04-21", "https://www.nasdaq.com/articles/eli-lilly-and-co-lly-stock-holders-choke-on-fda-letter-for-barictinib-2017-04-17", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-nvda-2017-04-17", "https://www.nasdaq.com/articles/sp-500-movers-incy-arnc-2017-04-17", "https://www.nasdaq.com/articles/eli-lillys-rheumatoid-arthritis-drug-gets-crl-in-the-u.s.-2017-04-17", "https://www.nasdaq.com/articles/lilly-and-incytes-loss-abbvie-and-regenerons-gain-2017-04-17", "https://www.nasdaq.com/articles/5-toxic-stocks-to-shun-or-play-short-right-now-2017-04-17", "https://www.nasdaq.com/articles/pre-market-most-active-apr-17-2017-alr-swc-mgi-bac-xiv-lly-xxia-incy-qqq-tlt-f-kep-2017-04", "https://www.nasdaq.com/articles/health-etfs-wobble-fda-spurns-arthritis-drug-blow-eli-lilly-2017-04-17", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-585679-5164-points-2017-04-17", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-1-mocon-shares-spike-higher-2017-04-17", "https://www.nasdaq.com/articles/monday-sector-laggards-energy-healthcare-2017-04-17", "https://www.nasdaq.com/articles/ido-inhibitor-race-improve-cancer-treatment-2017-04-13", "https://www.nasdaq.com/articles/nasdaq-100-movers-lila-alxn-2017-04-13", "https://www.nasdaq.com/articles/wednesday-412-insider-buying-report-incy-cbk-2017-04-12", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-583616-down-3061-points-2017-04-12", "https://www.nasdaq.com/articles/why-snyders-lance-incyte-and-tenet-healthcare-slumped-today-2017-04-17", "https://www.nasdaq.com/articles/sp-500-movers-amd-hes-2017-04-10", "https://www.nasdaq.com/articles/incy-crosses-above-average-analyst-target-2017-04-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-jd-esrx-2017-04-07", "https://www.nasdaq.com/articles/stock-exchange-finding-trading-ideas-low-volatility-market-2017-04-07", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-587781-down-114-points-2017-04-07", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-financial-2017-04-07", "https://www.nasdaq.com/articles/would-gilead-sciences-make-staggeringly-audacious-move-2017-04-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-tsla-2017-04-10", "https://www.nasdaq.com/articles/thursday-sector-laggards-utilities-healthcare-2017-04-06", "https://www.nasdaq.com/articles/agenus-agen-sharpens-focus-on-drug-development-programs-2017-04-05", "https://www.nasdaq.com/articles/why-newlink-genetics-shares-fell-103-today-2017-04-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-orly-tsla-2017-04-03", "https://www.nasdaq.com/articles/sp-500-movers-hpe-incy-2017-04-03", "https://www.nasdaq.com/articles/4-fda-decisions-watch-out-apr-2017-2017-04-03", "https://www.nasdaq.com/articles/bristol-myers-bmy-incyte-to-advance-clinical-program-2017-04-03", "https://www.nasdaq.com/articles/market-close-report-nasdaq-trading-volume-joins-top-ten-ranking-year-nasdaq-composite-24", "https://www.nasdaq.com/articles/4-drug-stocks-big-news-coming-april-2017-04-02", "https://www.nasdaq.com/articles/3-big-healthcare-stocks-wall-street-predicts-will-grow-fastest-2017-04-02", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ptc-covanta-holding-etsy-incyte-and-amag-pharmaceuticals", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-591174-down-260-points-2017-03-31", "https://www.nasdaq.com/articles/friday-sector-laggards-healthcare-services-2017-03-31", "https://www.nasdaq.com/articles/vo-fisv-aph-incy-large-inflows-detected-etf-2017-03-30", "https://www.nasdaq.com/articles/5-toxic-stocks-to-get-rid-of-or-play-short-to-make-gains-2017-03-30", "https://www.nasdaq.com/articles/monday-sector-leaders-healthcare-utilities-2017-04-03", "https://www.nasdaq.com/articles/best-case-scenario-gilead-sciences-inc-2017-03-24", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-581769-down-395-points-2017-03-23", "https://www.nasdaq.com/articles/thursday-sector-laggards-healthcare-energy-2017-03-23", "https://www.nasdaq.com/articles/nasdaq-100-movers-csx-mar-2017-03-21", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-579383-down-10770-points-2017-03-21", "https://www.nasdaq.com/articles/incyte-incy-up-26.2-since-earnings-report%3A-can-it-continue-2017-03-17", "https://www.nasdaq.com/articles/noteworthy-etf-outflows-ibb-biib-regn-incy-2017-03-16", "https://www.nasdaq.com/articles/strange-bullish-incy-analysts-actually-see-601-downside-2017-03-30", "https://www.nasdaq.com/articles/5-toxic-stocks-to-dump-or-play-short-to-make-gains-2017-03-15", "https://www.nasdaq.com/articles/3-reasons-why-gilead-sciences-will-buy-incyte-and-1-reason-why-it-wont-2017-03-15", "https://www.nasdaq.com/articles/sp-500-movers-tsco-dlph-2017-03-13", "https://www.nasdaq.com/articles/agenus-agen-reports-narrower-than-expected-loss-in-q4-2017-03-10", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-126-points-week-rising-3rd-straight-day-2017-03-10", "https://www.nasdaq.com/articles/incyte-corporation-cowen-healthcare-conference-4-things-youll-want-know-2017-03-09", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-covanta-holding-etsy-ptc-incyte-and-vertex-pharmaceuticals", "https://www.nasdaq.com/articles/wednesday-sector-leaders-services-healthcare-2017-03-08", "https://www.nasdaq.com/articles/friday-sector-leaders-healthcare-financial-2017-03-03", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-abercrombie-fitch-live-nation-entertainment-vertex", "https://www.nasdaq.com/articles/vxf-tsla-lbtya-incy-etf-inflow-alert-2017-02-28", "https://www.nasdaq.com/articles/5-toxic-stocks-to-abandon-or-play-short-right-now-2017-02-27", "https://www.nasdaq.com/articles/after-hours-most-active-feb-27-2017-enb-incy-ment-pg-swn-orcl-hun-xrx-yhoo-csco-qvca-tlt", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-incyte-2017-02-24", "https://www.nasdaq.com/articles/trip-8-year-bull-run-whats-whats-down-2017-03-09", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-584531-980-points-2017-02-24", "https://www.nasdaq.com/articles/heres-why-incyte-rose-much-8-today-2017-02-24", "https://www.nasdaq.com/articles/andreas-halvorsen-buys-maker-first-class-cancer-treatments-calithera-biosciences-2017-02", "https://www.nasdaq.com/articles/troubling-trial-data-weighed-agenus-inc-stock-today-2017-02-22", "https://www.nasdaq.com/articles/whats-driving-lillys-lly-shares-after-2016-decline-2017-02-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-siri-2017-02-15", "https://www.nasdaq.com/articles/biotech-stock-roundup-regenerons-praluent-remain-market-now-gild-presents-hiv-data-2017-02", "https://www.nasdaq.com/articles/nasdaq-100-movers-bidu-incy-2017-02-24", "https://www.nasdaq.com/articles/incytes-incy-beats-on-q4-earnings-provides-2017-outlook-2017-02-15", "https://www.nasdaq.com/articles/banks-loved-yellens-testimony-2017-02-15", "https://www.nasdaq.com/articles/why-agenus-stock-surging-today-2017-02-14", "https://www.nasdaq.com/articles/nasdaq-100-movers-logm-incy-2017-02-14", "https://www.nasdaq.com/articles/lillys-olumiant-gets-marketing-authorization-in-europe-2017-02-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-incyte-prothena-acorda-therapeutics-and-axovant", "https://www.nasdaq.com/articles/health-care-sector-update-02142017-incyagencynoholxavir-2017-02-14", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-581944-2017-02", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-ets-incyte-abercrombie-fitch-vertex-pharmaceuticals-and", "https://www.nasdaq.com/articles/vasco-vdsi-q4-earnings%3A-whats-in-store-for-the-stock-2017-02-13", "https://www.nasdaq.com/articles/should-you-sell-incyte-incy-before-earnings-2017-02-13", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-14-2017-tmus-incy-q-tap-dps-nbl-mlm-brx-disck-tru-ipgp", "https://www.nasdaq.com/articles/gilead-sciences-getting-ready-massive-acquisition-2017-02-12", "https://www.nasdaq.com/articles/alexion-alxn-q4-earnings%3A-can-the-stock-pull-a-surprise-2017-02-10", "https://www.nasdaq.com/articles/will-zoetis-zts-disappoint-estimates-this-earnings-season-2017-02-10", "https://www.nasdaq.com/articles/whats-in-store-for-avis-budget-car-this-earnings-season-2017-02-13", "https://www.nasdaq.com/articles/strange-bullish-incy-analysts-actually-see-372-downside-2017-02-09", "https://www.nasdaq.com/articles/5-toxic-stocks-to-dump-or-play-short-for-gains-2017-02-09", "https://www.nasdaq.com/articles/5-drug-stocks-poised-beat-earnings-estimates-q4-2017-02-09", "https://www.nasdaq.com/articles/can-prothena-prta-pull-a-surprise-this-earnings-season-2017-02-08", "https://www.nasdaq.com/articles/regeneron-regn-q4-earnings%3A-will-the-stock-disappoint-2017-02-08", "https://www.nasdaq.com/articles/gilead-sciences-gild-q4-earnings%3A-whats-in-the-cards-2017-02-03", "https://www.nasdaq.com/articles/gw-pharmaceuticals-gwph-q1-earnings%3A-whats-in-store-2017-02-02", "https://www.nasdaq.com/articles/4-stocks-under-4-could-double-2017-02-09", "https://www.nasdaq.com/articles/mallinckrodt-mnk-earnings-this-quarter%3A-stock-to-disappoint-2017-02-01", "https://www.nasdaq.com/articles/incyte-and-calithera-enter-into-deal-for-oncology-candidate-2017-01-31", "https://www.nasdaq.com/articles/calithera-biosciences-cala-in-focus%3A-stock-jumps-46.7-2017-01-31", "https://www.nasdaq.com/articles/midday-update-outcry-surrounding-travel-ban-spooks-investors-2017-01-30", "https://www.nasdaq.com/articles/health-care-sector-update-01302017-jnj-pfe-abt-mrk-amgn-ocrx-cala-eyeg-2017-01-30", "https://www.nasdaq.com/articles/mid-day-market-update-dow-falls-over-150-points-calithera-biosciences-shares-spike-higher", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-booz-allen-profit-misses-estimates-2017-01-30", "https://www.nasdaq.com/articles/forget-anavex-life-sciences-corp-these-2-biotech-stocks-are-better-buys-2017-02-01", "https://www.nasdaq.com/articles/close-update-immigration-ban-unnerves-wall-street-travel-stocks-pummeled-2017-01-30", "https://www.nasdaq.com/articles/health-care-sector-update-01302017-rglscalaincy-2017-01-30", "https://www.nasdaq.com/articles/mid-afternoon-market-update-tempur-sealy-drops-after-loss-mattress-firm-contract-digital", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-live-nation-entertainment-conns-conocophillips-etsy-and", "https://www.nasdaq.com/articles/forget-incyte-gilead-sciences-would-be-better-buying-company-2017-01-25", "https://www.nasdaq.com/articles/5-toxic-stocks-to-dump-or-play-short-now-2017-01-25", "https://www.nasdaq.com/articles/incyte-has-insight-market-potential-blockbuster-drugs-2017-01-23", "https://www.nasdaq.com/articles/better-buy-inovio-pharmaceuticals-vs-incyte-corp-2017-01-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-csx-swks-2017-01-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-dltr-2017-01-17", "https://www.nasdaq.com/articles/lilly-incyte-rheumatoid-arthritis-drug-pdufa-date-extended-2017-01-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-swks-incy-2017-01-12", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-ibb-regn-alxn-incy-2017-01-10", "https://www.nasdaq.com/articles/4-stocks-focus-biotech-ma-hopes-surge-takeda-ariad-deal-2017-01-10", "https://www.nasdaq.com/articles/incyte-merck-to-start-more-epacadostat-keytruda-studies-2017-01-10", "https://www.nasdaq.com/articles/incyte-has-insight-market-potential-blockbuster-drugs-2017-01-20", "https://www.nasdaq.com/articles/nasdaq-100-movers-vod-incy-2017-01-09", "https://www.nasdaq.com/articles/incyte-reaches-analyst-target-price-2017-01-09", "https://www.nasdaq.com/articles/market-close-report-historical-high-reached-nasdaq-composite-index-closes-553182-2017-01", "https://www.nasdaq.com/articles/3-stocks-expected-more-double-their-earnings-2017-2017-01-08", "https://www.nasdaq.com/articles/biotech-investing-3-bold-predictions-2017-2017-01-06", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-cbrl-incy-bwld-2017-01-06", "https://www.nasdaq.com/articles/3-reasons-geron-corporation-plunged-57-2016-2017-01-05", "https://www.nasdaq.com/articles/incytes-prospects-get-even-brighter-merck-announcement-2017-01-10", "https://www.nasdaq.com/articles/bluerock-residential-growth-reit-cal-maine-foods-incyte-eli-lilly-and-synergy", "https://www.nasdaq.com/articles/incyte-treats-first-patient-in-phase-ii-gvhd-study-on-jakafi-2017-01-02", "https://www.nasdaq.com/articles/two-key-fda-decisions-watch-out-january-2017-2017-01-02", "https://www.nasdaq.com/articles/3-biotech-stocks-turned-10000-over-100000-2016-12-31", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-alexion-pharmaceuticals-celgene-incyte-eli-lilly", "https://www.nasdaq.com/articles/forget-alexion-alxn-buy-these-3-biotech-stocks-instead-2016-12-27", "https://www.nasdaq.com/articles/incyte-merus-ink-collaboration-for-bispecific-antibodies-2016-12-22", "https://www.nasdaq.com/articles/commit-buy-incyte-corporation-70-earn-107-using-options-2017-01-03", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-finish-line-misses-q3-expectations-2016-12-21", "https://www.nasdaq.com/articles/futures-mixed-after-another-record-setting-run-dow-and-nasdaq-2016-12-21", "https://www.nasdaq.com/articles/christmas-came-early-these-biotech-stocks-2016-12-21", "https://www.nasdaq.com/articles/close-update-wall-street-retreats-record-highs-leaving-dow-20000-another-day-2016-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-12212016-alxngildmrusincymack-2016-12-21", "https://www.nasdaq.com/articles/mid-afternoon-market-update-crude-oil-down-15-merus-shares-spike-higher-2016-12-21", "https://www.nasdaq.com/articles/health-care-sector-update-12212016-calabmymrusincymack-2016-12-21", "https://www.nasdaq.com/articles/midday-update-wall-street-retreats-record-highs-2016-12-21", "https://www.nasdaq.com/articles/3-biggest-risks-incyte-corporation-2016-12-17", "https://www.nasdaq.com/articles/could-geron-corporation-be-millionaire-maker-stock-2016-12-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-cost-2016-12-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-wdc-2016-12-07", "https://www.nasdaq.com/articles/nasdaq-composite-index-closes-2411-points-week-rising-4th-straight-day-2016-12-07", "https://www.nasdaq.com/articles/gw-pharmaceuticals-plc-adr-gwph-stock-is-just-getting-started-2016-12-06", "https://www.nasdaq.com/articles/gilead-sciences-incs-worst-moves-2016-2016-12-06", "https://www.nasdaq.com/articles/incyte-lilly-olumiant-wins-chmp-nod-for-rheumatoid-arthritis-2016-12-19", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-december-2016-12-01", "https://www.nasdaq.com/articles/3-biotech-stocks-buy-sale-2016-11-29", "https://www.nasdaq.com/articles/intellipharmaceutics-submits-nda-for-pain-treatment-rexista-2016-11-28", "https://www.nasdaq.com/articles/read-you-buy-any-marijuana-stocks-2016-11-26", "https://www.nasdaq.com/articles/merck-mrk-announces-2.2-increase-in-quarterly-dividend-2016-11-24", "https://www.nasdaq.com/articles/novo-nordisks-diabetes-combination-drug-gets-fdas-nod-2016-11-23", "https://www.nasdaq.com/articles/when-will-gilead-sciences-unlucky-streak-end-2016-11-23", "https://www.nasdaq.com/articles/agenus-incagn1876-in-phase-i-ii-study-for-solid-tumors-2016-12-01", "https://www.nasdaq.com/articles/ligands-partner-retrophin-provides-new-data-on-sparsentan-2016-11-22", "https://www.nasdaq.com/articles/aduro-reports-partial-hold-lift-on-ladd-studies-in-u.s.-2016-11-22", "https://www.nasdaq.com/articles/sanofi-sny-soliqua-approved-for-type-2-diabetes-in-adults-2016-11-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-hsic-nflx-2016-11-21", "https://www.nasdaq.com/articles/new-oriental-education-technology-group-bjs-restaurants-ariad-pharmaceuticals-incyte-and", "https://www.nasdaq.com/articles/endo-reports-positive-cellulite-treatment-data-on-xiaflex-2016-11-18", "https://www.nasdaq.com/articles/shire-launches-cuvitru-in-u.s.-for-primary-immunodeficiency-2016-11-17", "https://www.nasdaq.com/articles/astrazeneca%3A-fda-lifts-hold-on-head-neck-cancer-trials-2016-11-23", "https://www.nasdaq.com/articles/increased-earnings-estimates-seen-for-incyte-incy%3A-can-it-move-higher-2016-11-17", "https://www.nasdaq.com/articles/gilead-reports-phase-iii-myelofibrosis-data-on-momelotinib-2016-11-17", "https://www.nasdaq.com/articles/bad-news-gilead-sciences-good-news-incyte-2016-11-17", "https://www.nasdaq.com/articles/ionis-ions-offers-positive-interim-data-on-lipid-candidate-2016-11-16", "https://www.nasdaq.com/articles/celldex-stock-up-on-positive-data-on-new-cancer-candidate-2016-11-15", "https://www.nasdaq.com/articles/repros-rprx-reports-positive-top-line-data-on-proellex-2016-11-15", "https://www.nasdaq.com/articles/incyte-eli-lilly-offer-positive-phase-iii-data-on-baricitinib-2016-11-15", "https://www.nasdaq.com/articles/3-stocks-add-your-portfolio-biotech-ma-hopes-rise-2016-11-17", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-enzo-biochem-exelixis-genmab-a-s-heska-and-incyte-2016", "https://www.nasdaq.com/articles/incy-crosses-above-average-analyst-target-2016-11-10", "https://www.nasdaq.com/articles/drug-stocks-surge-trump-win-5-stocks-buy-now-2016-11-10", "https://www.nasdaq.com/articles/why-incyte-incy-could-be-a-potential-winner-2016-11-09", "https://www.nasdaq.com/articles/ariad-aria-stock-up-on-narrower-than-expected-q3-loss-2016-11-08", "https://www.nasdaq.com/articles/nasdaq-100-movers-lvnta-biib-2016-11-07", "https://www.nasdaq.com/articles/3-things-you-really-need-know-about-ariad-pharmaceuticals-inc-q3-results-2016-11-07", "https://www.nasdaq.com/articles/3-highest-growth-stocks-market-today-2016-11-11", "https://www.nasdaq.com/articles/gilead-gild-misses-q3-earnings-estimates-retains-view-2016-11-02", "https://www.nasdaq.com/articles/waiting-game-sends-geron-corporation-lower-another-18-october-2016-11-02", "https://www.nasdaq.com/articles/zoetis-zts-tops-q3-earnings-estimates-updates-outlook-2016-11-02", "https://www.nasdaq.com/articles/incyte-incy-stock-up-as-q3-earnings-revenues-rise-y-y-2016-11-02", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-515358-down-3556-points-2016-11-01", "https://www.nasdaq.com/articles/noteworthy-etf-inflows-xbi-srpt-tsro-incy-2016-10-28", "https://www.nasdaq.com/articles/biomarin-bmrn-q3-loss-narrows-y-y-pipeline-in-focus-2016-10-28", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-504637-down-1204-points-2016-11-04", "https://www.nasdaq.com/articles/agenus-agen-reports-wider-than-expected-loss-in-q3-2016-10-28", "https://www.nasdaq.com/articles/celgene-celg-beats-on-q3-earnings-raises-16-outlook-2016-10-27", "https://www.nasdaq.com/articles/bristol-myers-bmy-beats-on-q3-earnings-ups-2016-view-2016-10-27", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-incyte-legacytexas-financial-group-exelixis-bayerische", "https://www.nasdaq.com/articles/merck-mrk-beats-on-q3-earnings-revenues-lifts-view-2016-10-25", "https://www.nasdaq.com/articles/5-profitable-stocks-for-outstanding-returns-2016-10-25", "https://www.nasdaq.com/articles/aduro-stock-down-on-partial-clinical-hold-on-ladd-studies-2016-10-25", "https://www.nasdaq.com/articles/ariad-aria%3A-is-a-beat-in-the-cards-this-earnings-season-2016-10-28", "https://www.nasdaq.com/articles/agenus-agen%3A-whats-ahead-for-the-stock-in-q3-earnings-2016-10-24", "https://www.nasdaq.com/articles/roche-rhhby-misses-q3-sales-estimates-2016-view-intact-2016-10-21", "https://www.nasdaq.com/articles/spdr-sp-biotech-etf-experiences-big-outflow-2016-10-20", "https://www.nasdaq.com/articles/roches-tecentriq-wins-fda-nod-for-additional-indication-2016-10-19", "https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q3-earnings-narrows-2016-view-2016-10-19", "https://www.nasdaq.com/articles/regeneron-teva-hit-by-clinical-hold-on-chronic-pain-study-2016-10-18", "https://www.nasdaq.com/articles/shire-shpg-updates-vyvanse-label-with-new-efficacy-data-2016-10-18", "https://www.nasdaq.com/articles/novartis-nvs-tops-q3-earnings-misses-sales-estimates-2016-10-25", "https://www.nasdaq.com/articles/intercept-icpt-ocaliva-wins-positive-chmp-opinion-for-pbc-2016-10-17", "https://www.nasdaq.com/articles/celgene-to-present-phase-ib-data-on-crohns-disease-drug-2016-10-17", "https://www.nasdaq.com/articles/bristol-myers-wins-chmp-nod-for-opdivo-label-expansion-2016-10-17", "https://www.nasdaq.com/articles/oculars-ocul-stock-jumps-on-collaboration-with-regeneron-2016-10-14", "https://www.nasdaq.com/articles/biomarin-issues-encouraging-update-on-hemophilia-a-drug-2016-10-14", "https://www.nasdaq.com/articles/merck-kgaa-offers-portfolio-updates-at-market-day-event-2016-10-14", "https://www.nasdaq.com/articles/horizon-hznp-stock-down-on-dull-q3-view-cuts-16-outlook-2016-10-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-mat-2016-10-17", "https://www.nasdaq.com/articles/mylan-up-on-epipen-medicaid-settlement-cuts-2016-outlook-2016-10-12", "https://www.nasdaq.com/articles/biotech-stock-roundup-alnylam-slumps-revusiran-update-tesaro-impresses-esmo-2016-10-12", "https://www.nasdaq.com/articles/3-biotechs-most-likely-be-acquired-2016-10-11", "https://www.nasdaq.com/articles/xbi-srpt-ions-incy-large-outflows-detected-etf-2016-10-11", "https://www.nasdaq.com/articles/new-strong-buy-stocks-october-11th-2016-10-11", "https://www.nasdaq.com/articles/will-gilead-sciences-inc-set-its-sights-incyte-2016-10-10", "https://www.nasdaq.com/articles/can-the-rally-in-incyte-incy-shares-continue-2016-10-10", "https://www.nasdaq.com/articles/alnylam-alny-to-continue-phase-iii-study-on-patisiran-2016-10-12", "https://www.nasdaq.com/articles/nasdaq-100-movers-lbtyk-incy-2016-10-07", "https://www.nasdaq.com/articles/these-are-fastest-growing-profitable-biotech-stocks-2016-10-07", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-529241-down-1444-points-2016-10-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-tsla-lrcx-2016-10-06", "https://www.nasdaq.com/articles/ariad-aria-leukemia-drug-iclusig-gets-approval-in-japan-2016-09-30", "https://www.nasdaq.com/articles/nasdaq-100-movers-payx-incy-2016-09-28", "https://www.nasdaq.com/articles/market-close-report-nasdaq-composite-index-closes-531855-1284-points-2016-09-28", "https://www.nasdaq.com/articles/10-hot-stocks-that-made-millionaires-in-10-years-2016-10-10", "https://www.nasdaq.com/articles/national-research-corporation-nrcia-ex-dividend-date-scheduled-september-28-2016-2016-09", "https://www.nasdaq.com/articles/national-research-corporation-nrcib-ex-dividend-date-scheduled-september-28-2016-2016-09", "https://www.nasdaq.com/articles/nasdaq-100-movers-ntes-wdc-2016-09-26", "https://www.nasdaq.com/articles/3-buyout-targets-could-get-snatched-2016-09-21", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-swks-2016-09-15", "https://www.nasdaq.com/articles/implied-analyst-12-month-target-qqew-2016-09-15", "https://www.nasdaq.com/articles/2-companies-johnson-johnson-should-consider-buying-2016-09-09", "https://www.nasdaq.com/articles/wednesdays-etf-unusual-volume-ftc-2016-09-28", "https://www.nasdaq.com/articles/car-t-isnt-only-play-immunotherapy-stocks-2016-09-07", "https://www.nasdaq.com/articles/cti-biopharma-reports-mixed-pacritinib-study-data-stock-up-2016-08-30", "https://www.nasdaq.com/articles/incy-crosses-above-key-moving-average-level-2016-08-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-intu-incy-2016-08-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-myl-amat-2016-08-23", "https://www.nasdaq.com/articles/mondays-etf-movers-bbh-sil-2016-08-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-viab-incy-2016-08-22", "https://www.nasdaq.com/articles/notable-etf-outflow-detected-pbe-incy-bmrn-regn-2016-09-08", "https://www.nasdaq.com/articles/car-t-isnt-only-play-immunotherapy-stocks-2016-09-07", "https://www.nasdaq.com/articles/add-pieces-guru-could-be-worth-27-2016-08-15", "https://www.nasdaq.com/articles/better-buy-inovio-pharmaceuticals-inc-vs-incyte-corporation-2016-08-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-yhoo-2016-08-11", "https://www.nasdaq.com/articles/why-ariad-pharmaceuticals-gained-269-july-2016-08-10", "https://www.nasdaq.com/articles/repros-rprx-q2-loss-narrower-yy-focus-pipeline-2016-08-10", "https://www.nasdaq.com/articles/nasdaq-100-movers-nflx-qvca-2016-08-08", "https://www.nasdaq.com/articles/2-cancer-therapy-stocks-are-ridiculously-cheap-right-now-2016-08-18", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-9-2016-chtr-exc-ppl-hcp-incy-tdg-coh-lng-wwav-nclh-br", "https://www.nasdaq.com/articles/can-transdigm-tdg-spring-a-surprise-in-q3-earnings-2016-08-05", "https://www.nasdaq.com/articles/whats-in-store-for-myriad-genetics-mygn-in-q4-earnings-2016-08-05", "https://www.nasdaq.com/articles/biodelivery-bdsi-q2-earnings-will-stock-disappoint-2016-08-05", "https://www.nasdaq.com/articles/jazz-jazz-q2-earnings-will-stock-disappoint-2016-08-05", "https://www.nasdaq.com/articles/mylan-myl-q2-earnings%3A-will-the-stock-disappoint-2016-08-05", "https://www.nasdaq.com/articles/celldex-cldx-whats-ahead-stock-q2-earnings-2016-08-04", "https://www.nasdaq.com/articles/drug-stocks-to-watch-for-earnings-on-aug-9%3A-myl-incy-more-2016-08-08", "https://www.nasdaq.com/articles/repros-rprx-q2-earnings-whats-store-stock-2016-08-04", "https://www.nasdaq.com/articles/kite-kite-q2-earnings-whats-store-stock-2016-08-04", "https://www.nasdaq.com/articles/ariads-aria-stock-q2-earnings-revenue-beat-2016-07-29", "https://www.nasdaq.com/articles/why-ariad-pharmaceuticals-shares-jumped-125-today-2016-07-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-akam-aapl-2016-07-27", "https://www.nasdaq.com/articles/ariad-aria-report-q2-earnings-will-stock-surprise-2016-07-26", "https://www.nasdaq.com/articles/incyte-breaks-above-200-day-moving-average-bullish-incy-2016-07-21", "https://www.nasdaq.com/articles/allergan-agn-q2-earnings-will-stock-disappoint-2016-08-04", "https://www.nasdaq.com/articles/agenus-or-ariad-pharmaceuticals-better-long-term-buy-2016-07-19", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-incy-2016-07-15", "https://www.nasdaq.com/articles/nasdaq-100-movers-nxpi-csx-2016-07-14", "https://www.nasdaq.com/articles/better-buy-alnylam-pharmaceuticals-inc-vs-incyte-2016-07-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-aal-endp-2016-07-06", "https://www.nasdaq.com/articles/why-agenus-stock-has-stumbled-2016-2016-06-27", "https://www.nasdaq.com/articles/incyte-gains-on-jakafis-breakthrough-status-for-acute-gvhd-2016-06-24", "https://www.nasdaq.com/articles/eli-lilly-lly-may-beat-q2-earnings-will-stock-gain-2016-07-21", "https://www.nasdaq.com/articles/commit-buy-incyte-corporation-45-earn-116-using-options-2016-06-21", "https://www.nasdaq.com/articles/should-pfizer-buy-beaten-down-immuno-oncology-company-2016-06-14", "https://www.nasdaq.com/articles/incytes-jakafi-positive-in-phase-iii-for-polycythemia-study-2016-06-10", "https://www.nasdaq.com/articles/3-reasons-ariad-pharmaceuticals-inc-stock-rose-233-may-2016-06-09", "https://www.nasdaq.com/articles/incyte-reports-five-year-data-from-phase-iii-study-on-jakafi-2016-06-07", "https://www.nasdaq.com/articles/nasdaq-100-movers-fast-wfm-2016-06-06", "https://www.nasdaq.com/articles/4-catalysts-send-incyte-corporation-17-higher-may-2016-06-03", "https://www.nasdaq.com/articles/incyte-reports-epacadostat-combination-study-initiation-2016-06-23", "https://www.nasdaq.com/articles/ariad-aria-q1-loss-narrower-revenues-disappoint-revised-2016-05-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-amzn-2016-05-10", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-horizon-pharma-incyte-juno-therapeutics-halozyme", "https://www.nasdaq.com/articles/qqews-underlying-holdings-could-mean-19-gain-potential-2016-05-09", "https://www.nasdaq.com/articles/biotech-stocks-reporting-may-9-incy-hznp-juno-more-2016-05-06", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-9-2016-jd-xel-tsn-hcp-incy-qvca-slw-aes-lvnta-stwd-rba-2016", "https://www.nasdaq.com/articles/nasdaq-100-movers-sbac-alxn-2016-05-03", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-srne-incy-bwld-2016-05-20", "https://www.nasdaq.com/articles/why-agenus-inc-stock-soared-43-march-2016-04-11", "https://www.nasdaq.com/articles/could-biotech-company-be-about-soar-higher-2016-04-10", "https://www.nasdaq.com/articles/3-big-battles-brewing-biotech-2016-04-10", "https://www.nasdaq.com/articles/last-weeks-best-healthcare-etf-2016-04-08", "https://www.nasdaq.com/articles/incyte-buys-rights-to-jakafi-for-graft-versus-host-disease-2016-04-07", "https://www.nasdaq.com/articles/analysts-anticipate-mtum-will-reach-81-2016-04-07", "https://www.nasdaq.com/articles/deal-sent-incyte-shares-soaring-12-today-2016-04-06", "https://www.nasdaq.com/articles/vanguard-boosts-stake-incyte-st-quarter-2016-05-03", "https://www.nasdaq.com/articles/nasdaq-100-movers-endp-incy-2016-03-31", "https://www.nasdaq.com/articles/buying-these-2-drug-developers-would-make-lot-sense-johnson-johnson-2016-03-31", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-down-28-kb-home-shares-surge-following-strong-results-2016", "https://www.nasdaq.com/articles/nasdaq-100-movers-pypl-incy-2016-03-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-nclh-bmrn-2016-03-22", "https://www.nasdaq.com/articles/nasdaq-100-movers-regn-wdc-2016-03-09", "https://www.nasdaq.com/articles/agenus-q4-loss-in-line-with-estimates-revenues-impress-2016-03-04", "https://www.nasdaq.com/articles/better-buy-juno-therapeutics-vs-incyte-2016-03-31", "https://www.nasdaq.com/articles/3-all-or-nothing-biotech-stocks-were-closely-watching-2016-02-20", "https://www.nasdaq.com/articles/top-insider-trades-past-week-2016-02-20", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-incyte-intercept-pharma-gilead-aegerion-and-clovis-2016", "https://www.nasdaq.com/articles/nasdaq-100-movers-cern-pcln-2016-02-17", "https://www.nasdaq.com/articles/biotech-stock-roundup-incyte-down-jakafi-update-intercept-buyout-target-2016-02-17", "https://www.nasdaq.com/articles/better-buy-inovio-pharmaceuticals-inc-vs-incyte-corporation-2016-02-16", "https://www.nasdaq.com/articles/incyte-incy-beats-on-q4-earnings-and-revenue-estimates-2016-02-12", "https://www.nasdaq.com/articles/frank-sands-acquires-stake-netflix-2016-02-24", "https://www.nasdaq.com/articles/why-incytes-shares-are-tumbling-today-2016-02-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-trip-2016-02-11", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-lower-pepsico-posts-line-q4-profit-2016-02-11", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-11-2016-pep-rai-tri-k-tu-nlsn-tap-incy-cce-aap-bg-mos", "https://www.nasdaq.com/articles/vxf-lnkd-incy-bmrn-etf-outflow-alert-2016-02-08", "https://www.nasdaq.com/articles/shares-incyte-corporation-plummeted-january-heres-why-2016-02-07", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-amgen-top-estimates-zika-virus-grabs-attention-2016-02-03", "https://www.nasdaq.com/articles/mid-day-market-update-dow-drops-over-300-points-cisco-shares-surge-following-strong-q2", "https://www.nasdaq.com/articles/forget-biosimilars-its-threat-could-dent-abbvies-top-line-2016-01-31", "https://www.nasdaq.com/articles/mid-day-market-update-facebook-surges-strong-results-servicenow-shares-slip-2016-01-28", "https://www.nasdaq.com/articles/notable-etf-inflow-detected-vxf-lnkd-incy-bmrn-2016-01-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-ebay-fb-2016-01-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-ford-tops-q4-views-2016-01-28", "https://www.nasdaq.com/articles/why-incytes-shares-crashed-12-today-2016-01-28", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-rises-over-100-points-ebay-shares-drop-disappointing", "https://www.nasdaq.com/articles/math-shows-qqq-can-go-129-2016-02-03", "https://www.nasdaq.com/articles/thursdays-etf-movers-oih-fbt-2016-01-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-incy-sbac-2016-01-26", "https://www.nasdaq.com/articles/nasdaq-100-movers-sndk-mat-2016-01-25", "https://www.nasdaq.com/articles/nasdaq-100-movers-sbux-sbac-2016-01-22", "https://www.nasdaq.com/articles/why-shares-agenus-are-breaking-out-today-2016-01-21", "https://www.nasdaq.com/articles/2-speculative-small-cap-biotech-stocks-could-double-2016-01-21", "https://www.nasdaq.com/articles/what-makes-incyte-incy-a-strong-sell-2016-01-20", "https://www.nasdaq.com/articles/incyte-halts-phase-ii-jakafi-stivarga-combination-study-2016-01-28", "https://www.nasdaq.com/articles/incyte-corporation-incy-in-focus%3A-stock-plunges-11-2016-01-14", "https://www.nasdaq.com/articles/incyte-incy-provides-update-on-pipeline-candidates-2016-01-13", "https://www.nasdaq.com/articles/geron-corporation-exploded-49-higher-2015-heres-why-2016-01-11", "https://www.nasdaq.com/articles/vxf-lnkd-incy-bmrn-etf-inflow-alert-2015-12-28", "https://www.nasdaq.com/articles/nasdaq-100-movers-bidu-ilmn-2015-12-24", "https://www.nasdaq.com/articles/nasdaq-100-movers-stx-mat-2015-12-14", "https://www.nasdaq.com/articles/pbe-bmrn-incy-vrtx-large-outflows-detected-etf-2015-12-10", "https://www.nasdaq.com/articles/incyte-reports-baricitinib-nda-filing-for-rheumatoid-arthritis-2016-01-20", "https://www.nasdaq.com/articles/vxf-ilmn-lnkd-incy-large-inflows-detected-etf-2015-11-18", "https://www.nasdaq.com/articles/january-2018-options-now-available-incyte-incy-2015-11-16", "https://www.nasdaq.com/articles/nasdaq-100-movers-bmrn-jd-2015-11-12", "https://www.nasdaq.com/articles/time-provides-best-cure-gerons-recent-weakness-2015-11-11", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-incy-2015-11-09", "https://www.nasdaq.com/articles/incyte-down-on-data-from-epacadostat-combination-study-2015-11-09", "https://www.nasdaq.com/articles/incyte-incy-shares-cross-below-200-dma-2015-11-06", "https://www.nasdaq.com/articles/thursdays-etf-movers-gdx-bbh-2015-12-03", "https://www.nasdaq.com/articles/incyte-q3-loss-narrower-than-expected-ups-jakafi-outlook-2015-11-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-gmcr-2015-11-03", "https://www.nasdaq.com/articles/pre-market-earnings-report-november-3-2015-emr-adm-sre-mhfi-k-trp-zts-incy-fis-s-hcp-nclh", "https://www.nasdaq.com/articles/nasdaq-100-movers-wynn-sndk-2015-10-19", "https://www.nasdaq.com/articles/5-immunotherapy-stocks-watch-treating-cancer-2015-10-16", "https://www.nasdaq.com/articles/why-incyte-corporation-incy-isnt-done-growing-earnings-yet-2015-10-14", "https://www.nasdaq.com/articles/incyte-merck-expand-melanoma-treatment-collaboration-2015-10-14", "https://www.nasdaq.com/articles/why-incyte-corporation-shares-are-crashing-today-2015-11-06", "https://www.nasdaq.com/articles/incyte-q3-loss-narrower-than-expected-ups-jakafi-outlook-2015-11-04", "https://www.nasdaq.com/articles/nasdaq-100-movers-vip-gmcr-2015-11-03", "https://www.nasdaq.com/articles/why-incyte-corporation-incy-could-shock-the-market-soon-2015-10-09", "https://www.nasdaq.com/articles/3-reasons-why-incyte-corporation-incy-is-a-great-momentum-stock-2015-10-07", "https://www.nasdaq.com/articles/3-large-cap-biotech-stocks-whose-valuations-should-make-you-skeptical-2015-10-07", "https://www.nasdaq.com/articles/could-cti-biopharmas-fda-shortcut-spell-trouble-incyte-2015-10-06", "https://www.nasdaq.com/articles/after-hours-most-active-oct-6-2015-yum-altr-csco-incy-ete-msft-intc-ge-oln-bac-cie-qqq", "https://www.nasdaq.com/articles/eli-lilly-incytes-baricitinib-scores-in-phase-iii-study-2015-10-14", "https://www.nasdaq.com/articles/incyte-eli-lilly-post-positive-phase-iii-data-on-baricitinib-2015-09-30", "https://www.nasdaq.com/articles/biotech-stock-roundup-pricing-concerns-hit-biotech-stocks-eu-nod-regenerons-praluent-2015", "https://www.nasdaq.com/articles/national-research-corporation-nrcia-ex-dividend-date-scheduled-september-28-2015-2015-09", "https://www.nasdaq.com/articles/aduro-adro-to-acquire-bionovion-in-cash-and-stock-deal-2015-09-25", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-november-20th-2015-09-23", "https://www.nasdaq.com/articles/could-these-2-biopharmas-be-real-apples-gilead-sciences-eye-2015-09-17", "https://www.nasdaq.com/articles/small-cap-biotech-could-wind-devouring-much-larger-foes-revenue-stream-2015-09-11", "https://www.nasdaq.com/articles/incyte-incy-shows-strength%3A-stock-adds-7.2-in-session-2015-10-05", "https://www.nasdaq.com/articles/heres-why-geron-corporations-stock-ripping-higher-today-2015-09-03", "https://www.nasdaq.com/articles/incyte-hengrui-to-develop-anti-pd-1-monoclonal-antibody-2015-09-03", "https://www.nasdaq.com/articles/are-3-best-performing-big-cap-biotech-stocks-2015-still-worth-buying-2015-08-17", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-december-2016-2015-08-14", "https://www.nasdaq.com/articles/why-incyte-corporation-incy-might-be-a-diamond-in-the-rough-2015-08-11", "https://www.nasdaq.com/articles/incyte-q2-loss-narrower-than-expected-ups-jakafi-outlook-analyst-blog-2015-08-05", "https://www.nasdaq.com/articles/health-care-sector-update-08052015-aria-scmp-incy-2015-08-05", "https://www.nasdaq.com/articles/aduro-incyte-in-clinical-trial-agreement-for-ovarian-cancer-2015-09-11", "https://www.nasdaq.com/articles/first-week-incy-march-2016-options-trading-2015-07-21", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-13th-tale-of-the-tape-2015-07-13", "https://www.nasdaq.com/articles/national-research-corporation-nrcia-ex-dividend-date-scheduled-june-26-2015-2015-06-25", "https://www.nasdaq.com/articles/what-caused-eli-lilly-and-co-shares-vault-higher-may-2015-06-04", "https://www.nasdaq.com/articles/agenus-gains-after-merck-extends-immuno-oncology-ties-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/why-shares-advaxis-inc-are-surging-higher-2015-06-01", "https://www.nasdaq.com/articles/highest-paid-ceos-biotech-2015-05-30", "https://www.nasdaq.com/articles/pre-market-earnings-report-august-4-2015-cvs-regn-aet-emr-adm-sre-zts-hcn-k-chtr-incy-hcp", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q1-loss-jakafi-grows-analyst-blog-2015-05-04", "https://www.nasdaq.com/articles/3-growth-stocks-near-52-week-highs-worth-selling-2015-05-01", "https://www.nasdaq.com/articles/3-stable-large-cap-biotech-stocks-to-buy-now-analyst-blog-2015-04-29", "https://www.nasdaq.com/articles/why-agenus-inc-shares-surged-higher-early-trading-today-2015-04-28", "https://www.nasdaq.com/articles/why-agenus-inc-shares-are-soaring-today-2015-04-24", "https://www.nasdaq.com/articles/fxh-incy-uthr-mdvn-large-inflows-detected-etf-2015-04-22", "https://www.nasdaq.com/articles/will-agenus-agen-disappoint-in-q1-earning-season-analyst-blog-2015-04-22", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-incyte-incy%3A-time-to-buy-tale-of-the-tape-2015-05-27", "https://www.nasdaq.com/articles/reason-behind-geron-corporations-25-catapult-higher-march-2015-04-09", "https://www.nasdaq.com/articles/why-its-not-too-late-buy-agenus-inc-stock-2015-03-31", "https://www.nasdaq.com/articles/national-research-corporation-nrcia-ex-dividend-date-scheduled-march-27-2015-2015-03-26", "https://www.nasdaq.com/articles/novartis-jakavi-gets-ec-approval-for-polycythemia-vera-analyst-blog-2015-03-18", "https://www.nasdaq.com/articles/commit-purchase-incyte-corporation-6750-earn-7-annualized-using-options-2015-03-11", "https://www.nasdaq.com/articles/why-cti-biopharma-corp-surging-higher-today-2015-03-09", "https://www.nasdaq.com/articles/eli-lillys-bil-filing-delayed-baricitinib-scores-phase-iii-analyst-blog-2015-02-24", "https://www.nasdaq.com/articles/mondays-etf-movers-xbi-gdxj-2015-04-13", "https://www.nasdaq.com/articles/should-you-sell-incyte-incy-before-earnings-tale-of-the-tape-2015-02-12", "https://www.nasdaq.com/articles/3-all-or-nothing-biotech-stocks-were-closely-watching-2015-02-09", "https://www.nasdaq.com/articles/incytes-phase-iii-response-data-on-jakafi-published-analyst-blog-2015-01-29", "https://www.nasdaq.com/articles/will-incyte-incy-continue-to-surge-higher-tale-of-the-tape-2015-01-28", "https://www.nasdaq.com/articles/astrazeneca-inks-immuno-oncology-agreement-with-omnis-analyst-blog-2015-01-14", "https://www.nasdaq.com/articles/biotech-stock-roundup-shire-acquire-npsp-celgene-pharmacyclics-give-strong-outlook-analyst", "https://www.nasdaq.com/articles/companys-first-profit-can-mean-big-profits-investors-screen-week-2015-01-13", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q4-loss-revenues-miss-analyst-blog-2015-02-13", "https://www.nasdaq.com/articles/agenus-soars-on-immuno-oncology-agreement-with-incyte-analyst-blog-2015-01-12", "https://www.nasdaq.com/articles/midday-update-stock-market-rally-stalls-following-anemic-wage-growth-more-energy-sector", "https://www.nasdaq.com/articles/us-stock-futures-edge-after-more-expected-jobs-added-economy-unemployment-drops-56-2015-01", "https://www.nasdaq.com/articles/us-futures-slip-ahead-jobs-report-2015-01-09", "https://www.nasdaq.com/articles/abbvie-2015-earnings-guidance-projects-strong-y-y-growth-analyst-blog-2015-01-09", "https://www.nasdaq.com/articles/closing-update-stocks-end-volatile-week-lower-after-weak-wages-taint-strong-hiring-report", "https://www.nasdaq.com/articles/health-care-sector-update-01092015-agenincyedapcnat-2015-01-09", "https://www.nasdaq.com/articles/agenus-agen-worth-watching%3A-stock-soars-28.7-tale-of-the-tape-2015-01-12", "https://www.nasdaq.com/articles/eli-lilly-maintains-14-view-growth-to-resume-in-2015-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/alexion-reports-disappointing-phase-ii-data-on-soliris-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/biodel-posts-positive-preliminary-data-on-its-diabetes-drug-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/alkermes-soars-on-positive-schizophrenia-drug-results-analyst-blog-2015-01-08", "https://www.nasdaq.com/articles/alkermes-gains-on-positive-depression-drug-study-data-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/gilead-to-purchase-liver-disease-program-from-phenex-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/celsion-submits-study-protocol-for-oncology-candidate-analyst-blog-2015-01-07", "https://www.nasdaq.com/articles/why-shares-agenus-inc-spiked-2015-01-09", "https://www.nasdaq.com/articles/minerva-neurosciences-min-301-positive-in-primate-study-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/akebia-progresses-with-chronic-kidney-disease-candidate-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/immunomedics-breast-cancer-drug-gets-fast-track-status-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/amgen-upgraded-to-strong-buy-is-it-in-your-portfolio-analyst-blog-2015-01-05", "https://www.nasdaq.com/articles/bull-day-incyte-incy-bull-day-2015-01-02", "https://www.nasdaq.com/articles/3-biotech-stocks-could-double-2015-2014-12-29", "https://www.nasdaq.com/articles/national-research-corporation-nrcia-ex-dividend-date-scheduled-december-29-2014-2014-12-26", "https://www.nasdaq.com/articles/salix-ceo-to-step-down-inventory-issues-remain-in-focus-analyst-blog-2015-01-06", "https://www.nasdaq.com/articles/incyte-incy-gains-on-positive-baricitinib-study-results-analyst-blog-2014-12-10", "https://www.nasdaq.com/articles/novartis-reports-encouraging-data-on-biosimilar-of-neupogen-analyst-blog-2014-12-09", "https://www.nasdaq.com/articles/incytes-jakafi-gets-fda-approval-for-polycythemia-vera-analyst-blog-2014-12-05", "https://www.nasdaq.com/articles/1-big-fda-decision-im-watching-month-2014-12-04", "https://www.nasdaq.com/articles/after-hours-most-active-nov-25-2014-hban-siri-intc-swks-pgh-aapl-incy-btu-hpq-pfe-t-avp", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-incyte-incy-tale-of-the-tape-2014-11-21", "https://www.nasdaq.com/articles/incyte-building-blockbuster-drug-one-disease-time-2014-11-17", "https://www.nasdaq.com/articles/national-research-corporation-nrcib-ex-dividend-date-scheduled-december-29-2014-2014-12-26", "https://www.nasdaq.com/articles/incyte-incy-looks-good%3A-stock-moves-10.9-higher-tale-of-the-tape-2014-10-31", "https://www.nasdaq.com/articles/incyte-gains-on-q3-earnings-and-revenue-beat-raises-view-analyst-blog-2014-10-31", "https://www.nasdaq.com/articles/will-abbvie-abbv-disappoint-in-this-earnings-season-analyst-blog-2014-10-29", "https://www.nasdaq.com/articles/incyte-breaks-above-200-day-moving-average-bullish-incy-2014-10-23", "https://www.nasdaq.com/articles/biotech-stock-roundup-sunesis-tanks-study-results-chimerix-ebola-update-analyst-blog-2014", "https://www.nasdaq.com/articles/incyte-receives-%2460m-milestone-payment-related-to-jakavi-analyst-blog-2014-10-06", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-incyte-corporation-incy%3A-time-to-buy-tale-of-the-tape", "https://www.nasdaq.com/articles/biotech-and-yet-weve-just-begun-2014-11-14", "https://www.nasdaq.com/articles/etf-outlook-spdr-sp-biotech-etf-xbi-2014-08-13", "https://www.nasdaq.com/articles/incyte-posts-wider-than-expected-q2-loss-raises-sales-view-analyst-blog-2014-08-01", "https://www.nasdaq.com/articles/incytes-jakafi-fails-to-provide-relief-in-polycythemia-vera-analyst-blog-2014-07-24", "https://www.nasdaq.com/articles/incyte-incy-enters-oversold-territory-tale-of-the-tape-2014-07-16", "https://www.nasdaq.com/articles/incyte-earns-milestone-payment-on-japanese-approval-of-jakavi-analyst-blog-2014-07-09", "https://www.nasdaq.com/articles/moving-average-crossover-alert%3A-incyte-incy-tale-of-the-tape-2014-07-02", "https://www.nasdaq.com/articles/merck-kgaa-morphosys-sign-deal-immuno-oncology-in-focus-analyst-blog-2014-06-12", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-incy-2014-08-25", "https://www.nasdaq.com/articles/weekly-insider-sells-highlight-armk-incy-esc-hun-2014-06-08", "https://www.nasdaq.com/articles/biotech-stock-roundup-gilead-pharmacyclics-impress-asco-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/incyte-gains-on-positive-jakafi-data-analyst-blog-2014-06-04", "https://www.nasdaq.com/articles/data-on-incytes-jakafi-analyst-blog-2014-06-03", "https://www.nasdaq.com/articles/incy-makes-notable-cross-below-critical-moving-average-2014-06-02", "https://www.nasdaq.com/articles/incyte-joins-forces-with-bristol-myers-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/interesting-incy-put-and-call-options-july-19th-2014-05-20", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-aramark-incyte-corp-ltd-facebook-inc-2014-06-09", "https://www.nasdaq.com/articles/celldex-gains-on-bristol-myers-squibb-deal-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/thursdays-etf-movers-bscf-fbt-2014-05-15", "https://www.nasdaq.com/articles/wider-than-expected-q1-loss-at-incyte-analyst-blog-2014-05-02", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-lower-pre-market-mylan-q1-earnings-top-street-view-2014-05", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-05-01-1", "https://www.nasdaq.com/articles/incyte-breaks-below-200-day-moving-average-notable-incy-2014-04-14", "https://www.nasdaq.com/articles/update-on-mercks-mk-3475-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/incyte-to-collaborate-with-astrazeneca-analyst-blog-2014-05-15", "https://www.nasdaq.com/articles/fridays-etf-movers-gxc-bbh-2014-03-21", "https://www.nasdaq.com/articles/positive-data-on-novartis-jakavi-analyst-blog-2014-03-10", "https://www.nasdaq.com/articles/first-trust-health-care-alphadex-fund-experiences-big-inflow-2014-02-24", "https://www.nasdaq.com/articles/weekly-cfo-sells-highlight-pandora-media-inc-incyte-corp-ltd-google-inc-american-airlines", "https://www.nasdaq.com/articles/wider-than-expected-q4-loss-at-incyte-analyst-blog-2014-02-13", "https://www.nasdaq.com/articles/first-trust-health-care-alphadex-fund-experiences-big-inflow-2014-02-11", "https://www.nasdaq.com/articles/stocks-scream-yellen-2014-02-11", "https://www.nasdaq.com/articles/bear-day-genomic-health-ghdx-bear-day-2014-04-03", "https://www.nasdaq.com/articles/incyte-incy-jumps%3A-stock-rises-6.8-tale-of-the-tape-2014-01-13", "https://www.nasdaq.com/articles/incyte-reiterated-at-neutral-analyst-blog-2014-01-07", "https://www.nasdaq.com/articles/incyte-corporation-incy-new-analyst-report-zacks-equity-research-zacks-equity-research", "https://www.nasdaq.com/articles/positive-data-on-incytes-jakafi-analyst-blog-2013-12-10", "https://www.nasdaq.com/articles/incytes-q3-loss-in-line-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/4-pharma-stocks-set-to-deliver-earnings-surprises-earnings-esp-2013-10-22", "https://www.nasdaq.com/articles/incyte-progresses-with-jak-inhibitors-analyst-blog-2013-10-07", "https://www.nasdaq.com/articles/pre-market-earnings-report-february-12-2014-de-tri-lo-rci-incy-dps-hsp-val-oc-spw-twtc-wcg", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-10-03-1", "https://www.nasdaq.com/articles/bear-day-genomic-health-ghdx-bear-day-2013-10-03", "https://www.nasdaq.com/articles/maxygen-inc-maxy-ex-dividend-date-scheduled-august-30-2013-2013-08-29", "https://www.nasdaq.com/articles/incyte-soars-on-positive-jakafi-data-analyst-blog-2013-08-22", "https://www.nasdaq.com/articles/new-stock-coverage-time-hit-brakes-tesla-motors-inc-2013-08-22", "https://www.nasdaq.com/articles/sector-update-healthcare-lower-pre-market-incyte-22-phase-ii-results-ruxolintinib-2013-08", "https://www.nasdaq.com/articles/pre-market-most-active-aug-21-2013-spls-code-tgt-low-nok-aeo-incy-bac-fb-aapl-qqq-tsla", "https://www.nasdaq.com/articles/sector-update-healthcare-stocks-flat-incyte-psoriasis-drug-show-effective-phase-2-study", "https://www.nasdaq.com/articles/benzinga-market-wrap-august-21-fomc-minutes-send-markets-spinning-2013-08-21", "https://www.nasdaq.com/articles/earnings-miss-at-incyte-in-q2-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/biomarin-files-vimizim-ma-in-brazil-analyst-blog-2013-07-05", "https://www.nasdaq.com/articles/positive-data-on-novartis-jakavi-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/positive-data-on-incytes-jakafi-analyst-blog-2013-06-18", "https://www.nasdaq.com/articles/positive-data-on-incyte-llys-baricitinib-analyst-blog-2013-06-14", "https://www.nasdaq.com/articles/incytes-jakafi-label-updated-analyst-blog-2013-06-13", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-08-21", "https://www.nasdaq.com/articles/incyte-reveals-data-on-oncology-candidate-analyst-blog-2013-06-04", "https://www.nasdaq.com/articles/after-hours-most-active-may-30-2013-fcx-hpq-msft-dpz-mrk-pfe-pxp-intc-siri-qqq-vmed-incy", "https://www.nasdaq.com/articles/alnylam-narrows-loss-sales-fall-analyst-blog-2013-05-07", "https://www.nasdaq.com/articles/arena-pharma-narrows-loss-analyst-blog-2013-05-06", "https://www.nasdaq.com/articles/narrower-than-expected-loss-at-incyte-analyst-blog-2013-05-03", "https://www.nasdaq.com/articles/optimers-dificid-cleared-down-under-analyst-blog-2013-05-01", "https://www.nasdaq.com/articles/biomarin-widens-loss-maintains-view-analyst-blog-2013-04-29", "https://www.nasdaq.com/articles/incyte-presents-positive-jakafi-data-analyst-blog-2013-06-05", "https://www.nasdaq.com/articles/incyte-reveals-data-on-oncology-candidate-analyst-blog-2013-06-04", "https://www.nasdaq.com/articles/national-research-corporation-nrci-ex-dividend-date-scheduled-february-14-2013-2013-02-12", "https://www.nasdaq.com/articles/update-on-lillys-tabalumab-analyst-blog-2013-02-11", "https://www.nasdaq.com/articles/incyte-pharmaceuticals-primed-run-2013-02-05", "https://www.nasdaq.com/articles/eli-lilly-scraps-a-phase-iii-study-analyst-blog-2012-12-17", "https://www.nasdaq.com/articles/novartis-presents-jakavi-data-analyst-blog-2012-12-12", "https://www.nasdaq.com/articles/mid-day-market-update-markets-trim-losses-incyte-drops-2013-03-18", "https://www.nasdaq.com/articles/incyte-progresses-on-ra-candidate-analyst-blog-2012-11-20", "https://www.nasdaq.com/articles/incyte-narrows-loss-analyst-blog-2012-11-06", "https://www.nasdaq.com/articles/novartis-jakavi-gains-eu-approval-analyst-blog-2012-08-28", "https://www.nasdaq.com/articles/incyte-corp.-enters-oversold-territory-tale-of-the-tape-2012-08-10", "https://www.nasdaq.com/articles/revenues-rise-at-incyte-analyst-blog-2012-08-06", "https://www.nasdaq.com/articles/after-hours-most-active-aug-2-2012-sd-kcg-nok-bac-orcl-itub-jpm-fb-qqq-aapl-incy-onnn-2012", "https://www.nasdaq.com/articles/incyte-stays-neutral-analyst-blog-2012-05-24-0", "https://www.nasdaq.com/articles/nvs-discusses-data-readout-plans-analyst-blog-2012-11-29", "https://www.nasdaq.com/articles/after-hours-most-active-apr-30-2012-pfe-svu-lly-exc-so-aep-incy-acas-eric-msft-csco-intc", "https://www.nasdaq.com/articles/loss-at-incyte-widens-on-higher-costs-analyst-blog-2012-04-30", "https://www.nasdaq.com/articles/incyte-upped-to-neutral-analyst-blog-2012-03-26", "https://www.nasdaq.com/articles/complex-trade-used-incyte-hedge-2012-03-09", "https://www.nasdaq.com/articles/incyte-cut-to-underperform-analyst-blog-2012-02-24", "https://www.nasdaq.com/articles/drab-quarter-at-incyte-shares-down-analyst-blog-2012-02-16", "https://www.nasdaq.com/articles/incyte-in-neutral-lane-analyst-blog-2012-02-10", "https://www.nasdaq.com/articles/weekly-ceo-sells-highlight-dis-lmt-incy-adbe-2012-05-14", "https://www.nasdaq.com/articles/incyte-drug-cleared-in-the-us-analyst-blog-2011-11-17", "https://www.nasdaq.com/articles/bears-target-incyte-fda-ruling-2011-11-08", "https://www.nasdaq.com/articles/exelixis-setting-facts-straight-2011-11-07", "https://www.nasdaq.com/articles/10-biotech-stocks-trading-deep-discounts-analyst-target-prices-2011-10-31", "https://www.nasdaq.com/articles/pfizer-poised-introduce-blockbuster-arthritis-pill-2011-09-11", "https://www.nasdaq.com/articles/cancer-conference-trade-picking-biotech-bargains-2011-07-21", "https://www.nasdaq.com/articles/top-20-most-undervalued-healthcare-stocks-target-price-2011-01-14", "https://www.nasdaq.com/articles/five-etfs-started-2012-strong-2012-01-31"], "Content": []}